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Abstract:  
 
This document provides clinical recommendations for the management of severe asthma. 
Comprehensive evidence syntheses, including meta-analyses, were performed to 
summarise all available evidence relevant to the Task Force’s questions. The evidence was 
appraised using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) approach and the results were summarized in evidence profiles. The 
evidence syntheses were discussed and recommendations formulated by a 
multidisciplinary Task Force of asthma experts, who made specific recommendations on 6 
specific questions. After considering the balance of desirable and undesirable consequences, 
quality of evidence, feasibility, and acceptability of various interventions, the Task Force 
made the following recommendations: 1) Suggest using anti-IL5 and anti IL-5R for severe 
uncontrolled adult eosinophilic asthma phenotypes; 2) suggest using blood eosinophil cut-
point of ≥ 150/μl to guide anti-IL5 initiation in adult patients with severe asthma; and 3) 
Suggest considering specific eosinophil (≥ 260 /μl) and FeNO (≥19.5 ppb) cutoffs to identify 
adolescents or adults with the greatest likelihood or response to anti-IgE therapy; 4) 
Suggest using inhaled tiotropium for adolescents and adults with severe uncontrolled 
asthma despite GINA step 4-5 or NAEPP step 5 therapies; 5) Suggest a trial of chronic 
macrolide therapy to reduce asthma exacerbations in persistently symptomatic or 
uncontrolled patients on GINA step 5 or NAEPP step 5 therapies, irrespective of asthma 
phenotype ; 6) Suggest using anti-IL4/13 for adult patients with severe eosinophilic asthma, 
and for those with severe corticosteroid-dependent asthma regardless of blood eosinophil 
levels. These recommendations should be reconsidered as new evidence becomes available. 
 
 
 
 
Introduction 
 
 
The first European Respiratory Society (ERS) - American Thoracic Society (ATS) 
guidelines on severe asthma in adults and school age children were published in 
2014 (1).  Severe asthma was defined as follows: ‘When the diagnosis of asthma is 
confirmed and comorbidities addressed, severe asthma is defined as asthma that 
requires treatment with high dose inhaled corticosteroids plus a second controller 
and/or systemic corticosteroids to prevent it from becoming ‘‘uncontrolled’’ or that 
remains ‘‘uncontrolled’’ despite this therapy’. Emphasis was placed on the necessity 
to confirm the diagnosis of asthma and exclude other conditions that may mimic 
asthma. In addition, the guidelines recognised that severe asthma is a 
heterogeneous condition consisting of phenotypes such as severe eosinophilic 
asthma and specific recommendations were made on the use of sputum eosinophil 
count and exhaled nitric oxide to guide therapy. Recommendations were also made 
for the use of methotrexate, macrolide antibiotics, antifungal agents, bronchial 
thermoplasty and the anti-IgE antibody (omalizumab) in severe asthma. 
 
This current guideline, for which work commenced in 2017, is also an ERS-ATS 
collaboration and was initiated in view of the rapid introduction of new treatments 
for severe asthma, particularly the new biologic treatments approved for the 
management of severe eosinophilic asthma. Six specific and important questions 
were formulated using the Patient population, Intervention, Comparison and 
Outcome (PICO) format. The GRADE approach was used to assess the strength of 
evidence and develop recommendations (2)  
The six questions chosen and developed by the Task Force are shown in Table 1: 
 
Table 1. ERS/ATS Severe Asthma Task Force Questions   
1. Should a monoclonal anti-IL5 antibody be used in adults and children (for the 
purposes of this guideline, age >5 years) with severe asthma? 
2. Should a measurement of a specific biomarker be used to guide initiation of treatment 
with a monoclonal anti-IL5 antibody or anti-ILR in adults and children with severe 
asthma? (chosen biomarkers being exhaled NO, peripheral or sputum eosinophils, 
and serum periostin) 
3. Should a measurement of a specific biomarker be used, in addition to total IgE level, to 
guide initiation of treatment with a monoclonal anti-IgE antibody in adults and 
children with severe asthma? (chosen biomarkers being exhaled NO, peripheral or 
sputum eosinophils, and serum periostin) 
4. Should a long-acting inhaled muscarinic antagonist (LAMA) be used in adults and 
children with severe asthma? 
5. Should a macrolide (i.e., azithromycin, clarithromycin) be used in adults and children 
with severe asthma?   
6. Should a monoclonal anti-IL4Rα be used in adults and children with severe asthma? 
 
During the deliberations of the Task Force, it became clear that the IL4Rα blocker, 
which modulates the effects of IL4 and IL13 would receive  approval by the 
regulatory authorities, so the 6th PICO was instituted, having originally not been 
considered.  The Task Force was focused on these specific PICOs, and, unlike the 
first Task Force, did not consider general management strategies for severe asthma. 
 
Methods 
A detailed description of the methodology used to develop the questions, rate the 
outcomes, select the studies, and synthesising, formulating and grading the evidence 
is available in previous ERS/ATS guidelines and in the on-line supplement(3, 4). 
 
Group composition 
The ERS and ATS selected the Task Force co-chairs (F.H, A.B), who led the project 
and selected the other panelists, which included 23 clinicians and researchers with 
experience in severe asthma and two severe asthma patient representatives (B.F, 
D.H). Two methodologists (D.R, R.M), lead by the ERS senior methodologist (T.T), 
supervised and ensured that all the methodological requirements were met. 
Systematic reviews and application of the GRADE approach were performed by 
members of the TF (DF, SD) and externally commissioned (Iberoamerican Cochrane 
Centre). The methodologist took part in the Task Force meetings but did not 
participate in the formulation of recommendations and had no voting rights.  
The co-chairs and panelists discussed the evidence and formulated the 
recommendations. Evidence profiles and Evidence to Decision (EtD) tables (See 
supplement) developed with the GRADEpro Guideline Development Tool (McMaster 
University, 2015; available from gradepro.org.) were used to facilitate the 
discussions, which was followed by voting on the recommendations.  All panel 
members disclosed their conflicts of interest.  Both co-chairs were required to be 
free from conflicts of interest relating to the management of asthma. Individuals 
with relevant conflicts of interest (COI) took part in the discussions about the 
evidence but did not participate in the formulation of recommendations related to 
the questions where they had a relevant COI.  
Thresholds for clinically important differences between treatment groups primarily 
in adults (used to judge imprecision according to GRADE) included the following 
absolute reductions:  St George’s Respiratory Questionnaire (SGRQ) score change of 
4 units, Asthma Control Questionnaire (ACQ-5, ACQ-6, and ACQ-7) score change of 
0.5 units, Asthma Quality of Life Questionnaire (AQLQ) score change of 0.5 units, 
Forced Expiratory Volume in one second (FEV1) change in Liters 0.23 and change in 
percentage 10.38%%(5-7).  
Literature searches 
The librarians (S.K, L. K) conducted the literature search strategies in Medline In-
Process & Other Non-Indexed Citations, MEDLINE, Embase, and Cochrane Central 
Register of Controlled Trials (CCTR), beginning in 2008 and ending with a final 
update on 27 September 2018.  These dates were selected to capture developments 
in severe asthma therapy since the previous ERS/ATS guidelines.  The literature 
searches included systematic reviews of randomised clinical trials including 
(moderate to severe) asthma population receiving the interventions of interest. We 
excluded: Phase I (pharmacokinetic or pharmacodynamic studies), real-life non-
randomised extension studies, and research reported in abstract form only such as 
poster or congress presentations. 
 
Results were limited to human subjects and to reports in the English language. Each 
strategy incorporated medical subject headings and text words for the topic of 
asthma, with search hedges for specific concepts defined in the PICOs.  To 
supplement the electronic search, contacted experts were contacted journals and 
reference lists were hand-searched. 
 
Evidence Synthesis.  
Study characteristics, types of participants, interventions, outcome measures and 
results were extracted from each study. If the data were amenable to pooling, effects 
were estimated by meta-analysis using Review Manager (version 5.3; The Nordic 
Cochrane Centre, Copenhagen, Denmark). For the meta-analyses, the random effects 
model was utilised unless otherwise specified. Dichotomous outcomes were 
reported as relative risks and continuous outcomes were reported as mean 
differences unless otherwise specified.   Absolute differences are reported in the 
accompanying documents in the appendix. Judgements on the quality of evidence 
were reviewed by the TF members and validated by the ERS Methodologists (TT, 
DR, RM). 
Formulating and grading recommendation  
The evidence profiles were sent to the Task Force members for review. Using an 
iterative consensus process conducted face-to-face and also via teleconference and 
via email, and finally a vote by all members of the Task Force who had no relevant 
conflicts, recommendations were formulated on the basis of the following 
considerations: the balance of desirable (benefits) and undesirable consequences 
(burden, adverse effects and cost) of the intervention, the quality of evidence, 
patient values and preferences, and feasibility [10]. A strong recommendation was 
made for or against an intervention when the panel was certain that the desirable 
consequences outweighed the undesirable consequences (or the converse for 
recommendation against). A strong recommendation is one that most well informed 
patients would follow. 
A conditional recommendation was made for or against an intervention when the 
panel was uncertain that the desirable consequences of the intervention outweighed 
the undesirable consequences (or the converse, for recommendation against). 
Reasons for uncertainty included low or very low quality of evidence, the desirable 
and undesirable consequences being finely balanced, the population in reviewed 
studies not uniformly meeting ERS/ATS severe asthma criteria, or the underlying 
values and preferences playing an important role. A conditional recommendation 
indicates that well-informed patients may make different choices regarding whether 
to have or not have the intervention.  
Manuscript preparation 
The two co-chairs, ERS methodologists and one panelist (KFC) developed the initial 
manuscript draft. The ERS methodologists and PICO leaders prepared the EtD tables 
in the supplementary material. All materials were edited and approved by all panel 
members. 
Supporting documentation, including GRADE Evidence profiles and the Evidence to 
Decision Frameworks tables is included in the online supplement.  
 
Results:  
Should a monoclonal anti-IL5 antibody be used in adults and children with 
severe asthma? 
 
Interleukin 5 (IL-5) is a principal cytokine driving eosinophilic inflammation in 
asthma. Monoclonal antibodies that target IL-5 (mepolizumab, reslizumab) or its 
receptor IL-5Rα (benralizumab) have been found to be efficacious in randomized 
controlled trials (RCTs) in improving asthma-related outcomes, and are currently 
approved by the U.S. Federal Drug Administration (FDA)/European Medicines 
Agency (EMA). We identified 12 RCTs that met inclusion criteria. We included data 
only for participants on FDA/EMA licensed doses or the 20 mg SC dose from phase 2 
benralizumab trials. The evidence from meta-analyses of these trials is summarized 
below. Asthma exacerbations, symptoms, asthma control, quality of life, use of 
systemic corticosteroids and adverse events were considered ‘critical outcomes”. 
Change in lung function was deemed an ‘important’ outcome. 
 
Summary of the evidence 
Mepolizumab:  
Three studies in adolescents and adults met inclusion criteria (8-10). All three were 
randomized placebo-controlled trials in patients with severe eosinophilic asthma 
(blood eosinophil count > 300 cells/mm3 in the 12 months prior to screening or > 
150 cells/mm3 during screening/oral corticosteroid [OCS] optimization period) 
considered by this Task Force to represent a population of severe asthmatics as 
defined by the ERS/ATS Guidelines on Severe Asthma. Two studies required 
patients to have had at least two attacks in the previous year despite regular use of 
high dose inhaled corticosteroid (ICS) plus another controller (9, 10), whereas the 
other investigated the steroid-sparing effect of mepolizumab in OCS-dependent 
asthma (8).  
Mepolizumab therapy was associated with a 50% reduction in the rate of any 
exacerbation (rate ratio  0.5; 95%CI 0.39, 0.65; absolute risk 0.92 versus 1.69 
events/patient/year ) and 64% reduction in exacerbations requiring emergency 
department (ED) visit or hospitalization (rate ratio 0.36; 95% CI 0.20, 0.66; 0.05 
versus 0.15 events/patient/year). Compared to placebo, those assigned to 
mepolizumab experienced an absolute 0.43-point decrease (i.e. improvement) in 
ACQ-5 (95% CI -0.56, -0.31); and an absolute 7.14 decrease (i.e. improvement) in 
the SGRQ scale (95% CI -9.07, -5.21). Mepolizumab, relative to placebo, resulted in a 
50% median reduction in the dose of maintenance oral corticosteroids (OCS) (95% 
CI 20, 75) in one study of 135 patients(8). The effect of mepolizumab on FEV1 was 
less than the minimal clinically important difference (MCID) threshold.  
 
Reslizumab: 
Four publications that included five RCTs met the inclusion criteria (11-14). Castro 
et al, 2015 reported on two duplicate trials (13). Three of the five RCTs included 
adolescents in addition to adult participants (11, 13). All studies except one (12) 
included patients with mixed severity (moderate and severe) asthma. Three RCTs 
used inclusion criteria of blood eosinophils > 400 cells/mm3 (11, 13, 14) and one 
RCT used sputum eosinophil > 3% (12). One RCT included participants unselected 
for blood eosinophil count but subsequently performed a subgroup analysis using a 
blood eosinophil cutoff of 400 cells/mm3 (14). Overall, reslizumab therapy was 
associated with a 54% reduction in any exacerbation (rate ratio 0.46; 95%CI 0.37, 
0.58; 0.84 versus 1.81 events/patient/year ) relative to placebo and 33% reduction 
in exacerbations requiring ED visits or hospitalizations (rate ratio 0.67; 95% CI 0.39, 
1.17; 0.077 versus 0.12 events/patient/year ). Reslizumab therapy also reduced the 
risk of patients having at least one exacerbation (29.2% versus 46.7%; risk ratio 
[RR] 0.63; 95%CI 0.53, 0.76). In a study of participants meeting the ATS/ERS criteria 
for diagnosis of severe asthma , reslizumab therapy was associated with a 60% 
reduction in the risk of having ≥ 1 exacerbation (7.5% versus 18.9%; RR 0.40; 95% 
CI 0.13, 1.20) 
Relative to participants on placebo, those assigned to reslizumab experienced an 
absolute 0.26-point decrease (i.e. improvement) in ACQ-7 (95% CI -0.33, -0.18); and 
an absolute 0.28-point increase (i.e. improvement) in AQLQ scale (95% CI 
0.17,0.39). The effect of reslizumab on FEV1 did not cross the MCID threshold.  
 
Benralizumab: 
Five RCTs evaluating benralizumab met the inclusion criteria(15-19). Four studies 
included a mixed population of patients with moderate or severe asthma (15-18). 
Two of the five RCTs included adolescents in addition to adult participants (15, 17). 
One study investigated the steroid-sparing effect of benralizumab in OCS-dependent 
asthma (18) 
Overall, benralizumab therapy was associated with a 42% reduction in the rate of 
any exacerbation (rate ratio 0.58; 95%CI 0.47, 0.73; 0.64 versus 1.19 
events/patient/year ) and a 38% reduction in the number of patients with ≥1 
exacerbation (35.9% versus 51.1%; RR 0.62; 95%CI 0.36, 1.06) relative to placebo. 
In study participants meeting ATS/ERS criteria for diagnosis of severe asthma, 
benralizumab therapy was associated with 55% reduction in exacerbations 
(number of patients with ≥1 exacerbation 23.3% versus 52%; RR 0.45; 95% CI 0.28, 
0.72). Those requiring ED visits or hospitalizations were also reduced (rate ratio 
0.45; 95% CI 0.14, 1.47; 0.043 versus 0.18 events/patient/year), and with a greater 
magnitude for patients meeting ATS/ERS criteria for diagnosis of severe asthma 
(rate ratio 0.07; 95% CI 0.01, 0.63; 0.02 versus 0.32 events/patient/year ) 
Relative to participants on placebo, those assigned to benralizumab experienced an 
absolute 0.29-point decrease in ACQ-6 (95% CI -0.4, -0.17); and an absolute 0.32-
point increase (i.e. improvement) in AQLQ scale (95% CI 0.19, 0.45). The effect of 
benralizumab on FEV1 was below the MCID. The median OCS dose reduction from 
baseline (range) at the final visit (week 28) was 25.0% (–150% to 100%) in the 
placebo group (n=75) and 75.0% (–50% to 100%) in the benralizumab group 
(n=73) (18). 
 
Adverse effects: 
Compared to placebo, the risk ratio of developing any adverse event for a 
participant was 0.93 (95% CI 0.88, 0.99) for mepolizumab (74.8% versus 79.6%); 
0.88 (95% CI 0.81, 0.96) for reslizumab (67.1% versus 80.4%), and 0.96 (95% CI 
0.91 – 1.01) for benralizumab (73.6% versus 75.5%). Similarly, participants 
experienced a lower risk of serious adverse events when assigned to anti-IL5 
strategy drugs (see on-line supplement). The lower risk for having any adverse 
events is likely driven by the reduction in severe asthma exacerbations by these 
drugs.   
Data are available on drug-related adverse events from all 3 mepolizumab trials, but 
only from 2 of 5 reslizumab trials and 1 of 5 benralizumab trials. These data show 
that, relative to placebo, participants assigned to mepolizumab had a greater  risk of 
drug-related adverse events (13.3% versus 9.2%; RR 1.35, 95%CI 1.01, 1.80); those 
assigned to reslizumab had a lower risk (8% versus 11.9%; RR 0.69; 95%CI 0.44, 
1.09) and those assigned to benralizumab had a greater risk (13.3% versus 9.2%; 
RR 1.46; 95%CI 0.96, 2.21). Because the outcome drug-related adverse events were 
not pre-defined, the TF members did not consider this outcome in the overall 
certainty of the evidence of effects. 
 
Benefits 
Anti-IL5 and anti-IL5Rα therapies reduce exacerbations and hospitalizations in 
patients with severe eosinophilic asthma. Mepolizumab and benralizumab are 
effective in reducing maintenance OCS dose in patients with corticosteroid-
dependent severe asthma.    
 
Harms 
All three anti-IL5 strategy drugs were well tolerated. Frequency of adverse effects 
was similar when compared with placebo.   
 
 
Conclusions  
Anti-IL5 strategy reduces exacerbations in patients with severe eosinophilic asthma. 
Mepolizumab and benralizumab are effective in reducing OCS dose in 
corticosteroid-dependent asthma. The effects on asthma control, quality of life and 
FEV1 are modest for all drugs and did not meet the MCID threshold.  
 
Research needs and additional considerations 
Direct comparisons will be needed to further guide selection of the appropriate anti-
IL5 drug. Uncertainty exists around the best biomarker and blood eosinophil 
threshold that would predict response to anti-IL5 therapy.  In addition to blood 
eosinophils, the efficacy of anti-IL5 therapy depends on the degree of preexisting 
asthma exacerbations. This should be taken into consideration when considering 
the clinical and cost effectiveness of this form of therapy. Data from adolescents are 
unavailable for mepolizumab and reslizumab, whereas for benralizumab, there are 
data on a limited number of adolescents with severe asthma. There are no data on 
younger children. Therefore, more evidence is needed to provide greater quality 
recommendations in the pediatric age group.  
 
What others are saying 
Global Initiative for Asthma (GINA) (20) and the National Institute for Health and 
Care Excellence (NICE)(21) technology appraisal guidance TA431, TA479 and 
TA565 include mepolizumab, reslizumab and benralizumab as add-on therapeutic 
option for severe eosinophilic asthma (at Step 5 of GINA ).  
ERS/ATS recommendation 
We suggest anti-IL5 strategy as add-on therapy for adult patients with severe 
uncontrolled asthma with an eosinophilic phenotype (The task force gave this a 
conditional recommendation because inclusion criteria across studies did not 
consistently aligned with the ERS/ATS severe asthma definition).  
Remarks: The high cost of these drugs and its impact on cost effectiveness, equity 
and feasibility to implementation must be weighed by clinicians in relation to the 
benefits on asthma outcomes shown by all anti-IL5 and anti-IL5Ra strategy 
drugs(22). Due to limited number of treated adolescents or children, the TF was 
unable to provide a recommendation for the use of anti-IL5 and anti-IL5Ra 
antibodies in this age group.  
 
Should a measurement of a specific biomarker be used to guide initiation of 
treatment with a monoclonal anti-IL5 or IL5Rα antibody in adults and 
children with severe asthma? (biomarkers being exhaled NO, peripheral or 
sputum eosinophils, and serum periostin) 
 
Summary of the evidence 
 
We identified 12 randomized controlled trials of anti-IL5 therapies in children and 
adults 12-75 years of age that evaluated differential response to therapy amongst 
subgroups of individuals with higher or lower levels of eosinophils in blood or 
sputum in post hoc analyses (10-17, 19, 23, 24).  One paper was a meta-analysis of 2 
RCTs of mepolizumab’s therapeutic responsiveness combining the 100 mg SC and 
75 mg IV doses for the analysis by blood eosinophil level (24). Notably, four of the 
studies recruited only subjects with evidence of eosinophilic asthma, defined as a 
sputum eosinophil of ≥3% or blood eosinophil level of ≥300/uL (11-13, 23).  Six of 
the studies included children  12 years (10, 11, 13, 15, 17, 24).  The most 
commonly measured biomarker was blood eosinophil count.  Only one study 
evaluated sputum eosinophil level (12).  One additional study evaluated whether 
the presence of persistently elevated sputum or blood eosinophils was an indicator 
of therapeutic failure and justified the addition of an alternate anti-IL5 strategy (25). 
 
Cut-offs assessed for baseline blood eosinophil levels, and hence the definition of 
what constitutes eosinophilia, varied across anti-IL5 strategies.  Studies of 
mepolizumab specifically assessed a cut-off of blood eosinophils of ≥150/uL.  For 
mepolizumab, there was a 73% (95%CI -82, -59%) reduction in exacerbations 
amongst those with a blood eosinophil level of ≥ 500/uL compared to 36-39% 
reduction in all other groups with eosinophil levels ≥ 150/uL.  Notably, subjects 
with eosinophil levels of ≥150/uL constituted nearly three quarters of the severe 
asthma population in those studies.  Patients treated with reslizumab with a 
baseline eosinophil of ≥400/uL had a 54% reduction in exacerbations; higher cut-
offs were not associated with a greater reduction in exacerbations.  For 
benralizumab, a cut-off of ≥300/uL was associated with a significant reduction in 
exacerbations; however, it is not clear what the optimal cut-off should be since even 
subjects with an eosinophil level of <300/uL experienced a reduction in 
exacerbations.  
For effects on asthma control and quality of life, the data again varied by anti-IL5 
strategy; among those with a baseline eosinophil level of ≥150/uL, 63% treated with 
mepolizumab vs 41% treated with placebo, achieved a ≥ 0.5-point reduction from 
baseline in ACQ-5 (RR 1.53, 95%CI 1.27 – 1.84).  The improvement in asthma 
control was similar among those with higher baseline levels of eosinophils (≥300 or 
≥500).  For benralizumab, only subjects with a baseline eosinophil level of ≥300/uL 
experienced a significant improvement in asthma control, assessed as change in 
ACQ-6 score from baseline (mean difference -0.28 [95%CI -0.41, - 0.15]); whereas 
those with an eosinophil level of <300/uL did not (-0.20 [95%CI -0.44, 0.3]).  
Similarly for reslizumab, a cut-off of ≥ 400/uL was associated with improved asthma 
control (mean difference in ACQ-7) from baseline -0.27 (95%CI -0.36, -0.19); 
whereas those below 400/uL did not have a significant benefit (-0.12 [95%CI -0.33, 
0.09]).  Sputum eosinophil level was only considered in one study of reslizumab 
(12) and sputum levels were categorized as ≥ or < 10%.  There were no statistical 
differences found between groups in level of asthma control. There was a trend for 
higher blood eosinophil levels to be associated with a greater improvement in 
asthma control. 
 
One additional study, which was not included in the meta-analysis, assessed 
treatment response of weight-adjusted IV reslizumab in patients previously treated 
with 100-mg SC mepolizumab (25).  It reported that persistently high levels of 
eosinophils (blood >300/uL and sputum >3%) after treatment with mepolizumab 
characterized responders.  In those subjects a weight-adjusted dose of reslizumab 
was administered.  It was found that further improvements in symptoms and 
reductions in eosinophilia were possible with addition of Reslizumab.  These data 
suggest that evidence of uncontrolled eosinophilic inflammation, as manifested by a 
high sputum or blood eosinophil level, may be useful in determining which subjects 
may benefit from additional anti-IL5 strategies; however, this need further requires 
confirmation. 
 
Benefits 
The specific cut-off  blood eosinophil count to predict improved asthma control and 
reduction in exacerbations varies across anti-IL5 strategies.  However, there is very 
low quality evidence that mepolizumab may provide further benefit in reducing 
exacerbations in patients with baseline blood eosinophilia ≥ 500/µL compared to 
those with an eosinophil level <150/µL, 150 to < 300/µL and 300 to <500/µL.   
 
Harms 
There were 5 papers that assessed adverse events in benralizumab or reslizumab 
(11, 13-17).  The data for mepolizumab did not assess differences in adverse event 
rates based on blood eosinophil level.  There was no difference in adverse events 
amongst those with higher vs lower eosinophil counts for benralizumab.  For 
Reslizumab, only subjects with a baseline eosinophilia of >400/uL during screening 
were recruited; the fewest adverse events occurred in the group who had no data on 
eosinophil count at the time of recruitment compared to patients with baseline 
eosinophilia ≥400/uL.  There was a 5% reduction in the number of adverse events 
amongst those with an eosinophil count of ≥400/uL which, although statistically 
relevant, may not be clinically meaningful. More recent studies have now shown 
that both benralizumab and mepolizumab, maintain an adequate safety profile 
during long term use for up to 2 and 4.5 years, respectively (26, 27).  
 
Other considerations 
Most of the studies focused on blood eosinophils as a biomarker and there was 
limited data on sputum eosinophils and no data on FeNO or serum periostin.  Blood 
eosinophils can be measured in any standard laboratory increasing its feasibility as 
a biomarker, yet additional testing beyond the point of care maybe required to 
ascertain baseline levels, particularly among patients on or recently taking systemic 
corticosteroids.  It is more acceptable than sputum eosinophil levels, which are 
currently only performed in specialized centers. It should be noted that there may 
be causes other than atopy (e.g. parasitic infections) for peripheral blood 
eosinophilia specially in low and middle-income settings.  
 
Cut-offs to assess response varied across studies of anti-IL5 medications and there 
was no data comparing therapeutic regimens using different cut-off levels.  Finally, 
most of the anti-IL5 strategies use a fixed dose regimen based on RCT data 
suggesting a plateau in the dose response; however, one study suggested that 
persistent eosinophilia, despite anti-IL5 strategies, should be considered as an 
opportunity to add on reslizumab using a weight-adjusted dose regimen(25). 
 
Conclusions and research needs: 
Although the data suggest that subjects with higher levels of blood eosinophil 
counts benefit more from anti-IL5 strategies, the evidence we reviewed does not 
show that a specific level of blood eosinophils greater than or equal to 150/µL for 
mepolizumab, ≥300/µL for benralizumab and ≥400/µL for reslizumab is an absolute 
response threshold, as clinical benefit can still be observed in some patients below 
these values.  Based on currently available evidence (which is very limited) sputum 
eosinophils may not add to the prediction of response greater than blood eosinophil 
level.  
Determining a patient’s baseline eosinophil count may require more than one 
measurement, as this biomarker is highly variable and significantly reduced by 
systemic and inhaled corticosteroids.  It is not known if eosinophil levels obtained 
during periods of asthma exacerbation are better predictors of treatment response 
when compared to those measured during periods of clinical stability. Future 
studies should focus on developing additional non-invasive biomarkers for adults 
and children that can be used at point-of-care to predict responsiveness to different 
anti-IL5 strategies.  
What others are saying:  
GINA 2018 guideline for difficult to treat and severe asthma recommends the use of 
an anti-IL5 and anti-IL5Ra strategy for patients who are continuing to experience 
severe exacerbations despite step 4 or 5 therapy who have blood eosinophils ≥ 
300/μL. 
ERS/ATS recommendation: 
We suggest that a blood eosinophil count cut-off point of ≥ 150 /μL can be used to 
guide anti-IL5 initiation in adult patients with severe asthma and a history of prior 
asthma exacerbations (conditional recommendation, low quality evidence).   
Remarks 
The TF placed a high value on reducing exacerbations and a greater feasibility of 
biomarker measurement and a lower value on cost and invasiveness.  
 
Should a measurement of a specific biomarker be used, in addition to total IgE 
level, to guide initiation of treatment with a monoclonal anti-IgE antibody in 
adults and children with severe asthma? (biomarkers being exhaled NO, 
peripheral or sputum eosinophils, and serum periostin) 
 
Summary of the evidence 
We identified three randomised, double blind placebo-controlled trials(28-30) 
which recruited participants aged 12-75 years. Of these, two studies(29, 30) 
involving 1014 eligible participants formed the evidence for the taskforce 
recommendation. These two trials included individuals with uncontrolled asthma; 
in one of them (30), patients had uncontrolled symptoms whilst taking an inhaled 
corticosteroid (ICS) with or without a controller. In the other study (29), only 
participants with severe persistent asthma were recruited, whose asthma remained 
uncontrolled despite ICS and a long acting beta2 agonist.  
 
In both trials eligible participants were randomised 1:1 to receive omalizumab or 
placebo. Omalizumab dose was determined on the basis of pretreatment serum total 
IgE level (IU/mL) and body weight (kg) according to the European (30) or ATS (29) 
omalizumab dosing table, which ensured a minimum omalizumab dose of 0.008 
mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) 
every 4 weeks. 
 
Busse et al.(30) preplanned an analysis that divided participants into two subgroups 
according to eosinophil counts at screening; low (<300/μl) and high (≥300/μl). A 
subgroup analysis was performed by Hanania(29), which divided participants into 
high and low subgroups as follows: FeNO - low<19.5 ppb, high ≥19.5 ppb; peripheral 
blood eosinophils - low<260/μl and high ≥260/μl and serum periostin levels – low 
<50 ng/ml and high ≥50 ng/ml.  
 
Pooling of the data from the two studies was not possible. In Busse et al (30) there 
were significant improvements in exacerbation rates (hazard ratio [HR] 0.41 
[95%CI 0.20, 0.84]) and a clinically trivial but statistically significantly greater 
change in FEV1 %predicted at 24 weeks (mean difference [MD] 7.35 ml [95%CI 1.38, 
13.32]) with omalizumab compared to placebo in patients with a high eosinophil 
count, whereas there were no differences in patients with low eosinophils (less than 
300/uL). In the study by Hanania(29) there was a significantly longer time to first 
asthma exacerbation with omalizumab compared to placebo in patients with high 
(260/uL or more) eosinophil count at 48 weeks follow-up (HR 0.64 [95%CI 0.48. 
0.85]), whereas there were no differences in patients with low (less than 260/uL) 
eosinophil count (HR 0.95 [95%CI 0.68, 1.33]). However, there were no statistically 
significant differences between these subgroups. There were no differences in AQLQ 
at 48 weeks, when omalizumab was compared to placebo in patients with high 
eosinophils (260/uL or more) (MD 0.14 [95%CI -0.11, 0.30]), while there was a 
small statistically, but not clinically significant, difference in the low eosinophil 
subgroup (MD 0.26 [95%CI 0.06, 0.46]).  
 
In the subgroup analysis by FeNO (29), there was a significant relative reduction of 
exacerbation rates with omalizumab compared to placebo in patients with high 
(19.5 ppb or more) FeNO level at 48 weeks follow-up (53% [95% Cl 37-70]), 
whereas there were no differences for those patients with low (less than 19.5 ppb) 
FENO levels (16% [95% CI: -32 to 46]). The time to first asthma exacerbation with 
omalizumab, compared to placebo, was significantly longer in patients with high 
(19.5 ppb or more) FeNO level at 48 weeks follow-up (HR 0.38 [95%CI 0.24, 0.60]), 
whereas there were no differences in patients with low (less than 19.5 ppb) FeNO 
(HR 1.00 [95%CI 0.62, 1.61]). There were also larger changes of mean AQLQ with 
omalizumab compared to placebo in FeNO high patients (19.5 ppb or more) at 48 
weeks of follow-up (MD 0.39 [95%CI 0.06, 0.72]), whereas there were no 
differences in FeNO low patients (less than 19.5 ppb) (MD 0.24 [95%CI -0.09, 0.57]). 
 
There were no differences in the relative reduction of exacerbation rates at 48 
weeks or FEV1 when omalizumab was compared to placebo in periostin high (50 
ng/ml or more) or low (less than 50 ng/ml) patients(29). However, compared to 
placebo, omalizumab improved AQLQ in patients with low (less than 50 mg/ml) 
periostin levels at 48 weeks follow-up (MD 0.50 [0.22,0.78]), whereas there were no 
differences patients with high (50 ng/ml and more) serum periostin levels (MD 0.10 
[95%CI -0.19,0.39]).  
 
Benefits 
In patients treated with omalizumab compared to placebo, the presence of a 
baseline blood eosinophil count of greater or equal to 260/μl is associated with 
greater improvements in FEV1, and a decreased rate of exacerbations as well as 
longer time to first exacerbation, compared to those with a blood eosinophil count 
less than 260/μl.  
 
In patients treated with omalizumab compared to placebo, the presence of FeNO 
level of greater or equal 19.5 ppb is associated with improvements in AQLQ, 
reduced exacerbation rate and longer time to first exacerbation, compared to those 
with a FeNO level less than 19.5 ppb.  In patients treated with omalizumab 
compared to placebo, the presence of a periostin level less than 50ng/ml was 
associated with improvements in AQLQ, compared to those with a periostin level 
greater than or equal to 50ng/ml. Periostin levels, however, did not predict 
response in exacerbations or lung function. There is no evidence that periostin is a 
suitable biomarker to guide asthma treatment in children or adolescents. Levels are 
influenced by age, skeletal growth and puberty (31).   
 
 
Harms 
There were no differences in the adverse effects in patients treated with 
omalizumab versus placebo according to high or low FeNO, blood eosinophils or 
periostin.   
 
Other considerations 
The estimates of effect included one single study (meta-analysis of the two RCT was 
not possible), which introduced some uncertainty due to the limited number of 
patients included in each subgroup according to biomarker’s threshold..  
Furthermore, the risk of bias was high for completeness of data, due to a 
considerable number of patients that were not evaluated at baseline for the 
biomarkers. 
. 
Conclusions and research needs 
Blood eosinophil counts and FeNO levels may be useful in choosing patients most 
likely to achieve a more positive effect on exacerbations and lung function when 
treated with omalizumab compared to placebo. There were no differences in 
adverse effects based on the biomarker high and low subgroups, suggesting that the 
blood eosinophil- and FeNO-high patients achieve clinical benefit without additional 
adverse effects, whereas, biomarker low patients are at risk of adverse effects while 
potentially having less clinical benefit. 
 
Other excluded studies also make important observations regarding the use of blood 
eosinophil to select patients most likely to respond to omalizumab. Of particular 
note is the study by Casale et al., who reported an analysis that pooled the results of 
two RCTs (32).  The studies by Busse et al (33) and Soler et al (34) were both phase 
III, double blind placebo controlled trials, comprising a total of 1071 participants 
comparing omalizumab to placebo in participants with moderate to severe asthma. 
The pooled analysis published in 2018 investigated the annualized exacerbation 
rates in the omalizumab group versus placebo according to the subgroups of blood 
eosinophil high (≥300/μl) and low (<300/μl)(32). The results support the 
recommendations of the taskforce. There was a more pronounced reduction in 
exacerbations rates in the omalizumab versus placebo group for the biomarker high 
subgroup; i.e., for those with an eosinophil count ≥300/μl there was a 67% 
reduction in exacerbations, in contrast to a 45% reduction in the < 300/μl group.  
 
In contrast to the previous studies, one publication found that omalizumab’s 
effectiveness did not vary across biomarker levels. This retrospective study of 872 
patients with severe allergic asthma showed that omalizumab reduced 
exacerbations by 58.4% (95% CI 52.7, 63.4%) in the biomarker high (eosinophil 
count ≥300/μl) group, vs. 58.1% (95% CI 52.7, 63.4%) in the biomarker low group 
(eosinophil count <300/μl)(35).   
 
Future randomised controlled trials should evaluate baseline blood eosinophils and 
FeNO as individual and combined biomarkers to further determine their ability to 
predict response to treatment for multiple outcomes including exacerbations, lung 
function as well as patient reported outcomes such as AQLQ and asthma control. 
Furthermore, there is a need to identify biomarkers that support clinical decision-
making regarding the continuation versus discontinuation of a monoclonal anti-IgE 
strategy in adults and children with severe asthma. 
 
What others are saying 
The 2018 GINA guidelines for the Diagnosis and Management of Severe Asthma in 
adolescent and adult patients state that a blood eosinophil level of ≥260/μl and 
FeNO ≥20 ppb are factors that may predict a good response to treatment.  
Neither the British Thoracic Society nor the NICE asthma guidelines make comment 
about predictor biomarkers  foranti-IgE treatment response.  
ATS/ERS recommendation 
In adult and adolescent patients with severe asthma being considered for 
omalizumab we suggest:  
 Using a blood eosinophil cut-off of ≥ 260 /μl to identify adolescents 
(>12 years) and adults with severe allergic asthma more likely to 
benefit from anti-IgE treatment (conditional recommendation, low 
quality of evidence). 
 Using a FeNO cut-off of ≥ 19.5 ppb to identify adolescents (>12 years) 
and adults with severe allergic asthma more likely to benefit from anti-
IgE treatment (conditional recommendation, low quality of evidence). 
Remarks: Since these recommendations have not been prospectively evaluated, 
treatment decisions should consider these biomarker thresholds cautiously, as 
patients with eosinophil or FeNO values below the proposed cutoffs can still benefit 
from omalizumab. In addition, these thresholds were largely determined by one 
particular study (29). Periostin was omitted from these recommendations, as this 
biomarker is not clinically available, and it is not useful in children < 12 yrs because 
it is also produced from growing bone.  
 
Remarks 
The recommendation places a high value on an increased treatment response when 
blood eosinophil and FeNO are used to select patients and a low value on the use of 
periostin. 
 
Should a long-acting inhaled muscarinic antagonist (LAMA) be used in adults 
and children with severe asthma? 
 
Summary of the evidence 
 
We identified three randomized, placebo-controlled trials in adults 18-75 years of 
age, one crossover and two parallel designs; one trial in adolescents (age 12-17 
years), and one trial in children (age 6-11 years) (36-38). These trials included 
individuals with severe uncontrolled asthma on GINA step 4-5 or NAEPP step 5 
therapies. Adults were treated with at least a high-dose ICS in combination with a 
long-acting beta2-adrenergic receptor agonist while adolescents and children were 
treated with medium-dose ICS and LABA with a third controller.  
 
In the adolescent and pediatric studies, eligible patients were randomized in a 1:1:1 
ratio to receive tiotropium 5 ug (two puffs of 2.5 ug) or 2.5 ug (two puffs of 1.25 ug) 
or placebo (two puffs), each delivered for 12 weeks via the Respimat Soft Mist 
inhaler as add-on to pre-enrollment background therapy with ICS plus one or more 
controller therapies. Whereas two adult studies (37) compared 5 ug tiotropium (2 
puffs of 2.5 ug) delivered by Respimat over 48 weeks to placebo; one adult study 
(36) involved an 8 week, three-way crossover design with 5 ug tiotropium (2 puffs 
of 2.5 ug), 10 ug triotropium (2 puffs of 5 ug) and placebo and was excluded from 
further analyses and the primary meta-analyses. The remaining four trials enrolled 
a total of 1,433 participants (2.5 ug dose, n=528) and were pooled for meta-analyses 
to inform the Task Force’s judgments. 
 
Across the four parallel arm trials including children, adolescents, and adults, the 
addition of tiotropium 5ug resulted in improvements in mean peak FEV1 response 
compared to placebo (123 ml [95%CI = 88.2, 158.7]), which was statistically 
significant but a clinically trivial difference. Serious imprecision in the certainty 
estimates was also noted for each age group. The addition of tiotropium 5 ug also 
marginally improved ACQ-7 (-0.11 [95%CI = -0.2, 0.01]) and prevented asthma 
worsening (based on exacerbations or symptoms, RR=0.79 [95%CI = 0.7, 0.89]; AR 
133 fewer worsening episodes per 1,000 [95CI% 54 – 122]) compared to placebo, 
but again, serious imprecision in the certainty estimates was noted for children and 
adolescents. In children and adolescents, addition of tiotropium 2.5ug did not 
improve asthma control scores but did improve FEV1 % predicted (MD, 4.99 [95%CI 
= 2.84, 7.15] and reduced asthma worsening (RR=0.66 [95%CI = 0.45, 0.97]. Post 
hoc analyses of adjusted mean trough FEV1/FVC responses in children also 
demonstrated statistically significant improvements at all-time points versus 
placebo with both tiotropium doses, with the exception of tiotropium 2.5 mg at 
week 8.  
 
In the two adult trials, treatment with tiotropium 5 ug did not result in significant 
differences in AQLQ (MD, 0.10 [95%CI = -0.04, 0.23] but did increase the time to 
first exacerbation requiring OCS (HR for placebo, 0.79 [95%CI = 0.62, 1.01]). Asthma 
exacerbations requiring hospitalization were too infrequent in both the tiotropium 
(16 of 453 subjects) and placebo (20 of 454) arms to draw conclusions (37). The 
cross-over study in adults (36) that was excluded from the primary analysis, 
similarly noted beneficial effects of tiotropium 5 ug (MD, 139ml [95%CI = 96, 
181ml]) and 10 ug (MD, 170ml [95%CI = 128, 213]) on peak FEV1 response in 
adults. 
 
Adverse events were less frequent in the tiotropium arms compared to placebo in 
these four trials (RR=0.92 [95%CI=0.86-0.98]. Severe adverse events were equally 
infrequent across treatment arms.  
Benefits 
Long-acting muscarinic antagonist treatment in children, adolescents and adults 
with severe asthma may improve FEV1 and may reduce loss of asthma control. In 
adults, treatment with tiotropium 5 ug also improves asthma control and increases 
time to the first exacerbation. 
Harms 
There was a lower frequency of adverse events in children, adolescents and adults 
treated with tiotropium 5 ug compared to placebo. The frequency of severe adverse 
events was also low and nearly equal to placebo. 
 
Conclusions and research needs: 
The addition of tiotropium improves FEV1 and provides beneficial effects on 
symptom control in children, adolescents, and adults with severe asthma not 
controlled with GINA step 4-5 and NAEPP step 5 combination therapies. There were 
too few severe exacerbations requiring OCS to draw definitive conclusions as to 
benefit. Based on the estimated beneficial effects observed for tiotropium, the Task 
Force judged that these benefits outweigh the adverse effects, burdens, and costs 
associated with this treatment for the management of severe asthma. 
In the combined age groups, tiotropium was effective in preventing the composite 
outcome for asthma worsening inclusive of symptom control and exacerbations. 
However, the effect of treatment was not significant in adolescents and children 
likely due to the smaller sample sizes and shorter study duration of these trials. 
There is insufficient evidence for the beneficial effects of tiotropium on severe 
exacerbations in children and adolescents with severe asthma, which should be 
investigated in longer-term trial cohorts of sufficient size. There are additional long-
acting muscarinic antagonists (umeclidinium, glycopyrronium) currently available 
which could be alternative long-term bronchodilator therapies for severe asthma. 
Treatment with umeclidinium and glycopyrronium have beneficial effects on lung 
function and symptom control in individuals with mild-to-moderate, persistent 
asthma (39-41), but have not been evaluated as an adjunct therapy for severe 
asthma.  
Future studies should also focus on the identification of severe asthma subgroups 
preferentially responsive to long-acting muscarinic antagonists that might benefit 
from the step-wide addition of muscarinic antagonists compared to alternative step-
up options such as long-acting beta agonists or increased ICS dosing. Subgroup 
analyses of trial cohorts with mild-to-moderate persistent asthma subjects have 
suggested that subgroups with fixed or baseline airflow obstruction might 
preferentially respond to long-acting muscarinic antagonists (41, 42). Three 
randomized-controlled trials only included subjects with an FEV1<80% predicted. 
Kerstjens and colleagues showed beneficial effects in both those with screening 
FEV1<60% or 60-80% predicted(43). Two trials in children and adolescents 
enrolled asthma patients with an FEV1 between 60-90% predicted (38, 44). Hence, it 
is not clear whether individuals, particularly adults, with severe asthma and higher 
lung function on combination therapy with high-dose inhaled glucocorticoids and a 
long-acting beta agonist will benefit from the addition of a long-acting muscarinic 
antagonist. 
A responder analysis of a severe asthma trial cohort showed equally beneficial 
effects when comparing subgroups based on baseline lung function, age, sex, 
ethnicity, BMI, and racial groups. Differential inter-racial effects are difficult to 
ascertain since minority racial groups (African Americans and Asians) and Hispanic 
ethnic groups represented the vast minority of subjects in these trials (43). Future 
trials in increasingly ethnically diverse severe asthma cohorts should provide 
insight into the beneficial effects of long-acting muscarinic antagonists in these 
groups, which experience a substantial proportion of asthma-related morbidity. 
Studies to evaluate responder subgroups based on genetic variation 
(pharmacogenetic studies) should also be performed using DNA samples from prior 
and future clinical trials. 
What others are saying:  
GINA guidelines for the Diagnosis of Management of Severe Asthma published in 
2018 recommend the use of tiotropium as an add-on therapeutic option at step 4 or 
5 for patients with exacerbations despite treatment with ICS and LABA. The NAEPP 
guidelines do not outline any role for the muscarinic antagonists. 
ATS/ERS recommendation 
For children, adolescents, and adults with severe asthma uncontrolled despite GINA 
step 4-5 or NAEPP step 5 therapies, we recommend the addition of tiotropium 
(strong recommendation, moderate quality of evidence). 
 
 
Remarks 
While the taskforce only found data on the efficacy of 5ug in adults with severe asthma, 
the effects on lung function were similar to the FDA-approved 2.5ug and 5mcg doses 
evaluated in parallel, placebo-controlled trials of adults with mild-moderate asthma. In 
addition, clinical trials in adolescents with moderate and severe asthma showed that the 
2.5 and 5ug doses were similarly effective. This recommendation places a high value 
on improving symptom control and reducing exacerbations. The strength of the 
recommendations is based on the following considerations when comparing the 
addition of tiotropium versus no addition. The evidence suggested with moderate 
certainty a large benefit and trivial harm with the balance of effects clearly favoring 
the intervention. Tiotropium was considered probably acceptable and probably 
feasible to implement. This recommendation also accounts for the feasibility of this 
inhaled therapy compared to the cost and burden of alternative add-on biologic 
therapies for severe asthma. 
 
Should a macrolide (i.e., azithromycin, clarithromycin) be used in adults and 
children with severe asthma?   
Summary of the evidence 
 
The previous ERS/ATS guidelines made a conditional recommendation that long-
term macrolide antibiotics should not be used in the treatment of adults or children 
with severe asthma, based on available evidence. Since then, 6 RCTs have been 
conducted (45-50), of which 5 included only adults and 1 included only children 6 to 
< 18 years of age.  There were varying definitions of persistent symptomatic or 
uncontrolled asthma, and none met ERS/ATS criteria for severity.  Three studies 
used azithromycin; of these, two (totaling 529 participants) used doses ranging 
from 250 mg to 500 mg  three times per week for a treatment period of 26 – 48 
weeks(45, 46). The other (n=97) used a dose of 600mg/day for 3 days and 
600mg/week thereafter for 11 weeks(48). The clarithromycin RCTs (totaling 171 
participants) used 600mg twice daily ranging from 8 to 16 weeks in treatment 
duration(49, 50). In children (n=55), azithromycin nightly doses were given 
according to body weight, ranging from 250 mg for 25 – 40kg and 500mg for > 40kg 
for a total of 12 months (the study was prematurely terminated at 30 weeks due to 
lack of clinical efficacy) (47).  
Compared to placebo, during 48 weeks of follow up, azithromycin reduced the 
number of combined moderate and severe exacerbations (1.07 vs. 1.86 
events/patient/year; RR=0.59; 95% CI 0.47, 0.74)(46). Additionally, macrolides 
reduced the number of patients with at least one moderate or severe asthma 
exacerbation and the time to first exacerbation. It did not, however, reduce the rate 
of severe exacerbations (25.3% vs. 34.6%; RR 0.77; 95%CI 0.44, 1.34) in children or 
adults, during a follow up period ranging from 24 – 48 weeks (45-47).  Neither 
azithromycin nor clarithromycin treatment improved ACQ-7 (MD 0.11; 95%CI -0.34, 
0.12) or AQLQ (MD 0.16; 95%CI -0.06, 0.37) in adults beyond the MCID.   
Relative to placebo, treatment with azithromycin or clarithromycin in adults or 
children was not associated with changes in postbronchodilator FEV1% predicted 
(MD 1.95; 95%CI -2.42, 6.32) or prebronchodilator FEV1 L (MD 0.37; 95%CI -2.17, 
2.91) that reached the MCID (45, 48, 49).  
The effects of clarithromycin on airway inflammation were inconsistent with only 
one of two studies showing significant reductions in airway neutrophilia(50).  
Compared to placebo, macrolide therapy in adults was associated with a lower 
number of lower respiratory tract infections requiring antibiotics (20.9% vs. 35.6%; 
RR 0.60; 95%CI 0.45, 0.79)(45, 46).  
The number of study participants with at least 1 adverse event (67.3% vs. 72.2%; 
RR 0.93; 95%CI 0.73, 1.19) and the number of serious adverse events (9.1% vs. 
11.4%; RR 0.81; 95%CI 0.52, 1.24) in adults or children, were not different from 
placebo(45, 46, 48, 49).  
 
Benefits 
Macrolides reduce the number of asthma exacerbations, and at least one study 
suggests that this effect is similar for participants with or without eosinophilia(46). 
The effect on asthma control and quality of life does not reach the MCID.   
 
Harms 
Chronic macrolide therapy has been associated with increased incidence of 
diarrhea; however, the number of serious adverse events or number of participants 
with at least 1 adverse event is not different to placebo. Although macrolides have a 
potential risk for QT prolongation or hearing loss, the frequency of these events are 
not reported to be higher than in the placebo arm in patients whom at baseline had 
no hearing deficits or abnormally prolonged QTc (46).  Relative to placebo, the 
prevalence of nasal and oropharyngeal macrolide-resistant Streptococcus increased 
in one study (45) but not in another (46). Those treated with azithromycin for 48 
weeks, had reduced airway H. influenzae load, with no changes to total or 
pathogenic bacterial loads. Although sputum macrolide resistance genes increased 
in this group, there was a lower rate of antibiotic use and of adverse events due to 
clinically diagnosed infections (46, 51).   
 
Conclusions and research needs 
Relative to placebo, chronic macrolide therapy reduces the risk of having an asthma 
exacerbation. However, there is no conclusive evidence that treatment shows any 
effect in reducing severe exacerbations or hospitalisations. The effects of macrolides 
on asthma has been limited to participants with uncontrolled or persistently 
symptomatic disease that may or may not be exacerbation prone; therefore, it is 
unknown whether this therapy will improve outcomes among those meeting 
ERS/ATS criteria for severe asthma. The emergence of antimicrobial resistance 
associated with prolonged antibiotic use such as macrolide therapy is a critical 
public health issue. Potential benefits in severe asthma need to be carefully 
considered against this background risk from both the perspective of an individual 
patient and the wider community.   
 
 
 
 
What others are saying 
GINA guidelines  recommend prescribing add-on low-dose macrolide in patients 
who do not respond to standard treatment, but classify its use off-label and suggest 
weighing the benefits against the potential for antibiotic resistance.  In the 
BTS/SIGN 2016 guidelines , the use of macrolide antibiotics in asthma was not 
recommended; new guidelines for the long-term use of macrolides are under 
preparation. The FDA has not approved the use of chronic macrolide therapy for 
asthma.  
ERS/ATS Recommendation 
We suggest a trial of macrolide treatment to reduce asthma exacerbations in adult 
asthmatics on GINA/NAEPP step 5 therapy that remain persistently symptomatic or 
uncontrolled (conditional recommendation, low quality of evidence) 
We suggest against the use of chronic macrolide treatment in children and 
adolescents with severe uncontrolled asthma (conditional recommendation, low 
quality of evidence). 
Remarks: This recommendation is conditional and based on the need to avoid 
exacerbations and reduce OCS.  The benefits and safety of using macrolides for 
asthma beyond 1 year has not been determined.  
 
 
 
 
 
 
Should an anti-interleukin 4/13 strategy be used for adults and children with 
severe asthma? 
Summary of the evidence 
Dupilumab is a fully human monoclonal antibody directed against the alpha subunit 
of interleukin-4 receptor. It blocks signaling of two key type-2 cytokines; IL-4 and 
IL-13.   We identified three randomized, placebo-controlled trials evaluating 
dupilumab as add-on therapy in patients with moderate-to-severe asthma (52-54). 
Two RCTs included adolescent (ages 12-17) and adult (age >18 years) participants 
(53, 54) and one trial included only adult participants (52).  
In the phase 2b dose-ranging clinical trial (52), four dosing regimens of dupilumab 
were studied: 200 or 300 mg of the drug administered subcutaneously every 2 or 4 
weeks for 24 weeks. 769 adult patients with uncontrolled asthma, despite use of 
medium to high dose ICS and LABA, were randomized 1:1:1:1:1 into four treatment 
arms or placebo. Primary endpoint was change in FEV1 (L) at 12 weeks in patients 
with blood eosinophil counts of at least 300 cells/mm3. Prespecified secondary 
endpoints at weeks 12 & 24 included asthma exacerbation rate, time to severe 
exacerbation, asthma symptom score, asthma quality of life and change in FEV1 
(%predicted). 
One phase 3 efficacy and safety RCT (53) was in adolescents and adults with 
moderate to severe uncontrolled asthma and it evaluated dupilumab add-on 
therapy at doses 200 mg (after a loading dose of 400mg) or 300 mg (after a loading 
dose of 600 mg) every 2 weeks for 52 weeks. A total of 1902 participants were 
randomized 2:2:1:1 with matched volume placebo. The primary endpoints were 
annualized exacerbation rates (week 52) and absolute change in FEV1 (week 12). 
Secondary endpoints included change in FEV1% predicted, ACQ, AQLQ as well as 
subgroup analysis by blood eosinophil count.  
 
The second phase 3 RCT (54) evaluated dupilumab (300 mg every 2 weeks for 24 
weeks) in 210 adolescents and adults with severe oral glucocorticoid-dependent 
asthma. After a steroid dose-optimization period, patients were randomized 1:1 to 
receive dupilumab or placebo. OCS dose was adjusted down during weeks 4-20. 
Primary endpoint was percent reduction in OCS dose required to maintain asthma 
control. Secondary endpoints included proportion of patients with at least 50% 
reduction in OCS dose and proportion of patients with reduction in OCS dose to <5 
mg/d. 
 
These three trials were pooled for meta-analysis (see evidence profiles in the 
supplementary material). Effects of dupilumab on exacerbation rate, asthma control, 
asthma quality of life, lung function and side effects were assessed for 200mg and 
300mg doses at 24 and 52 weeks. Differences in effect size by blood eosinophils 
were also assessed. 
 
Relative to participants assigned to placebo, those assigned to dupilumab (200 mg 
or 300 mg every 2 weeks; 24 and 52 weeks) experienced substantial (46-70.5%) 
reduction in annualized rates of asthma exacerbations.  Dupilumab therapy resulted 
in greater proportion of participants with OCS-dependent severe asthma 
experiencing > 50% reduction in OCS dose (relative risk [RR]1.49; 95% Ci 1.22-1.83; 
AR 26 more achieved 50% reduction per 100 [95%CI 12 – 44]), reduction in OCS 
dose to < 5mg/d (RR 1.92; 95%CI 1.46-2.53; AR 344 more per 1,000 [95%CI 172 – 
572]) and discontinuation of maintenance OCS (RR 1.81; 95%CI 1.28-2.57). 
Improvements in FEV1, ACQ-5 and AQLQ were statistically significant but did not 
reach MCID.  
 
The effect size for all above outcomes was larger in patients with blood eosinophil 
counts > 300 cells/mm3 when compared with eosinophils <300 cells/mm3 (see 
evidence profiles in supplementary material).  One study further stratified the study 
cohort by blood eosinophils <150 cells/mm3, 150-300 cells/mm3 and > 300 
cells/mm3 (53).  Rate ratio for annualized severe exacerbation event rate at 52 
weeks, pooled for doses 200 and 300 mg every 2 weeks, was 0.33 (95% CI 0.26-
0.42); 0.386 versus 1.158 events/patient/year for subgroup with blood eosinophils 
> 300 cells/mm3, 0.60 (96% CI 0.43-0.83); 0.515 versus 0.855 events/patient/year 
for blood eosinophils 150 - 300 cells/mm3 and 1.04 (95% CI 0.76-1.43); 0.604 
versus 0.576 events/patient/year for blood eosinophils < 150 cells/mm3.  The same 
study reported similar results for exacerbations and lung function when stratified 
by FeNO >50 ppb, > 25-<50 ppb and <25 ppb. A post-hoc biomarker interaction 
analysis found the greatest treatment response in patients with FeNO > 25 ppb and 
blood eosinophils > 150 cells/mm3. 
 
Benefits 
Dupilumab, as add-on therapy in patients with asthma that is uncontrolled on 
medium-high dose ICS + LABA, may reduce exacerbations and improve asthma 
symptoms and lung function. The efficacy is greater in patients with type 2 
biomarkers (blood eosinophils > 150 cells/mm3 or FeNO > 25 ppb) Dupilumab may 
reduce OCS dose in patients with severe CS-dependent asthma.   
Harms 
The risk of dupilumab therapy appears to be small with injection site reaction as the 
most common treatment related adverse effect. Frequency of serious and any side 
effects were similar with dupilumab when compared with placebo. However, the 
mechanisms and potential clinical significance of treatment-related transient blood 
eosinophilia is not fully understood and needs further elucidation. Because 
dupilumab-mediated eosinophilia has not been associated with adverse events, 
there are no specific monitoring recommendations.  
 
Conclusions and research needs 
Dupilumab add-on therapy substantially decreases exacerbations in moderate to 
severe uncontrolled asthma (52-54). It is effective in reducing OCS dose in patients 
with severe OCS-dependent asthma. Dupilumab therapy is also associated with 
improvements in lung function, asthma control and quality of life. More robust 
improvements were observed in patients with greater eosinophil levels.  
 
Ongoing and future studies should provide additional information on long-term 
safety and durability of response to dupilumab therapy. More data on efficacy and 
safety are also needed in children and adolescents. Future studies should also focus 
on identifying specific disease and population characteristics that can predict 
response to this therapy.  
 
What others are saying 
GINA recommends dupilumab as add-on option for patients with severe 
eosinophilic or Type-2 asthma uncontrolled on high dose ICS-LABA, or requiring 
maintenance OCS. NICE guidelines do not currently include dupilumab as add-on 
therapeutic option for asthma.  
 
ERS/ATS recommendation 
We suggest dupilumab as add-on therapy for adult patients with severe eosinophilic 
asthma, and for those with severe corticosteroid-dependent asthma regardless of 
eosinophil levels (conditional recommendation).  
 
Remark: These recommendations place a high value on reducing exacerbations and 
steroid exposure and a lower value on cost or burden of the intervention. 
The high cost of dupilumab and its impact on cost effectiveness, equity and 
feasibility to implementation must be weighed by clinicians in relation to its benefits 
on asthma outcomes). Due to limited number of adolescents treated with anti-
IL4/13, the TF was unable to provide a recommendation for this age group and no 
available evidence exists for children < 12 yrs.  
 
  
Discussion 
The ERS/ATS severe asthma Task Force evaluated 6 questions that were not 
addressed in previous guidelines. We conducted a systematic literature search and 
GRADE analysis to inform recommendations for each specific PICO question 
regarding the management of severe asthma. The balance of benefits versus 
burdens, adverse effects and costs; the quality of evidence; the feasibility and the 
acceptability were all considered in developing each recommendation (See Table 2) 
A conditional recommendation was made for the use of anti-IL5 & anti-IL4/13 
strategies for severe uncontrolled eosinophilic phenotype. Anti-IL4/13 is also 
indicated for systemic corticosteroid dependent severe asthmatics regardless of 
eosinophilic status. Specific eosinophil and FeNO cutoffs were recommended to 
identify those with the greatest likelihood or response to anti-IL5 or anti-IgE 
therapy. The use of inhaled tiotropium was recommended for adolescents and 
adults with severe asthma uncontrolled despite GINA step 4-5 or NAEPP step 5 
therapies. A trial of chronic macrolide therapy was conditionally suggested to 
reduce asthma exacerbations in persistently symptomatic or uncontrolled patients 
on GINA step 5 or NAEPP step 5 therapies. These recommendations should be 
reconsidered when new evidence becomes available. 
 
 
It has long been appreciated that the conventional requirements for a good 
randomised controlled clinical trial do not reflect the reality of patients seen in the 
clinics(55-57). Stringent diagnostic requirements are imposed, for example in adults 
often smoking asthmatics are excluded to avoid an inadvertent mis-diagnosis of 
COPD. However, this is illogical; non-smokers also get COPD, and those who smoke 
and have asthma may be more steroid resistant and thus more, not less likely to 
profit from biologicals. Frequently there is a requirement for acute bronchodilator 
reversibility to be demonstrated, even though this is not predictive of a response to 
treatment and there is no uniform definition.  
 
There could be two reasons for excluding a severe asthmatic patient from a trial of 
(for example) an anti-type-2 monoclonal(55, 57). The first entirely logical reason, 
would be the absence of any evidence of  type-2 activity, and the second, far more 
dubious, the presence of type-2 activation but a co-existent disqualification such as 
smoking or the absence of variable airflow obstruction. The Wessex group recently 
evaluated 37 RCTs of type-2 biologicals, and found that just fewer than 10% of all 
their patients could have been enrolled, commonest reasons for exclusion being 
failure to demonstrate either or both of fixed and variable airflow obstruction(55). 
The exclusion rate for patients with eosinophilic asthma was even higher. In the 
accompanying editorial(58), it was argued that the right approach for future trials 
of, for example, anti-type-2 strategies, would be to include all those with the 
treatable trait of airway eosinophilia, irrespective of whether there were any other 
features of asthma present. This is in line with the approach advocated by the Lancet 
commission(57), and also the finding of benefit of anti-type-2 strategies in 
‘eosinophilic COPD’(59, 60). Fortunately the licensing authorities have taken the 
approach of focusing on the treatable trait of airway eosinophilia, because 
otherwise, many patients who could benefit would not have access to these 
medications. It would be important in post-marketing surveillance, which should be 
mandated for expensive medications, to confirm that features such as smoking and 
fixed airflow obstruction do not affect response to therapy. 
 
Another important question arising is whether only patients with genuine severe, 
therapy resistant asthma should be eligible for biologicals. The initial ERS-ATS Task 
Force definition, as with so many others, defined severity by the level of prescribed 
treatment in association with adverse outcomes such as asthma, chronic symptoms 
and risk. Inherent in the definition is that adherence to medication has been 
checked and found to be adequate. However, it is increasingly clear that patients 
prescribed much lower doses of medication are at risk of asthma attacks and death. 
In the UK National Review of Asthma Deaths(61, 62), around 60% of those who died 
did not meet ERS-ATS criteria for severe asthma. Important factors, as well as the 
expected positive predictive effect of a previous acute attack, were: under-use of 
ICS, over use of short-acting β-2 agonists, and failure to engage with regular 
monitoring visits. Severe asthma specialty clinics can help these patients become 
well controlled by addressing reversible factors like poor adherence. However, 
there are a hard core of patients, termed ‘refractory difficult asthma’ who continue 
with poor adherence and other risk-taking activities despite multiple interventions; 
in other words, adherence has been optimized as far as possible, but is still 
inadequate. It has been argued elsewhere that such children – or other non-
adherent patients – should be offered biologicals if they have the necessary 
treatable airway trait, to prevent asthma deaths(63, 64). The same argument has 
been advanced in adults. This is not a group that are included in randomised 
controlled trials, so we cannot make evidence based recommendations. However, it 
seems not unreasonable that a persistent treatable trait, whether steroid resistant 
or uncontrolled because of social factors, should be treated the same way 
irrespective of cause. However, the condition of giving biologicals to the non-
adherent must be that it is directly observed in hospital, such patients cannot be a 
candidate for home therapy. 
 
A future challenge is to ensure that children who might benefit from biologicals 
actually receive them. There are clear phenotypic differences between paediatric 
and adult asthma(65), and although atopy is very common in severe paediatric 
asthma, it is by no means clear that airway eosinophilia is necessarily type-2 
driven(66). Indeed, even in adult asthma, non-type-2 eosinophilic endotypes are 
being discovered(67). Also, there is reason to suppose that anti-eosinophil 
strategies may be deleterious in children, given the role of the eosinophil in immune 
homeostasis(68). There are extensive paediatric data on efficacy and safety of the 
anti-IgE monoclonal omalizumab(69-71), so there should be no reason not to 
replicate these studies for other anti-IL5 trategies, in the absence of a reliable 
biomarker of efficacy. In summary, it is essential to do paediatric trials of these new 
agents that evaluate the impact of these treatments on development and long-term 
outcomes, and also to pursue research into biomarkers of efficacy(72). 
 
There is another troubling aspect concerning the application of biologicals in 
children. The conventional sequence of medication testing is in adults first, and then 
if safety and efficacy is demonstrated, performing studies in children. If there is no 
efficacy in adults, then the medication is not tested further. An obvious example is 
the anti-IL13 monoclonal Tralokinumab(73, 74). At least three randomised 
controlled studies in adults failed to show significant clinical efficacy(75-77), and 
there are no plans to do a paediatric trial, on the basis that the data shows that the 
IL13 pathway is not crucial in airway eosinophilia. It is true that adolescents age 
over 12 years are included in these studies, but the actual numbers enrolled are 
dwarfed by adult participants. Although this seems a logical conclusion in adults, 
there are no data to confirm or refute this in children; is it conceivable that a 
potentially valuable paediatric monoclonal has been discarded wrongly? It would be 
very difficult to prioritise a paediatric Tralokinumab trial at present, but it does 
highlight the need to better understand the similarities and differences between 
adult and paediatric endotypes. 
 
Although this document has reviewed a large body of high quality evidence, and 
highlighted new evidence that OCS dose and asthma attack risk can be substantially 
reduced, there is much work still to be done. Mepolizumab, benralizumab and 
reslizumab all target the type-2 pathways, and it is more than likely that further 
similar compounds will be licensed. The question that arises is, how to determine 
which of an overlapping series of biologicals should be prescribed for the individual 
patient. Although the majority of studies reviewed here focused on peripheral 
eosinophils as a marker of type-2 inflammation, other biomarkers such as FeNO 
could offer additional information in identifying sub-endotypes. We speculate that 
additional type-2 pathway biomarkers will need to be identified in order to do this 
effectively, and in this regard, the systematic analyses of  existing severe asthma 
cohorts such as SARP and U-BIOPRED will be invaluable. Although group data may 
show one or other is marginally better, it is inconceivable that one will be superior 
for all individuals. Of course, a series of N-of-1 trials can be carried out, but this is 
hardly scientific therapeutics. Furthermore, combination of biologics may prove to 
be better on the  speculation e that Type 2 inflammation may be most effectively 
abrogated by blocking all the signature type-2 cytokines, IL4, IL5 and IL13 with 
dupilumab combined with an anti-IL-5  or anti-IL5Ra strategy. Pragmatic clinical 
trials may potentially provide answers to these questions for real-life clinical 
practice(78).   
Another future challenge is the role of biologicals in low and middle income (LMIC) 
settings, as the majority of data derive from a developed world setting. There may 
well be different asthma endotypes across the world, and more importantly, the 
significance of a raised blood eosinophil count in a region with a high burden of 
parasitic infections may be different. The WHO defined three groups of severe 
asthma of which untreated severe asthma is most relevant to LMIC(79). The first 
priority must be to ensure that basic asthma medications are uniformly available 
across the world, which will then enable us to obtain data on the true prevalence of 
severe, therapy resistant asthma and refractory difficult asthma in a LMIC setting. 
The most difficult challenge will be the cost of these medications, and making them 
available to those who would benefit outside a resource-rich area. This challenge is 
not of course unique to asthma. 
 
Finally, most of the work on the new asthma therapies has been on their role in 
preventing asthma attacks, where they have been very successful. In the future, they 
may have a role in the aftermath of an acute asthma attack. Provided the patient 
reaches an emergency facility in time, the basic treatment of an asthma attack is 
straightforward. Much more difficult is to prevent a further attack, and it has been 
highlighted that the period of highest risk is in the month after the signal attack(61, 
62). Given that outside the pre-school years, asthma attacks are caused by 
respiratory viral infection on the background of uncontrolled type-2-driven airway 
inflammation, and anti-type-2 strategy as a single injection might well be a 
promising strategy to reduce relapse, especially as it would not require adherence, 
and would potentially be efficacious to buy time while other social and 
environmental factors are addressed. More data are needed before this strategy can 
be recommended.  
 
In summary, the PICOs studied here have enabled the Task Force to make 
recommendations for the treatment of severe asthma, which should lead to 
modifications of guidelines and improvement in outcomes which are important to 
patients, namely reduction in OCS dose and exacerbation frequency, and improved 
quality of life. However, we recognize that these recommendations will not be 
effective across all severe asthmatics and that more precise phenotype-driven 
research is needed. We also reiterate that, prior to adopting these novel and in many 
cases invasive and expensive approaches, every effort should be made to deploy 
standard medications to maximum benefits. However for the minority of patients 
with asthma who, for whatever reason, do not respond to standard therapies and 
continue to experience  frequent exacerbations, we are in an exciting new and 
evolving world of novel, beneficial approaches.     
 
Table 2. Task Force recommendations for the management of severe asthma  
Recommendation  Strength  Quality of evidence  
We suggest anti-IL5 strategy as add-on therapy for 
adult patients with severe uncontrolled asthma with 
an eosinophilic phenotype and for those with severe 
corticosteroid-dependent asthma 
 
Conditional Varied by treatment* 
We suggest that a blood eosinophil cut-point of ≥ 
150/μl can be used to guide anti-IL5 initiation in adult 
patients with severe asthma and prior exacerbations.  
Conditional  Low 
We suggest using a blood eosinophil cut-off of ≥ 260 
/μl to identify adolescents (>12 years) and adults with 
severe allergic asthma more likely to benefit from 
anti-IgE treatment 
Conditional  Low  
We suggest using a FeNO cut-off of ≥ 19.5 ppb to 
identify adolescents (>12 years) and adults with 
severe allergic asthma more likely to benefit from 
anti-IgE treatment  
Conditional  Low 
For children, adolescents, and adults with severe 
asthma uncontrolled despite GINA step 4-5 or NAEPP 
step 5 therapies, we recommend the addition of 
tiotropium 
Strong Moderate 
We suggest a trial of macrolide treatment to reduce 
asthma exacerbations in adult asthmatics on 
GINA/NAEPP step 5 therapy that remain persistently 
symptomatic or uncontrolled. We suggest against the 
use of chronic macrolide treatment in children and 
adolescents with severe uncontrolled asthma 
Conditional  Low 
We suggest dupilumab for adult patients with severe 
eosinophilic asthma, and for those with severe 
corticosteroid-dependent asthma regardless of 
eosinophil levels 
Conditional Low 
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GRADE Evidence Profile: MEPOLIZUMAB 
Bibliographya: Bel 2014, Chupp 2017, Ortega 2014  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Mepolizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Quality of life (change from baseline) (follow up: range 24 weeks to 32 weeks; assessed with: St George's Respiratory Questionnaire; Scale from: 0 to 100; higher scores indicate more limitations; MCID 4 
units) 
3 1,2,3 randomised 
trials 
not serious  not serious  not serious 
b 
not serious  none  537  534  -  MD 7.14 lower 
(9.07 lower to 5.21 
lower) 
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Asthma control (change from baseline) (follow up: range 24 weeks to 32 weeks; assessed with: Asthma Control Questionnaire (ACQ-5); Scale from: 0 to 6; lower values indicate better asthma control; MCID 
0.5) 
3 1,2,3 randomised 
trials  
not serious  not serious  not serious 
b 
serious c none  537  534  -  MD 0.43 lower 
(0.56 lower to 0.31 
lower) 
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Asthma symptoms (change from baseline) (follow up: 24 weeks; assessed with: Asthma symptom score; Scale from: 0 to 5; higher scores indicate more frequent symptoms and more limitations) 
1 2 randomised 
trials  
serious d not serious  not serious 
e 
not serious  none  266  259  -  MD 0.2 units lower 
(0.03 lower to 0.37 
lower) 
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Lung function (Pre-bronchodilator FEV1 % predicted) (follow up: range 24 weeks to 32 weeks; MCID 10.38%4) 
2 1,3 randomised 
trials  
serious f not serious  not serious 
b 
not serious 
g  
none  Graphs presenting results from Bel 2014 and Ortega 2014  showed 
the mepolizumab group had higher FEV1 % predicted than the 
placebo group at the end of the studies, however the 95% CI around 
the central estimate from each treatment arm overlap. This suggests 
the difference between groups in non-significant.  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Lung function (Pre-bronchodilator FEV1 litres, change from baseline) (follow up: range 24 weeks to 32 weeks; MCID 0.23 litre4) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Mepolizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
2 1,2 randomised 
trials  
not serious  not serious  not serious 
b 
not serious 
h 
none  468  468  -  MD 0.11 higher 
(0.06 higher to 0.17 
higher)  
⨁⨁⨁⨁ 
HIGH  
IMPORTANT  
Lung function (Post-bronchodilator FEV1 litres, change from baseline) (follow up: range 24 weeks to 32 weeks; MCID 0.23 litre4) 
3 1,2,3 randomised 
trials  
serious i not serious  not serious 
b 
not serious  none  Ortega 2014 reported the mean difference from placebo (95%CI) = 
0.138 L (0.043 to 0.232 L), P = 0.004. Two studies reported a non-
significant difference favouring mepolizumab: Bel 2014,  (0.128 L, P = 
0.06) and Chupp 2017 (data not shown). 
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Rate of any exacerbation (follow up: range 24 weeks to 32 weeks) 
3 1,2,3 randomised 
trials  
not serious  not serious  not serious 
b 
not serious  none  537  534  Rate ratio 
0.50 
(0.39 to 0.65)  
Incidence rate 
(events/patient/year): 
mepolizumab 0.92; 
placebo 1.69  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Time to first asthma exacerbation (follow up: 32 weeks) 
1 1 randomised 
trials  
not serious  not serious  not serious j not serious  none  Hazard ratio (95% CI) (mepolizumab/placebo) = 0.44 (0.32, 0.60), p 
<0.001. Number of patients: 194 (mepolizumab) and 191 (placebo).  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Rate of exacerbations requiring emergency department visit or hospitalisation (follow up: range 24 weeks to 32 weeks) 
2 1,2 randomised 
trials  
not serious  not serious  not serious 
b 
not serious  none  468  468  Rate ratio 
0.36 
(0.20 to 0.66)  
 Incidence rate 
(events/patient/year): 
mepolizumab 0.05; 
placebo 0.15  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Rate of exacerbations requiring hospitalisation (follow up: range 24 weeks to 32 weeks) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Mepolizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
2 1,2 randomised 
trials  
not serious  not serious  not serious 
b 
not serious  none  468  468  Rate ratio 
0.31 
(0.13 to 0.73)  
Incidence rate 
(events/patient/year): 
mepolizumab 0.02; 
placebo 0.07 (from 
Chupp 2017) 
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Adverse events (follow up: range 24 weeks to 32 weeks) 
3 1,2,3 randomised 
trials  
not serious  not serious  not serious 
b 
not 
seriousk,l 
none  401/536 
(74.8%)  
426/535 
(79.6%)  
RR 0.93 
(0.88 to 0.99)k  
56 fewer per 1,000 
(from 8 fewer to 96 
fewer)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Drug-related adverse events (follow up: range 24 weeks to 32 weeks) 
3 1,2,3 randomised 
trials  
not serious  not serious  not serious 
b 
not serious 
l 
none 91/536 
(17.0%) 
67/535 
(12.5%) 
RR 1.35    
(1.01 to 1.80) 
44 more per 1,000 
(from 1 more to 100 
more) 
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Serious adverse events (follow up: range 24 weeks to 32 weeks) 
3 1,2,3 randomised 
trials  
not serious  not serious m not serious 
b 
not serious 
n 
none  32/536 (6.0%)  62/535 
(11.6%)  
RR 0.50 
(0.24 to 1.05)  
58 fewer per 1,000 
(from 88 fewer to 6 
more)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Systemic steroids (absolute final dose) (follow up: 24 weeks) 
1 3 randomised 
trials  
not serious  not serious  not serious  serious o none  Prednisone dose (mg) at study weeks 20-24 were: placebo group, 
mean (standard deviation, SD) = 10.5 (7.8); median (range) = 10.0 (0-
30). Mepolizumab group, mean (SD) = 8.6 (11.9); median (range) = 
3.1 (0-67). No statistical test comparing results from the two groups 
has been reported.p 
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Systemic steroid (percent reduction) (follow up: 24 weeks) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Mepolizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 3 randomised 
trials  
not serious  not serious  not serious  serious o none  Median percent reduction from baseline in daily oral glucocorticoid 
dose (95% CI): Placebo = 0.0 (-20.0 to 33.3), Mepolizumab = 50.0 
(20.0 to 75.0), p = 0.007.q   
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Loss of work or school days, Intensive care unit admission, Non-invasive ventilation, Intubation, Comorbidities, Upper airway symptoms - not reported 
-  -  -  -  -  -  -  -  -  -  -  -   
CI: Confidence interval; FEV1: forced expiratory volume in 1 second; MCID: minimal clinically important difference: MD: Mean difference; HR: Hazard Ratio; RR: Risk ratio 
Explanations 
a. The participants included in the three studies have been considered by the Task Force to represent a population of severe asthmatics as defined by the ERS/ATS Guidelines on Severe Asthma 20145.  
b. Chupp 2017 and Ortega 2014 inclusion criteria for participants 12-17 years of age required treatment with inhaled corticosteroids at lower doses than those recommended by the ERS/ATS Guidelines on Severe Asthma 
20145. The proportion of included participants 12-17 years of age was not specified, however we have assumed this proportion was small relative to each study's total population and therefore we have not downgraded for 
indirectness.  
c. The ends of the 95% confidence interval include appreciable clinical benefit (MCID = 0.5) and no benefit and could lead to different clinical decisions.  
d. This outcome has been planned by Bel 2014 and Ortega 2014, as specified in the study protocols, but has not been reported.   
e. Chupp 2017 inclusion criteria for participants 12-17 years of age required treatment with inhaled corticosteroids at lower doses than those recommended by the ERS/ATS Guidelines on Severe Asthma 20145. The 
proportion of included participants 12-17 years of age was not specified, however we have assumed this proportion was small relative to the total study population and therefore we have not downgraded for indirectness.  
f. This outcome has been reported incompletely by Bel 2014 and Ortega 2014 so that results cannot be entered in a meta-analysis (high risk of selective outcome reporting bias).  
g. The results of the primary studies have been presented in graphical format only and cannot be entered in a meta-analysis. As we have downgraded the rating of risk of bias for this same reason, we have decided not to 
downgrade the rating of imprecision. 
h. Bel 2014 reported the mean difference in pre-bronchodilator FEV1 between the mepolizumab and placebo groups to be 0.114 liters (p = 0.15). These results have been reported incompletely so that they cannot be 
entered in the meta-analysis. However the sample size on Bel 2014 is the smallest among the three included studies and the effect estimate (0.114) is very close to that from Chupp 2017 and Ortega 2014, so we 
considered it unlikely that inclusion of Bel's results would change the pooled effect estimate significantly.  
i. This outcome has been reported incompletely by Bel 2014 and Chupp 2017 so that results cannot be entered in a meta-analysis (high risk of selective outcome reporting bias).  
j. Ortega 2014 inclusion criteria for participants 12-17 years of age required treatment with inhaled corticosteroids at lower doses than those recommended by the ERS/ATS Guidelines on Severe Asthma 20145. The 
proportion of included participants 12-17 years of age was not specified, however we have assumed this proportion was small relative to the total study population and therefore we have not downgraded for indirectness.  
k.There was a high incidence of adverse events in both mepolizumab and placebo groups. The apparent benefit from mepolizumab might be explained by a reduction of asthma-related adverse events with the active drug.  
l. This judgement was based on a arbitrary clinical decision threshold of 15% increase or decrease in absolute effect.   
m. I2 = 57% (P=0.10) may represent moderate heterogeneity. However the point estimates from the 3 studies have the same direction of effect and the 95% confidence intervals overlap. For these reasons we have not 
rated down for inconsistency.  
n. This judgement was based on a arbitrary clinical decision threshold of 10% increase or decrease in absolute effect.  
o. Single study including only 135 patients.  
p. The mean and median from the mepolizumab group are very different (8.6 and 3.1). We have performed data checks (http://handbook-5-1.cochrane.org/chapter_9/9_4_5_3_meta_analysis_of_skewed_data.htm) using 
the reported mean and standard deviations which indicate a skewed distribution. So we have not used the mean and standard deviation to calculate the mean difference in systemic steroid use.  
q. Bel 2014 reported the median difference and associated confidence intervals were calculated with the use of the Hodges–Lehman estimation. P values were calculated with the use of a Wilcoxon rank-sum test. 
References 
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GRADE Evidence Profile: RESLIZUMAB 
Bibliography: Bjermer 2016, Castro 2011, Castro 2015, Corren 2016 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Reslizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Quality of life (change from baseline) (follow up: range 16 weeks to 52 weeks; assessed with: Asthma Quality of Life Questionnaire (AQLQ); Scale from: 1 to 7; higher values indicate better quality of life; 
MCID 0.5) 
3 1,2 randomised 
trials  
not serious  not serious  serious a not serious  none  576  577  -  MD 0.28 higher 
(0.17 higher to 0.39 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL 
Asthma control (change from baseline) (follow up: range 15 weeks to 52 weeks; assessed with: Asthma Control Questionnaire (ACQ-7); Scale from: 0 to 6; lower values indicate better asthma control; MCID 
0.5) 
5 1,2,3,4 randomised 
trials  
not serious  not serious  serious b not serious  none  1024  727  -  MD 0.26 lower 
(0.33 lower to 0.18 
lower)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Asthma control (change from baseline) (follow up: 15 weeks; assessed with: Asthma Control Questionnaire (ACQ-7); Scale from: 0 to 6; lower values indicate better asthma control; MCID 0.5) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 6 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious c 
none  53  53  -  MD 0.4 lower 
(0.79 lower to 0.01 
lower)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Asthma symptoms (change from baseline) (follow up: range 16 weeks to 52 weeks; assessed with: Asthma Symptom Utility Index; Scale from: 0 to 1; lower scores indicate worse asthma symptoms; MCID 
0.097) 
3 1,2 randomised 
trials  
not serious  not serious  serious a not serious  none  578  579  -  MD 0.05 higher 
(0.04 higher to 0.06 
higher)  
⨁⨁⨁◯ 
MODERATE 
CRITICAL  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Reslizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Lung function (Pre-bronchodilator FEV1 % predicted, change from baseline) (follow up: 15 weeks; MCID 10.38%5) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 6 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious d 
none  52  52  -  MD 8.63 higher 
(3.88 higher to 13.38 
higher)  
⨁⨁◯◯    
LOW  
IMPORTANT  
Lung function (Pre-bronchodilator FEV1 litres, change from baseline) (follow up: range 15 weeks to 52 weeks; MCID 0.23 litre 5) 
5 1,2,3,4 randomised 
trials  
not serious  not serious  serious b not serious  none  1024  726  -  MD 0.12 higher 
(0.07 higher to 0.17 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Lung function (Pre-bronchodilator FEV1 litres, change from baseline) (follow up: 15 weeks; MCID 0.23 litre5) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 6 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious e 
none  52  52  -  MD 0.24 higher 
(0.09 higher to 
0.39higher)  
⨁⨁◯◯ 
LOW  
IMPORTANT  
Exacerbations (patients with ≥1 exacerbation) (follow up: range 15 weeks to 52 weeks) 
3 2,4 randomised 
trials  
not serious  not serious  serious f not serious  none  155/530 
(29.2%)  
247/529 
(46.7%)  
RR 0.63 
(0.53 to 0.76)  
173 fewer per 1,000 
(from219fewer to 
112 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Exacerbations (patients with ≥1 exacerbation) (follow up: 15 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 6 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Reslizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious g,h 
none  4/53 (7.5%)  10/53 (18.9%)  RR 0.40 
(0.13 to 1.20)  
113 fewer per 1,000 
(from 164 fewer to 
38 more)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Rate of any exacerbation (follow up: 52 weeks) 
2 2 randomised 
trials  
not serious  not serious  serious f not serious  none  477  476  Rate ratio 
0.46 
(0.37 to 0.58)  
Incidence rate 
(events/patient/year): 
reslizumab 0.84; 
placebo 1.81 
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Time to first asthma exacerbation (follow up: 52 weeks) 
2 2 randomised 
trials  
not serious  not serious  serious f not serious  none  477  476  HR 0.54 
(0.44 to 0.66)  
- ⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Rate of exacerbations requiring emergency department visit or hospitalisation (follow up: 52 weeks ) 
2 2 randomised 
trials  
not serious  not serious  serious f serious g none  477  476  Rate ratio 
0.67 
(0.39 to 1.17)  
 Incidence rate 
(events/patient/year): 
reslizumab 0.08; 
placebo 0.12 
⨁⨁◯◯ 
LOW  
CRITICAL  
Exacerbations requiring emergency department visit  (patients with ≥1 exacerbation) (follow up: 15 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 6 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious g,h 
none  3/53 (5.7%) 4/53 (7.5%) Peto OR 0.74 
(0.16 to 3.40) 
19 fewer per 1,000 
(from 63 fewer to 
142 more) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Reslizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Exacerbations requiring hospitalisation  (patients with ≥1 exacerbation) (follow up: 15 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma6 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious g,h 
none  1/53 (1.9%) 0/53 (0.0%) OR 3.00 
(0.12 to 
72.02) 
NA ⨁⨁◯◯ 
LOW 
CRITICAL 
Adverse events (follow up: range 15 weeks to 52 weeks) 
5 1,2,3,4 randomised 
trials  
not serious  not serious i serious b serious j,k none  690/1028 
(67.1%)  
587/730 
(80.4%)  
RR 0.88 
(0.81 to 0.96)k  
96 fewer per 1,000 
(from 153 fewer to 
32 fewer)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Adverse events (follow up: 15 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 6 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious h,j 
none  38/53 (71.7%)  42/53 (79.2%)  RR 0.90 
(0.73 to 1.13)  
79 fewer per 1,000 
(from 214 fewer 
to103 more)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Drug-related adverse events (follow up: 16 weeks)   
2 1,3 randomised 
trials 
serious l serious m  serious a not serious 
n 
none 40/498   
(8.0%) 
24/202 
(11.9%) 
RR 0.78 
(0.22 to 2.72)  
26 fewer per 1,000 
(from 93 fewer to 
204 more)  
⨁◯◯◯ 
 VERY LOW  
CRITICAL  
Serious adverse events (follow up: range 15 weeks to 52 weeks) 
5 1,2,3,4 randomised 
trials  
not serious  not serious  serious b not serious 
o 
none  64/1028 
(6.2%)  
63/730 (8.6%)  RR 0.81 
(0.57 to 1.14)  
16 fewer per 1,000 
(from 37 fewer to 12 
more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Reslizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Serious adverse events (follow up: 15 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma6 
1 4 randomised 
trials  
not serious  not serious  not serious  very 
serious g,h 
none  2/53 (3.8%)  1/53 (1.9%)  OR 1.97 
(0.20 to 
19.40)  
18 more per 1,000 
(from 15 fewer to 
253 more) 
⨁⨁◯◯ 
LOW  
CRITICAL  
Systemic steroids (absolute final dose), Systemic steroids (percent reduction), Loss of work or school days, Intensive care unit admission, Non-invasive ventilation, Intubation, Comorbidities, Upper airway 
symptoms - not reported 
-  -  -  -  -  -  -  -  -  -  -  -   
CI: Confidence interval; FEV1: forced expiratory volume in 1 second; MCID: minimal clinically important difference; MD: Mean difference; OR: Odds ratio; RR: Risk ratio; HR: Hazard Ratio; NA: Not available 
Explanations 
a. All studies included a mixed population of patients with moderate and severe asthma.  
b. All studies except one (Castro 2011) included a mixed population of patients with moderate and severe asthma.  
c. The ends of the 95% confidence interval include appreciable clinical benefit (MCID = 0.5) and no benefit and could lead to different clinical decisions. Results from single study including only 106 patients.  
d. The ends of the 95% confidence interval include appreciable clinical benefit (MCID = 10.38%) and no benefit and could lead to different clinical decisions. Single study including only 104 patients.  
e. The ends of the 95% confidence interval include appreciable clinical benefit (MCID = 0.23 L) and no benefit and could lead to different clinical decisions. Results from single study including only 104 patients.  
f. The two studies reported by Castro 2015 included a mixed population of patients with moderate and severe asthma.  
g. The ends of the 95% confidence interval include appreciable benefit and harm and could lead to different clinical decisions.  
h. Single study including only 106 patients.  
i. I2 = 54% (P=0.07) may represent moderate heterogeneity. However the point estimates from the 5 studies have the same direction of effect and 4 of 5 studies have overlapping 95% confidence intervals. For these 
reasons we have not rated down for inconsistency.  
j. The ends of the 95% confidence interval include appreciable benefit and no benefit and could lead to different clinical decisions. This judgement was based on a arbitrary clinical decision threshold of 15% increase or 
decrease in absolute effect.  
k. There was a high incidence of adverse events in both reslizumab and placebo groups. The apparent benefit from reslizumab might be explained by a reduction of asthma-related adverse events with the active drug.  
l. High risk of selective outcome reporting bias because 5 studies have reported any adverse events but only 2 studies have reported drug-related adverse events.  
m. There is considerable statistical heterogeneity (I2= 83%, P = 0.01), the effect estimates point in different directions (one study suggests benefit and the other suggests harm) and the 95% confidence intervals show 
minimal overlap.  
n. This judgement was based on a arbitrary clinical decision threshold of 15% increase or decrease in absolute effect.  
o.This judgement was based on a arbitrary clinical decision threshold of 10% increase or decrease in absolute effect.  
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GRADE Evidence Profile: BENRALIZUMAB 
Bibliography: Bleecker 2016, Castro 2014, FitzGerald 2016, Nair 2017, Park 2016 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Benralizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Quality of life (change from baseline) (follow up: range 28 weeks to 56 weeks; assessed with: Asthma Quality of Life Questionnaire (AQLQ); Scale from: 1 to 7; higher values indicate better quality of life; 
MCID 0.5) 
4 1,2,3,4 randomised 
trials  
not serious  not serious  serious a not serious  none  592  657  -  MD 0.32 higher 
(0.19 higher to 0.45 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL 
  
Quality of life (change from baseline) (follow up: 28 weeks; assessed with: Asthma Quality of Life Questionnaire (AQLQ); Scale from: 1 to 7; higher values indicate better quality of life; MCID 0.5) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma7 
1 1 randomised 
trials  
not serious  not serious  not serious  very 
serious b 
none  72  75  -  MD 0.45 higher 
(0.14 higher to 0.76 
higher)  
⨁⨁◯◯ 
LOW  
IMPORTANT  
Asthma control (change from baseline) (follow up: range 28 weeks to 56 weeks; assessed with: Asthma Control Questionnaire (ACQ-6); Scale from: 0 to 6; lower values indicate better asthma control; MCID 
0.5) 
4 1,2,3,4 randomised 
trials  
not serious  not serious  serious a not serious  none  870  946  -  MD 0.29 lower 
(0.40 lower to 0.17 
lower)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Asthma control (change from baseline) (follow up: 28 weeks; assessed with: Asthma Control Questionnaire (ACQ-6); Scale from: 0 to 6; lower values indicate better asthma control; MCID 0.5) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 7 
1 1 randomised 
trials  
not serious  not serious  not serious  very 
serious b 
none  73  74  -  MD 0.55 lower 
(0.86 lower to 0.24 
lower)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Asthma symptoms (change from baseline) (follow up: range 28 weeks to 56 weeks; assessed with: different symptom scores; lower scores indicate less frequent and/or severe symptoms) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Benralizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
4 1,2,3,4 randomised 
trials  
not serious  not serious  serious a not serious  none  858  953  -  SMD 0.19 lower 
(0.28 lower to 0.09 
lower)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Asthma symptoms (change from baseline) (follow up: 28 weeks; assessed with: Total asthma symptom score; lower scores indicate less frequent and/or severe symptoms) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 7 
1 1 randomised 
trials  
not serious  not serious  not serious  very 
serious c 
none  68  67  -  MD 0.18 lower 
(0.52 lower to 0.16 
higher)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Lung function (FEV1 % of predicted) (follow up: 52 weeks; MCID 10.38%6) 
1 5 randomised 
trials  
not serious  not serious  serious d very 
serious e 
none  25  26  -  MD 5.3 lower 
(17.63 lower to 7.03 
higher)  
⨁◯◯◯ 
 VERY LOW  
IMPORTANT  
Lung function (Pre-bronchodilator FEV1 litres, change from baseline) (follow up: range 28 weeks to 56 weeks; MCID 0.23 litre 6) 
4 1,2,3,4 randomised 
trials  
not serious  not serious  serious a not serious  none  879  982  -  MD 0.11 higher 
(0.06 higher to 0.16 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Lung function (Pre-bronchodilator FEV1 litres, change from baseline) (follow up: 28 weeks; MCID 0.23 litre6) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 7 
1 1 randomised 
trials  
not serious  not serious  not serious  very 
seriousf 
none  69  73  -  MD 0.11 higher 
(0.03 lower to 0.26 
higher)  
⨁⨁◯◯ 
LOW  
IMPORTANT  
Lung function(Post-bronchodilator FEV1 litres, change from baseline) (follow up: range 48 weeks to 56 weeks; MCID 0.23 litre 6) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Benralizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
2 2,4 randomised 
trials  
not serious  not serious  serious g not serious  none  472  484  -  MD 0.1 higher 
(0.04 higher to 0.16 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Exacerbations (patients with ≥1 exacerbation) (follow up: range 28 weeks to 56 weeks) 
2 1,2 randomised 
trials  
not serious  serious h serious i serious j none  112/312 
(35.9%)  
165/323 
(51.1%)  
RR 0.62 
(0.36 to 1.06)  
194 fewer per 1,000 
(from 327 fewer to 
31 more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Exacerbations (patients with ≥1 exacerbation) (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma7 
1 1 randomised 
trials  
not serious  not serious  not serious  serious k none  17/73 (23.3%)  39/75 (52.0%)  RR 0.45 
(0.28 to 0.72)  
286 fewer per 1,000 
(from 374  fewer to 
146 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Rate of any exacerbation (Age range 12-75 years; follow up: range 28 weeks to 56 weeks) 
4 1,2,3,4 randomised 
trials  
not serious  not serious  serious a not serious  none  905  935  Rate ratio 
0.58 
(0.47 to 0.73)  
Incidence rate 
(events/patient/year): 
benralizumab 0.64; 
placebo 1.19 
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Rate of any exacerbation (Age range 12-17 years; follow up: range 48 weeks to 56 weeks) 
2 2,4 randomised 
trials  
not serious  not serious  serious g very 
serious j,l 
none  16  19  Rate ratio 
1.70 
(0.50 to 5.81)  
NA ⨁◯◯◯ 
VERY LOW  
CRITICAL  
Rate of any exacerbation (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 7 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Benralizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 1 randomised 
trials  
not serious  not serious  not serious  serious k none  73  75  Rate ratio 
0.30 
(0.17 to 0.53)  
 Incidence rate 
(events/patient/year): 
benralizumab 0.54; 
placebo 1.83 
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Time to first asthma exacerbation (follow up: range 28 weeks to 56 weeks) 
3 1,2,4 randomised 
trials  
not serious  not serious  serious g not serious  none  579  590  HR 0.57 
(0.40 to 0.81)  
- ⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Time to first asthma exacerbation (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma7 
1 1 randomised 
trials  
not serious  not serious  not serious  serious k none  73  75  HR 0.32 
(0.18 to 0.57)  
- ⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Rate of exacerbations requiring emergency department visit or hospitalisation (follow up: range 28 weeks to 56 weeks) 
3 1,2,4 randomised 
trials  
not serious  serious m serious g serious j none  579  590  Rate ratio 
0.45 
(0.14 to 1.47)  
Incidence rate 
(events/patient/year): 
benralizumab 0.04; 
placebo 0.18 
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Rate of exacerbations requiring emergency department visit or hospitalisation (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma7 
1 1 randomised 
trials  
not serious  not serious  not serious  serious k none  73  75  Rate ratio 
0.07 
(0.01 to 0.63)  
Incidence rate 
(events/patient/year): 
benralizumab 0.02; 
placebo 0.32  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Exacerbations requiring emergency department visit or hospitalisation (patients with ≥1 exacerbation) (follow up: 56 weeks) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Benralizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 2 randomised 
trials  
not serious  not serious  serious n serious j none  20/239 (8.4%)  20/248 (8.1%)  RR 1.04 
(0.57 to 1.88)  
3 more per 1,000 
(from 35 fewer to 71 
more)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Adverse events (follow up: range 28 weeks to 68 weeks) 
5 
1,2,3,4,5 
randomised 
trials  
not serious  not serious  serious o not serious 
p 
none  737/1001 
(73.6%)  
883/1169 
(75.5%)  
RR 0.96 
(0.91 to 1.01)q  
30 fewer per 1,000 
(from 68 fewer to 8 
more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Adverse events (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma7 
1 1 randomised 
trials  
not serious  not serious  not serious  very 
serious k,r 
none  55/73 (75.3%)  62/75 (82.7%)  RR 0.91 
(0.77 to 
1.08)
q
 
74 fewer per 1,000 
(from 190 fewer to 
66 more )  
⨁⨁◯◯ 
LOW  
CRITICAL  
Drug-related adverse events (follow up: 48 weeks) 
1 4 randomised 
trials  
serious s   not serious  serious d  not serious 
p  
none  47/354 
(13.3%) 
34/370    
(9.2%) 
RR 1.44 
(0.95 to 2.19) 
40 more per 1,000 
(from 5 fewer to 109 
more) 
⨁⨁◯◯ 
LOW  
CRITICAL  
Serious adverse events (follow up: range 28 weeks to 68 weeks) 
5 
1,2,3,4,5 
randomised 
trials  
not serious  not serious  serious o not serious t none  109/1001 
(10.9%)  
157/1169 
(13.4%)  
RR 0.79 
(0.63 to 1.00)  
28 fewer per 1,000 
(from 50 fewer to 0 
fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Serious adverse events (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma 7 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Benralizumab  placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 1 randomised 
trials  
not serious  not serious  not serious  very 
serious k,u 
none  7/73 (9.6%)  14/75 (18.7%)  RR 0.51 
(0.22 to 1.20)  
91 fewer per 1,000 
(from 146 fewer to 
37 more)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Systemic steroids (absolute final dose) (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma7 
1 1 randomised 
trials  
not serious  not serious  not serious  serious k none  The median oral prednisone or prednisolone dose (range) at the final 
visit (week 28) was 10.0 mg/day (0.0 to 40.0) in patients who received 
placebo (n=75) and 5.0 mg/day (0.0 to 30.0) in patients who received 
benralizumab (n=73) . No statistical test comparing results from the 
two groups has been reported.  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Systemic steroids (percent reduction) (follow up: 28 weeks) 
Study participants meet criteria for the diagnosis of severe asthma defined by the ERS/ATS Guidelines on Severe Asthma7 
1 1 randomised 
trials  
not serious  not serious  not serious  serious k none  The median prednisone or prednisolone dose reduction from baseline 
(range) at the final visit (week 28) was 25.0% (–150% to 100%) in the 
placebo group (n=75) and 75.0% (–50% to 100%) in the benralizumab 
group (n=73) ( Wilcoxon rank-sum test P<0.001). Negative values 
indicate an increase in the final oral prednisone or prednisolone dose 
from baseline.  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Loss of work or school days, Intensive care unit admission, Non-invasive ventilation, Intubation, Comorbidities, Upper airway symptoms - not reported 
-  -  -  -  -  -  -  -  -  -  -  -   
CI: Confidence interval; FEV1: forced expiratory volume in 1 second; MCID: minimal clinically important difference; MD: Mean difference; SMD: Standardised mean difference; RR: Risk ratio; HR: Hazard Ratio; NA: Not 
acvailable 
Explanations 
a. Three studies (Bleecker 2016, Castro 2014 and FitzGerald 2016) included a mixed population of patients with moderate and severe asthma.  
b. The ends of the 95% confidence interval include appreciable clinical benefit (MCID = 0.5) and no benefit and could lead to different clinical decisions. Results from single study with only 147 patients.  
c. The end of the 95% confidence interval could lead to different clinical decisions. Results from single study including only 135 patients.  
d. The study included a mixed population of patients with moderate and severe asthma.  
e. The ends of the 95% confidence interval include appreciable clinical harm (MCID = 10.38%) and no benefit and could lead to different clinical decisions. Results from single study with only 51 patients.  
f. The ends of the 95% confidence interval include appreciable clinical benefit (MCID = 0.23 ml) and no benefit and could lead to different clinical decisions. Results from single study with only 142 patients.  
g. Two studies (Bleecker 2016 and FitzGerald 2016) included a mixed population of patients with moderate and severe asthma.  
h. There is considerable statistical heterogeneity (I2= 79%, P = 0.03) and the 95% confidence intervals show little overlap.  
i. One study (Bleecker 2016) included a mixed population of patients with moderate and severe asthma.  
j. The ends of the 95% confidence interval include appreciable clinical benefit and harm and could lead to opposite clinical decisions.  
k. Single study including only 148 patients.  
l. Two studies including only 35 patients aged 12-17 years.  
m. There is considerable statistical heterogeneity (I2= 82%, P = 0.004) and the point estimates from individual studies vary widely.  
n. The study included a mixed population of patients with moderate and severe asthma  
o. Four studies (Bleecker 2016, Castro 2014, FitzGerald 2016 and Park 2016) included a mixed population of patients with moder ate and severe asthma.  
p. This judgement was based on a arbitrary clinical decision threshold of 15% increase or decrease in absolute effect.  
q. There was a high incidence of adverse events in both benralizumab and placebo groups. The apparent benefit from benralizumab might be explained by a reduction of asthma-related adverse events with the active 
drug.  
r.The ends of the 95% confidence interval include appreciable clinical benefit and no benefit, assuming an arbitrary clinical decision threshold of 15% increase or decrease in absolute effect. This could lead to different 
clinical decisions. 
s. High risk of selective outcome reporting bias because 5 studies have reported any adverse events but only 1 study has reported drug-related adverse events.  
 t. This judgement was based on a arbitrary clinical decision threshold of 10% increase or decrease in absolute effect.  
u. The ends of the 95% confidence interval include appreciable clinical benefit and no benefit, assuming an arbitrary clinical decision threshold of 10% increase or decrease in absolute effect. This could lead to different 
clinical decisions.  
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Evidence to Decision Framework 
 
Should an anti-interleukin 5 strategy versus no anti-interleukin 5 strategy be used for adults and children with severe asthma? 
POPULATION: Adults and children with severe asthma BACKGROUND:  
By definition, patients with severe asthma have disease that is either 
unresponsive to traditional therapies with inhaled corticosteroids and 
bronchodilators or require these therapies to maintain adequate control. To 
address this unmet need for improved therapies, several biologic therapies 
have been designed to target the inflammatory signature typical of most 
patients with asthma. Interleukin 5 (IL5) is the principal cytokine driving 
eosinophilic inflammation in most of these patients. Monoclonal antibodies that 
target the IL5 cytokine or its receptor have been found to be efficacious in 
randomized controlled trials in improving asthma-related outcomes. These 
three drugs in this category are mepolizumab, reslizumab, and benralizumab, 
and will henceforth be referred to as the anti-IL5 strategy. This systematic 
review and meta-analysis synthetizes the data from randomized controlled trials 
and meta-analyses investigating the anti-IL5 strategy and provides treatment 
recommendations based on the results. 
 
INTERVENTION: Anti-interleukin 5 strategy (monoclonal antibodies directed against the 
interleukin 5 or its receptor) 
COMPARISON: No anti-interleukin 5 strategy 
MAIN OUTCOMES: Rate of exacerbations 
Time to first asthma exacerbation 
Asthma exacerbations requiring ER visits or hospitalization  
Lung function  
Asthma control  
Maintenance corticosteroid dose reduction  
Adverse events 
Serious adverse events  
Quality of life  
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
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How substantial are the desirable anticipated effects? 
○ Trivial 
○ Small 
○ Moderate 
● Large 
○ Varies 
○Don't know 
 
Asthma exacerbations are a critically important outcome for the patients with 
asthma who experience these and the clinicians who care for them.  
Relative to participants assigned to placebo, those assigned to mepolizumab 
experienced a 50% reduction (95% CI 39-65%) (see evidence profiles) in their 
rates of asthma exacerbations; participants assigned to reslizumab and 
benralizumab demonstrated similar reductions in rates of asthma exacerbations 
[54% (95% CI 42-63%) and 42% (95% CI 27-53%), respectively]. Although a 
defined threshold for clinically meaningful reductions in asthma exacerbations 
has not been universally agreed upon, the effect sizes in reductions in asthma 
exacerbations for these three drugs are considered clinically substantial by most 
practitioners.  
Among adolescent participants (ages 12-17 years, n=35 between two trials), 
those assigned to benralizumab experienced a 1.7x increase (95% CI 0.50x-
5.81x) in their rates of asthma exacerbations (very low quality evidence). 
Another critically important outcome in asthma includes asthma symptom scores. 
Although the evidence favors all anti-IL5 strategy drugs relative to placebo on 
these outcomes, their relative change was not as large compared to the 
improvement observed with asthma exacerbations.  
 
Relative to participants assigned to placebo, those assigned to mepolizumab 
experienced a 0.43-point decrease (i.e. improvement) in Asthma Control 
Questionnaire (ACQ) (95% CI 0.31-0.56-point decrease); participants assigned 
to reslizumab and benralizumab demonstrated similar improvements in ACQ 
scores [0.26 (95% CI 0.18-0.33-point decrease) and 0.29 (95% CI 0.17-0.40 
point decreases), respectively]. Although these were statistically significant 
decreases in ACQ scores, on average these drugs did not surpass the 0.5-point 
decrease threshold traditionally assigned as the MCID in ACQ symptom score for 
trials in asthma. 
 
Meta-analytical results on other outcomes appear in the online supplement.  
 
 The decision to consider changes in 
lung function [forced expiratory volume 
in the first second (FEV1)] as „important‟ 
outcomes as opposed to „critical‟ 
outcomes is due to their place relative to 
other critical outcomes. We understand 
that most clinicians would prescribe anti-
IL5 strategy drugs due to their efficacy in 
reducing asthma exacerbations despite 
only modest improvements in lung 
function.  
 Data from children or adolescents are 
unavailable for mepolizumab and 
reslizumab. There are data available on 
the effects of benralizumab on 
adolescents with severe asthma, but this 
subset of the cohort is small. The 
resulting confidence intervals around 
effect estimates are large, which makes 
the quality of the data for adolescents 
very low. As noted in the FDA approval 
statement, the decision to allow the use 
of benralizumab in adolescents was 
based on the impracticality of conducting 
a sufficiently powered study among 
severe asthmatic adolescents due to the 
low prevalence of this population; the 
similarities in pharmacokinetic and 
pharmacodynamic values for this drug, 
and the absence of major safety 
concerns for the population. More data 
are needed in order to have greater 
quality recommendations for 
adolescents. 
 The meta-analysis for mepolizumab 
included only the trials that tested the 
FDA- and EMA-approved dose of 
100mg administered subcutaneously. 
 Taken together, however, the reduction 
in asthma exacerbations is substantial 
enough for this committee to judge the 
desirable effects of an anti-IL5 strategy 
as large, regardless of relatively smaller 
effects on lung function and symptom 
scores.  
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How substantial are the undesirable anticipated effects? 
○ Large 
○ Moderate 
● Small 
○ Trivial 
○ Varies 
○ Don't know 
 
In the RCTs analysed, the risk of a study participant developing either an adverse 
event or a serious adverse event was lower for those participants assigned to any 
of the 3 anti-IL5 strategy drugs compared to those assigned to placebo. Relative to 
placebo, the risk of developing an adverse event for a participant assigned to 
mepolizumab was 7% lower (95% CI 1-12% lower) and for those assigned to 
reslizumab it was 12% lower (95% CI 4-18% lower). This difference was not 
statistically significant for those assigned to benralizumab, but the direction of the 
effect was also toward a lower risk of adverse events (3% lower). Similarly, 
participants experienced a lower risk of serious adverse events (not statistically 
significant) when assigned to anti-IL5 strategy drugs.  
The lower risk of total adverse events is likely driven by the reduction in  asthma 
exacerbations shown by these drugs.  
Data are available on drug-related adverse events from all 3 mepolizumab trials, 
but only from 2 of 5 reslizumab trials and 1 of 5 benralizumab trials. These data 
show that, relative to placebo, participants assigned to mepolizumab had a 35% 
greater relative risk of drug-related adverse events (95% CI 1-81% greater RR); 
those assigned to reslizumab had a 22% lower relative risk and those assigned to 
benralizumab had a 44% greater relative risk, however the effect for last two drugs 
was not statistically significant. 
Research evidence reveals that the rates 
of adverse events with anti-IL5 therapies 
are not substantially different from 
placebo. Infrequent but severe adverse 
reactions, including hypersensitive 
reactions, can not be excluded since 
randomised clinical trials are not powered 
enough to detect them. Safety data from 
phase 3 extension studies have been 
recently published and are reassuring. 
Post-authorisation phamacovigilance 
systems, including larger cohorts of 
patients receiving these treatments, are 
expected to provide additional real-life 
safety data. 
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What is the overall certainty of the evidence of effects? 
● Very low 
● Low 
● Moderate 
○ High 
○ No included studies 
 
Mepolizumab (population meets the definition of severe asthma defined by the 
ERS/ATS Guidelines): moderate quality of evidence.  
Benralizumab:  
--overall population (patients with moderate and severe persistent asthma): very 
low quality of evidence;  
--population that meets criteria for the diagnosis of severe asthma defined by the 
ERS/ATS Guidelines: low quality of evidence 
Reslizumab:  
--overall population (patients with moderate and severe persistent asthma):low 
quality of evidence;  
--population that meets criteria for the diagnosis of severe asthma defined by the 
ERS/ATS Guidelines: low quality of evidence 
Our certainty assessment relies on study 
design (randomized controlled trials), risk 
of bias, inconsistency, indirectness , and 
imprecision .  
Further the certainty is based on the 
quality of evidence that is lowest among 
critical outcomes. 
 
The RCTs on all anti-IL5 strategy drugs 
were mainly designed to investigate 
changes in asthma exacerbations. 
Consequently, the certainty of the data for 
this critical outcome is high (mepolizumab 
and reslizumab) or moderate 
(benralizumab). However, the certainty of 
other outcomes such as respiratory 
symptoms was lower for all three drugs, 
and therefore downgraded the overall 
certainty of the evidence.   
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Is there important uncertainty about or variability in how 
much people value the main outcomes? 
○ Important uncertainty or variability 
○ Possibly important uncertainty or variability 
○ Probably no important uncertainty or variability 
● No important uncertainty or variability 
○ No known undesirable outcomes 
 
 
No evidence identified. 
There is no important uncertainty about 
how patients and the clinicians who care 
for them assess asthma exacerbations. 
On the other hand, asthma exacerbations 
is not the only critical outcome for patients 
and clinicians, who also consider the 
effect of interventions on other outcomes, 
such as changes in lung function, change 
in maintenance dose of systemic 
corticosteroids, asthma symptoms, and 
quality of life. Although the effect size of 
anti-IL5 strategy drugs is not uniform 
across these outcomes, these drugs 
tended to improve to varying degrees all 
asthma related outcomes.  For instance, 
although the reduction in asthma 
exacerbation rates is greater in magnitude 
than the change in lung function for all 3 
of these drugs, all 3 did improve lung 
function. Further, patients and clinicians 
rarely decide to prescribe these drugs 
based on only one of these outcomes in 
isolation.  
All three anti-IL5 strategy drugs are 
currently FDA and EMA approved in 
patients with severe eosinophilic asthma. 
Patients with asthma of greater severity 
are more likely to experience a greater 
rate of asthma exacerbations. Therefore, 
the decision to whether or not to prescribe 
these drugs is currently restricted to 
patients for whom the main outcome 
researched in the anti-IL5 strategy trials—
asthma exacerbations—is likely to be 
important. Further, many pharmacy 
formularies for physician groups and 
hospitals restrict these drugs to patients 
with severe asthma and a recent history 
of asthma exacerbations.   
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Does the balance between desirable and undesirable effects 
favor the intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
● Favors the intervention 
○ Varies 
○ Don't know 
All three anti-IL5 strategy drugs have been associated with large desirable 
effects and small undesirable effects.  
As noted above, both serious and non-
serious side effects were noted in clinical 
trials to have occurred more commonly in 
the placebo groups to which these drugs 
were compared. Thus, considering the 
substantial benefit in terms of reducing 
asthma exacerbations, the balance favors 
using an anti-IL5 strategy.   
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Does the cost-effectiveness of the intervention favor the 
intervention or the comparison? 
● Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
○ No included studies 
The December 2018 report by the Institute for Clinical and Economic Review 
(ICER) states that anti-IL5 strategy drugs cost >$340,000 per quality-adjusted life 
years (QALY) gained when compared to standard of care (ICER 2018). These 
figures far exceed the accepted threshold for a cost-effective intervention of 
$150,000 per QALY gained.  
Therefore, the alternative is favored over 
an anti-IL5 strategy from a cost-
effectiveness standpoint. 
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What is the certainty of the evidence of resource 
requirements (costs)? 
○ Very low 
○ Low 
○ Moderate 
● High 
○ No included studies 
The manufacturers‟ listed annual net prices are $29,500, $28,900, and $27,800 
for mepolizumab, reslizumab, and benralizumab, respectively, after applying 
discounts and rebates (ICER 2018).  
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What would be the impact on health equity? 
○ Reduced 
● Probably reduced 
○ Probably no impact 
○ Probably increased 
○ Increased 
 
No evidence identified. 
In the US, racial and ethnic minorities, 
and individuals of lower socioeconomic 
status have been documented to have 
less access to specialty clinics and are 
less likely to use controller therapy for 
asthma. Since anti-IL5 strategy drugs are 
mainly prescribed by specialists it is likely 
○ Varies 
○ Don't know 
that racial and ethnic minorities will be 
less likely to be prescribed one of these 
drugs. Other groups may thus experience 
greater reductions in asthma 
exacerbations due to access to these 
drugs, which will thus reduce health 
equity. Similarly, patients with severe 
asthma who live in regions with fewer 
specialists will be less likely to receive 
these drugs, thus reducing equity 
between areas with high and low access 
to specialty care.  
On the other hand, the manufacturers of 
these drugs have programs in place to 
reduce patients‟ out of pocket costs for 
these drugs, which may partly mitigate the 
decrease in equity posed by differences in 
access by socioeconomic status and 
race/ethnicity. 
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Is the intervention acceptable to key stakeholders? 
○ No 
○ Probably no 
○ Probably yes 
○ Yes 
● Varies 
○ Don't know 
No evidence identified.  Most patients with severe asthma 
welcome the possibility of relief from 
asthma through anti-IL5 strategy drugs.  
Health insurance companies and clinic 
administrations find anti-IL5 strategy 
drugs less acceptable due to their high 
cost. 
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Is the intervention feasible to implement? 
○ No 
○ Probably no 
○ Probably yes 
○ Yes 
● Varies 
○ Don't know 
No evidence identified.  The feasibility to implement is limited by 
the prescription of these drugs only by 
asthma specialists with the clinical 
resources to administer these drugs and 
monitor patients. Clinicians also need to 
have access to a laboratory that can 
document peripheral blood eosinophils in 
these patients. Patients without access to 
such clinicians would find it very difficult to 
receive these drugs.  
 
 
 
  
Should a measurement of a specific biomarker be used to guide initiation of treatment with a monoclonal anti-IL5 or IL5Rα antibody in adults and children 
with severe asthma? (biomarkers being exhaled NO, peripheral or sputum eosinophils, and serum periostin) 
GRADE Evidence Profile: MEPOLIZUMAB (according to baseline number of blood eosinophils) 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Asthma control (ACQ-5 responders 
defined as patients achieving a ≥0.5-
point reduction from baseline in 
ACQ-5 score) 
assessed with: Asthma Control 
Questionnaire (ACQ-5); Scale from: 0 
to 6; lower values indicate better 
asthma control; MCID 0.5. 
Follow up: 24 weeks 
№ of participants: 457 
(1 RCT) 1 
Importance: CRITICAL  
 
Percentage of patients treated with mepolizumab who achieved a ≥0.5-point reduction from baseline in 
ACQ-5 score compared to placebo were: Eosinophil ≥ 150/uL: 63% versus 41%, RR (95%CI) = 1.53 
(1.27 to 1.84), Absolute effect = 217 more per 1,000 (from 110 more to 343 more), n=457. Eosinophil ≥ 
300/uL: 63% versus 37%, RR (95%CI) = 1.68 (1.33 to 2.12), Absolute effect = 254 more per 1,000 (from 
123 more to 418 more), n=322. Eosinophil ≥ 500/uL: 62% versus 37%, RR (95%CI) = 1.67 (1.23 to 2.28), 
Absolute effect = 249 more per 1,000 (from 86 more to 477 more), n=187.  
 
⨁⨁⨁◯ 
MODERATE 
b,c 
There are significant increases in the number of 
patients treated with mepolizumab compared to 
placebo who achieve a reduction of at least 0.5 point 
in the ACQ-5 score. Increases are seen in patients 
with baseline blood eosinophil counts ≥150/uL, 
≥300/uL and ≥500/uL. However there is appreciable 
overlap of the 95% CIs.  
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Asthma control (change from 
baseline ) 
assessed with: Asthma Control 
Questionnaire (ACQ-5); Scale from: 0 
to 6; lower values indicate better 
asthma control; MCID 0.5. 
Follow up: 32 weeks 
№ of participants: 402                              
(1 RCT) 2 
Importance: CRITICAL 
Mean change from baseline to week 32 in patients treated with mepolizumab compared to placebo were: 
Eosinophil ≥150/uL: Mean difference (95%CI) = -0.52 (-0.70 to -0.34), n=402. Eosinophil ≥300/uL: Mean 
difference (95%CI) = -0.73 (-0.96 to -0.50), n=274. Eosinophil ≥500/uL: Mean difference (95%CI) = -0.76 
(-1.06 to -0.46), n=171.d 
 
 
⨁◯◯◯ 
VERY LOW 
b,c,e,f 
There are significant improvements in asthma control 
assessed by the ACQ-5 in patients treated with 
mepolizumab compared to placebo at 32 weeks of 
follow up. Improvements are seen in patients with 
baseline blood eosinophil counts ≥150/uL, ≥300/uL 
and ≥500/uL. However the 95% CI of the subgroups 
≥150 cells/uL and ≥500 cells/uL include a response 
below the MCID and there is appreciable overlap of 
the 95% CIs.  
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Quality of life (SGRQ responders 
defined as patients achieving a ≥4-
point reduction from baseline in 
SGRQ total score)  
assessed with: St George's Respiratory 
Questionnaire (SGRQ); Scale from: 0 to 
100; higher scores indicate worse 
quality of life; MCID 4 units. 
Follow up: 24 weeks 
№ of participants: 456 
(1 RCT) 1 
Importance: CRITICAL 
Percentage of patients treated with mepolizumab who achieved a ≥ 4 point reduction from baseline in 
SGRQ total score compared to placebo were: Eosinophil ≥ 150/uL: 73% versus 55%, RR (95%CI) = 1.33 
(1.16 to 1.53), Absolute effect = 182 more per 1,000 (from 88 more to 292 more), n=456. Eosinophil ≥ 
300/uL: 73% versus 54%, RR (95%CI) = 1.35 (1.14 to 1.61), Absolute effect = 189 more per 1,000 (from 
76 more to 329 more), n=321. Eosinophil ≥ 500/uL: 74% versus 57%, RR (95%CI) = 1.29 (1.05 to 1.60), 
Absolute effect = 167 more per 1,000 (from 29 more to 345 more), n=187.  
 
⨁⨁⨁◯ 
MODERATE 
b,c 
There are significant increases in the number of 
patients treated with mepolizumab compared to 
placebo who achieve a reduction of at least 4 points in 
the SGRQ total score. Increases are seen in patients 
with baseline blood eosinophil counts ≥150/uL, 
≥300/uL and ≥500/uL. However there is appreciable 
overlap of the 95% CIs.  
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Quality of life (change from baseline) 
assessed with: St George's Respiratory 
Questionnaire; Scale from: 0 to 100; 
higher scores indicate worse quality of 
life; MCID 4 units. 
Follow up: 32 weeks 
№ of participants: 420                            
(1 RCT) 2 
Importance: CRITICAL 
Mean change from baseline to week 32 in patients treated with mepolizumab compared to placebo were: 
Eosinophil ≥150/uL: Mean difference (95%CI) = -8.10 (-11.10 to -5.10), n=420. Eosinophil ≥300/uL: Mean 
difference (95%CI) = -10.40 (-14.10 to -6.70), n=288. Eosinophil ≥500/uL: Mean difference (95%CI) = -
11.30 (-16.20 to -6.40), n=179.d 
 
 
⨁⨁◯◯ 
LOW b,c,e 
There are significant improvements in respiratory 
symptoms measured by the SGRQ in patients treated 
with mepolizumab compared to placebo at 32 weeks 
of follow up. Improvements are seen in patients with 
baseline blood eosinophil counts ≥150/uL, ≥300/uL 
and ≥500/uL, however there is appreciable overlap of 
the 95% CIs.  
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Lung function (Pre-bronchodilator 
FEV1 litres, change from baseline); 
MCID 0.23 liter4 
follow up: 32 weeks 
№ of participants: 423                            
(1 RCT) 2 
Importance: IMPORTANT 
Mean change from baseline to week 32 in patients treated with mepolizumab compared to placebo were: 
Eosinophil ≥150/uL: Mean difference (95%CI) = 0.11 L (0.03 L to 0.20 L), n=423. Eosinophil ≥300/uL: 
Mean difference (95%CI) = 0.13 L (0.02 L to 0.23 L), n=290. Eosinophil ≥500/uL: Mean difference 
(95%CI) = 0.11 L (-0.02 L to 0.25 L), n=181.d 
 
⨁◯◯◯ 
VERY LOW 
b,c,e,f 
There is a significant change in pre-BD FEV1 (litres) 
with mepolizumab compared to placebo in the 
subgroups of patients with blood eosinophil counts 
≥150/uL and ≥300/uL at 32 weeks of follow up, 
whereas there are no differences in similar terms for 
those patients with blood eosinophils ≥500/uL at the 
same follow up. There is appreciable overlap of the 
95% CIs.  
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Lung function (Post-bronchodilator 
FEV1 litres, change from baseline); 
MCID 0.23 liter4 
follow up: 32 weeks 
№ of participants: 386                          
(1 RCT) 2 
Importance: IMPORTANT 
Mean change from baseline to week 32 in patients treated with mepolizumab compared to placebo were: 
Eosinophil ≥150/uL: Mean difference (95%CI) = 0.17 L (0.08 L to 0.27 L), n=386. Eosinophil ≥300/uL: 
Mean difference (95%CI) = 0.20 L (0.09 L to 0.31 L), n=268. Eosinophil ≥500/uL: Mean difference 
(95%CI) = 0.25 L (0.10 L to 0.39 L), n=166.d 
 
 
⨁◯◯◯ 
VERY LOW 
b,c,e,f 
There is a significant change in post-BD FEV1 (litres) 
with mepolizumab compared to placebo in the 
subgroups of patients with blood eosinophil counts 
≥150/uL, ≥300/uL and ≥500/uL at 32 weeks of follow 
up. However there is appreciable overlap of the 95% 
CIs.  
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Exacerbation rate (mean 
exacerbation rate per patient per 
year); lower rates, greater reduction in 
exacerbations; Follow up: 32 weeks 
№ of participants: 453 
(1 RCT) 2 
Importance: CRITICAL 
Annualised mean exacerbation rates per patient treated with mepolizumab compared to placebo were: 
Eosinophil ≥150/uL: 0.78 vs 1.65, Rate ratio (95%CI) = 0.47 (0.35 to 0.63), n=453. Eosinophil ≥300/uL: 
0.78 vs 1.98, Rate ratio (95%CI) = 0.39 (0.28 to 0.55), n=308. Eosinophil ≥400/uL: 0.66 vs 2.06, Rate 
ratio (95%CI) = 0.32 (0.22 to 0.46), n=248. Eosinophil ≥500/uL: 0.58 vs 2.11, Rate ratio (95%CI) = 0.27 
(0.18 to 0.41), n=190.  
 
⨁⨁◯◯ 
LOW b,c,e 
There is a significant reduction of exacerbation rates 
with mepolizumab compared to placebo in those 
patients with baseline blood eosinophil counts 
≥150/uL, ≥300/uL, ≥400/uL and ≥500/uL. However 
there is overlap of the 95% CIs.  
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Exacerbation rate (mean 
exacerbation rate per patient per 
year); lower rates, greater reduction in 
exacerbations; 
Follow up: 32 weeks 
№ of participants: 569 
(1 RCT) 2 
Importance: CRITICAL 
Annualised mean exacerbation rates per patient treated with mepolizumab compared to placebo were: 
Eosinophil <150/uL: 1.19 vs 1.92, Rate ratio (95%CI) = 0.62 (0.37 to 1.05), n=116. Eosinophil 150 to 
<300/uL: 0.66 vs 1.02, Rate ratio (95%CI) = 0.64 (0.35 to 1.16), n=145. Eosinophil 300 to <500/uL: 1.01 
vs 1.66, Rate ratio (95%CI) = 0.61 (0.35 to 1.07), n=118. Eosinophil ≥500/uL: 0.58 vs 2.11, Rate ratio 
(95%CI) = 0.27 (0.18 to 0.41), n=190. Test for subgroup differences, p=0.02.  
 
⨁⨁◯◯ 
LOW b,c,e 
There is a significant reduction of exacerbation rates 
with mepolizumab compared to placebo in those 
patients with baseline blood eosinophil counts 
≥500/uL, but not in patients with eosinophil counts 
<150/uL, 150 to <300/uL and 300 to <500/uL. There 
are statistically significant differences between 
subgroups.  
CI: Confidence interval; RR: Risk ratio; MD: Mean difference; OR: Odds ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. The participants included in these analyses have been considered to represent a population of severe asthmatics as defined by the ERS/ATS Guidelines on Severe Asthma 20143. 
b. Potential risk of bias associated with selective outcome reporting bias (non-predefined post-hoc analyses).  
c. The inclusion criteria for participants 12-17 years of age required treatment with inhaled corticosteroids at a lower dose than that recommended by the ERS/ATS Guidelines on Severe Asthma (2014)3. The proportion of included participants 12-17 
years of age was not specified. However we have assumed the proportion of included participants 12-17 years was small relative to the whole study population and therefore we have not downgraded for indirectness.  
d. The measure of effect was not clearly specified in Ortega 2016, but we have assumed it was presented as mean difference between change-from-baseline measures.  
e. Mepolizumab doses (100 mg SC and 75 mg IV) were combined for the analysis, as reported by Ortega 2016.  
f. The ends of the 95%  confidence interval of at least one subgroup include appreciable benefit and no benefit and could lead to different clinical decisions.  
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GRADE Evidence Profile: BENRALIZUMAB (according to baseline number of blood eosinophils) 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Quality of life (change from baseline) 
assessed with: Asthma Quality of Life 
Questionnaire (AQLQ) 
follow up: range 28 weeks to 56 weeks; 
Scale from: 1 to 7; higher values 
indicate better quality of life; MCID 0.5) 
№ of participants: 1194 
(3 RCTs) 1,2,3 
Importance: CRITICAL   
 
Mean change from baseline in AQLQ score in patients treated with benralizumab compared to placebo were: 
Eosinophil <300/µL: Mean difference (95% CI) = 0.85 (-0.39 to 2.09), n=55 ; Eosinophil ≥300/µL: Mean 
difference (95% CI) = 0.29 (0.15 to 0.43), n=1047 . Test for subgroup differences, p=0.38.  
 
 
⨁◯◯
◯ 
VERY 
LOW a,b,c 
There are significant improvements in asthma quality 
of life assessed by the AQLQ with benralizumab 
compared to placebo in patients with baseline blood 
eosinophil counts ≥300/µL but not <300/µL. There 
are no statistically significant differences between 
subgroups. 
Asthma control (change from 
baseline)  
assessed with: Asthma Control 
Questionnaire (ACQ-6) 
follow up: range 28 weeks to 56 weeks 
Scale from: 0 to 6; lower values indicate 
better asthma control; MCID 0.5 
№ of participants: 1236 
(3 RCTs) 1,2,3 
Importance: CRITICAL  
 
Mean change from baseline in ACQ-6 score in patients treated with benralizumab compared to placebo were: 
Eosinophil <300/µL: Mean difference (95% CI) = -0.20 (-0.44 to 0.03), n=580; Eosinophil ≥300/µL: Mean 
difference (95% CI) = -0.28 (-0.41 to -0.15), n=1089. Test for subgroup differences, p=0.56.  
 
⨁⨁◯
◯ 
LOW b,d 
There are significant improvements in asthma 
control assessed by the ACQ-6 with benralizumab 
compared to placebo in patients with baseline blood 
eosinophil counts ≥300/µL but not <300/µL. There 
are no statistically significant differences between 
subgroups. 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Asthma control (at week 52) 
assessed with: Asthma Control 
Questionnaire (ACQ-6); Scale from: 0 
to 6; lower values indicate better 
asthma control; MCID 0.5 
follow up: 52 weeks;                             
№ of participants: 51 
(1 RCT) 4 
Importance: CRITICAL  
 
Mean ACQ-6 score at week 52 in patients treated with benralizumab compared to placebo were: Unspecified 
blood eosinophil count: Mean difference (95% CI) = 0.20 (-0.30 to 0.70), n=51; Eosinophil ≥300/µL: Mean 
difference (95% CI) = 0.10 (-0.49 to 0.69), n=40.  
 
 
 
⨁◯◯
◯ 
VERY 
LOW e,f 
There are no significant improvements in asthma 
control assessed by the ACQ-6 with benralizumab 
compared to placebo in patients with baseline blood 
eosinophil counts ≥300/µL or with unspecified 
eosinophil counts at 52 weeks of follow up. There is 
appreciable overlap of the 95% CIs. 
Asthma symptoms (change from 
baseline) 
assessed with: different symptom 
scores; lower scores indicate less 
frequent and/or severe symptoms; 
follow up: range 28 weeks to 56 weeks 
№ of participants: 1220 
(3 RCTs) 1,2,3 
Importance: CRITICAL  
 
Mean change from baseline in asthma symptom scores in patients treated with benralizumab compared to 
placebo were: Eosinophil <300/µL: standardized mean difference (95% CI) = -0.19 (-0.47 to 0.10), n=591; 
Eosinophil ≥300/µL: standardized mean difference (95% CI) = -0.20 (-0.32 to -0.08), n=1085. Test for 
subgroup differences, p=0.93.  
 
⨁◯◯
◯ 
VERY 
LOW 
b,g,h 
There are significant improvements in asthma 
symptoms with benralizumab compared to placebo 
in those patients with baseline blood eosinophil 
counts ≥300/µL but not <300/µL. There are no 
statistically significant differences between 
subgroups. 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Lung function (FEV1% of predicted),i 
follow up: 52 weeks 
MCID 10.38% 6                                       
№ of participants: 40 
(1 RCT) 4 
Importance: IMPORTANT  
 
Mean FEV1% of predicted at week 52 in patients treated with benralizumab compared to placebo were: 
Unspecified blood eosinophil count: Mean difference (95% CI) = -5.30% (-17.63 to 7.03%), n=51; Eosinophil 
≥300/µL: Mean difference (95% CI) = -4.40% (-18.97 to 10.17%), n=40.  
 
 
⨁◯◯
◯ 
VERY 
LOW e,j 
There are no significant changes in FEV1% of 
predicted with benralizumab compared to placebo in 
patients with baseline blood eosinophil counts 
≥300/µL or with unspecified eosinophil counts at 52 
weeks of follow up. There is appreciable overlap of 
the 95% CIs. 
Lung function (Pre-bronchodilator 
FEV1 litres) 
follow up: range 28 to 56 weeks;         
MCID 0.23 litre6 
№ of participants: 611 
(3 RCTs) 1,2,3 
Importance: IMPORTANT  
 
Mean change from baseline in pre-bronchodilator FEV1 (litres) in patients treated with benralizumab compared 
to placebo were: Eosinophil <300/µL: Mean difference (95% CI) = 0.05 L (-0.03 to 0.14 L), n=611; Eosinophil 
≥300/µL: Mean difference (95% CI) = 0.15 L (0.09 to 0.21 L), n=1108. Test for subgroup differences, p=0.07.  
 
⨁⨁◯
◯ 
LOW b,g 
There is a significant increase in pre-BD FEV1 
(litres) with benralizumab compared to placebo in the 
subgroup of patients with blood eosinophil counts  
≥300/uL, whereas there are no differences for those 
patients with blood eosinophils <300/uL. However 
there are no statistically significant differences 
between subgroups. 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Rate of any exacerbation 
follow up: range 28 weeks to 56 weeks 
№ of participants: 1322 
(3 RCTs) 1,2,3 
Importance: CRITICAL 
 
Annualised mean exacerbation rates per patient treated with mepolizumab compared to placebo were: 
Eosinophil <300/uL: Rate ratio (95%CI) = 0.71 (0.52 to 0.97), n=518. Eosinophil ≥300/uL: Rate ratio (95%CI) = 
0.59 (0.47 to 0.73), n=1174. Test for subgroup differences, p=0.33.  
 
⨁⨁◯
◯ 
LOW b,g 
There are significant reductions in exacerbation 
rates with benralizumab compared to placebo in 
those patients with baseline blood eosinophil counts 
<300/µL and ≥300/ µL. However there are no 
statistically significant differences between 
subgroups. 
Adverse events  
follow up: range 48 weeks to 56 weeks 
№ of participants: 1525                        
(2 RCTs) 1,3 
Importance: IMPORTANT  
 
The proportion of patients treated with benralizumab who had any adverse event compared to placebo were: 
Eosinophil < 300/uL: 76.3% versus 79.8%, RR (95%CI) = 0.95 (0.87 to 1.04), Absolute effect = 40 fewer per 
1,000 (from 104 fewer to 32 more), n=515. Eosinophil ≥ 300/uL: 73.6% versus 75.9%, RR (95%CI) = 0.98 
(0.87 to 1.10), Absolute effect = 15 fewer per 1,000 (from 99 fewer to 76 more), n=1010. Test for subgroup 
differences, p=0.75.n  
 
 
 
⨁⨁◯
◯ 
LOW k,l,m 
There is no significant increase in the incidence of 
adverse events with benralizumab compared to 
placebo in patients with baseline blood eosinophil 
counts <300/µL and ≥300/ µL. There are no 
statistically significant differences between 
subgroups. 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Serious adverse events  
follow up: range 48 weeks to 56 weeks 
№ of participants: 1525 
(2 RCTs) 1,3 
Importance: IMPORTANT  
 
The proportion of patients treated with benralizumab who had any serious adverse event compared to placebo 
were: Eosinophil < 300/uL: 11.5% versus 15.3%, RR (95%CI) = 0.73 (0.32 to 1.66), Absolute effect = 41 fewer 
per 1,000 (from 104 fewer to 101 more), n=515. Eosinophil ≥ 300/uL: 11.7% versus 13.6%, RR (95%CI) = 0.86 
(0.62 to 1.19), Absolute effect = 19 fewer per 1,000 (from 52 fewer to 26 more), n=1010. Test for subgroup 
differences, p=0.71.  
 
 
⨁◯◯
◯ 
VERY 
LOW l,o,p 
There is no significant increase in the incidence of 
serious adverse events with benralizumab compared 
to placebo in patients with baseline blood eosinophil 
counts <300/µL and ≥300/ µL. There are no 
statistically significant differences between 
subgroups. 
Systemic steroids (absolute final 
dose)                                                            
follow up: 28 weeks 
№ of participants: 148                           
(1 RCT) 5                                                                             
Study participants meet criteria for 
the diagnosis of severe asthma 
defined by the ERS/ATS Guidelines 
on Severe Asthma7 
Importance: CRITICAL 
 
The median oral glucocorticoid dose (range) at the final visit (week 28) in the subgroup with baseline blood 
eosinophils ≥150 to <300/µL was: 5.0 mg/day (0.0–15.0) in patients who received placebo (n=11) and 6.25 
mg/day (0.0–30.0) in patients who received benralizumab (n=12). In the subgroup with baseline blood 
eosinophils ≥300/µL: 10.0 mg/day (0.0–40.0) in patients who received placebo (n=64) and 5.0 mg/day (0.0–
25.0) in patients who received benralizumab (n=61). No statistical test comparing results has been reported.  
 
⨁◯◯
◯ 
VERY 
LOW q,r 
Oral glucocorticoid dose is 5 mg/day less with 
benralizumab compared to placebo in the subgroup 
with baseline blood eosinophils ≥300/µL whereas in 
the  subgroup with baseline blood eosinophils ≥150 
to <300/µL oral glucocorticoid dose is 1.25 mg/day 
less with placebo. No statistcal test available.   
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Systemic steroids (percent 
reduction)                                       
follow up: 28 weeks 
№ of participants: 148                           
(1 RCT) 5                                                                      
Study participants meet criteria for 
the diagnosis of severe asthma 
defined by the ERS/ATS Guidelines 
on Severe Asthma7 
Importance: CRITICAL 
 
The median reduction in final oral glucocorticoid dose compared with baseline (range, %) in the subgroup with 
baseline blood eosinophils ≥150 to <300/µL was: 50.0% (0.0–100) in patients who received placebo (n=11) 
and 57.5% (-50.0–100) in patients who received benralizumab (n=12). In the subgroup with baseline blood 
eosinophils ≥300/µL: 0.0% (–150 to 100) in patients who received placebo (n=64) and 75.0% (–50.0 to 100) in 
patients who received benralizumab (n=61). No statistical test comparing results has been reported.  
⨁◯◯
◯ 
VERY 
LOW q,r 
There were similar oral glucocorticoid dose reduction 
with benralizumab or placebo in the subgroup with 
baseline blood eosinophils ≥150 to <300/µL (50% 
and 57.7%) whereas in the  subgroup with baseline 
blood eosinophils ≥300/µL the oral glucocorticoid 
dose reduction was 0% in placebo and 75% in 
benralizumab. No statistcal test available.   
CI: Confidence interval; FEV1: forced expiratory volume in 1 second; MCID: minimal clinically important difference; MD: Mean difference; SMD: Standardised mean difference; RCT: randomised controlled trial; RR: Risk 
ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Potential risk of bias associated with selective outcome reporting bias (ad hoc subgroup analysis in participants with blood eosinophil counts <300/µl in Castro 2014 ).  
b. Three studies (Bleecker 2016, Castro 2014 and FitzGerald 2016) included a mixed population of patients with moderate and severe asthma.  
c. A single study reported results for the subgroup with blood eosinophils counts <300/µL. This analysis included only 55 patients (4 in benralizumab arm and 51 in placebo arm).  
d. Potential risk of bias associated with selective outcome reporting bias in participants with eosinophil counts <300/µl (ad hoc subgroup analysis in Castro 2014; analysis not specified in protocols of Bleecker 2016 and 
FitzGerald 2016).  
e. The study included a mixed population of patients with moderate and severe asthma.  
f. For both subgroups the ends of the 95% confidence interval include appreciable clinical harm (MCID = 0.5) and no benefit and could lead to opposite clinical decisions. Results from single study with only 51 patients.  
g. Potential risk of bias associated with selective outcome reporting bias in participants with baseline blood eosinophil counts <300 cells/µl: ad hoc subgroup analysis in Castro 2014; additional analysis in patients with 
blood eosinophil counts <150/µL, 150-299/µL, 300-449/µL and ≥450/µL were stated in the protocol but not reported by Bleecker 2016 and FitzGerald 2016.  
h. For the subgroup with baseline blood eosinophils <300 cells/μl the ends of the 95% confidence interval include appreciable clinical benefit and no benefit and could lead to opposite clinical decision.  
i. FEV1% was not specified as pre- or post-bronchodilator in Park 2016 but we have assumed it to be pre-bronchodilator.  
j. For both subgroups the ends of the 95% confidence interval include appreciable clinical harm (MCID = 10.38%) and no benefit and could lead to opposite clinical decisions. Results from single study with only 51 
patients.  
k. I2=65% (p=0.09) may represent substantial statistical heterogeneity in the subgroup with baseline eosinophil count ≥300 cells/μl.  
l. The studies included a mixed population of patients with moderate and severe asthma.  
m. This judgement was based on a arbitrary clinical decision threshold of 15% increase or decrease in absolute effect.  
n. There was a high incidence of adverse events in both benralizumab and placebo groups. The apparent benefit from benralizumab might be explained by a reduction of asthma-related adverse events with the active 
drug. 
o. I2=69% (p=0.07) may represent substantial statistical heterogeneity in the subgroup with baseline eosinophil count <300 cells/μl.  
p. This judgement was based on a arbitrary clinical decision threshold of 10% increase or decrease in absolute effect in the subgroup with baseline blood eosinophil count <300 cells/μl.  
q. Potential risk of bias associated with selective outcome reporting bias: the protocol for Nair 2017 specified that percentage reduction in oral glucocorticoid dose would be summarized by treatment group in patients with 
baseline blood eosinophil counts 150-299/µL, ≥300/µL, 300-450/µL and >450/µL separately. However results have not been reported for patients with 300-450 eosinophils/µL and >450 eosinophils/µL. 
r. 95% confidence intervals could not be obtained and data from single study including only 148 patients.  
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GRADE Evidence Profile: RESLIZUMAB (according to baseline number of blood eosinophils) 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Asthma control (change from 
baseline)  
assessed with: Asthma Control 
Questionnaire (ACQ-7); Scale from: 0 
to 6; lower values indicate better 
asthma control; MCID 0.5 
follow up: range 16 weeks to 52 weeks 
№ of participants: 1645 
(4 RCTs) 1,2,3 
Importance: CRITICAL  
 
Mean change from baseline in ACQ-7 score in patients treated with reslizumab compared to placebo 
were: Eosinophil <400/µL: Mean difference (95% CI) = -0.12 (-0.33 to 0.09), n=392; Eosinophil ≥400/µL: 
Mean difference (95% CI) = -0.27 (-0.36 to -0.19), n=1253. Test for subgroup differences, p=0.19.  
 
⨁⨁⨁◯ 
MODERATE 
a 
There are significant improvements in asthma control 
assessed by the ACQ-7 with reslizumab compared to 
placebo in patients with baseline blood eosinophil 
counts ≥400/µL but not <400/µL. However there are 
no statistically significant differences between 
subgroups. 
Asthma control (change from 
baseline)                                           
assessed with: Asthma Control 
Questionnaire (ACQ-7); Scale from: 0 
to 6; lower values indicate better 
asthma control; MCID 0.5 
follow up: 15 weeks 
№ of participants: 106 
(1 RCT) 4                                                              
Study participants meet criteria for 
the diagnosis of severe asthma 
defined by the ERS/ATS Guidelines 
on Severe Asthma5 
Importance: CRITICAL  
Mean change from baseline in ACQ-7 score in patients treated with reslizumab compared to placebo 
were: Eosinophil <500/µL: Mean difference (95% CI) = -0.06 (-0.55 to 0.43), n=51; Eosinophil ≥500/µL: 
Mean difference (95% CI) = -0.57 (-1.19 to 0.05), n=55. Test for subgroup differences, p=0.21.  
 
⨁◯◯◯ 
VERY LOW 
b,c 
There are no significant improvements in asthma 
control assessed by the ACQ-7 with reslizumab 
compared to placebo in patients with baseline blood 
eosinophil counts <500/µL or ≥500/µL. There are no 
statistically significant differences between subgroups. 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Lung function (Pre-bronchodilator 
FEV1 litres) 
follow up: range 16 weeks to 52 weeks 
MCID 0.23 litre6 
№ of participants: 1646 
(4 RCTs) 1,2,3  
Importance: IMPORTANT  
 
Mean change from baseline in pre-bronchodilator FEV1 (litres) in patients treated with reslizumab 
compared to placebo were: Eosinophil <400/µL: Mean difference (95% CI) = 0.03 L (-0.07 to 0.14 L), 
n=392; Eosinophil ≥400/µL: Mean difference (95% CI) = 0.12 L (0.08 to 0.16 L), n=1254. Test for 
subgroup differences, p=0.13.  
 
⨁⨁⨁◯ 
MODERATE 
a 
There is a significant increase in pre-BD FEV1 (litres) 
with reslizumab compared to placebo in the subgroup 
of patients with blood eosinophil counts  ≥400/µL, 
whereas there are no differences for those patients 
with blood eosinophils <400/µL. However there are no 
statistically significant differences between subgroups. 
Lung function (Pre-bronchodilator 
FEV1 litres) 
follow up: 15 weeks                       
MCID 0.23 litre6 
№ of participants: 104 
(1 RCT) 4                                                               
Study participants meet criteria for 
the diagnosis of severe asthma 
defined by the ERS/ATS Guidelines 
on Severe Asthma5 
Importance: IMPORTANT  
 
Mean change from baseline in pre-bronchodilator FEV1 (litres) in patients treated with reslizumab 
compared to placebo were: Eosinophil <500/µL: Mean difference (95% CI) = 0.19 L (-0.02 to 0.40 L), 
n=49; Eosinophil ≥500/µL: Mean difference (95% CI) = 0.25 L (0.01 to 0.49 L), n=55. Test for subgroup 
differences, p=0.71.  
 
 
⨁◯◯◯ 
VERY LOW 
b,d 
There is a significant increase in pre-BD FEV1 (litres) 
with reslizumab compared to placebo in the subgroup 
of patients with blood eosinophil counts  ≥500/µL, 
whereas there are no differences for those patients 
with blood eosinophils <500/µL. However there are no 
statistically significant differences between subgroups. 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Rate of any exacerbation                
follow up: 52 weeks 
№ of participants: 953 
(2 RCTs) 2 
Importance: CRITICAL  
 
Annualised mean exacerbation rates per patient treated with reslizumab compared to placebo were: 
Eosinophil ≥400/µL: 0.84 versus 1.81 events/patient/year, Rate ratio (95%CI) = 0.46 (0.37, 0.58), n=953. 
Eosinophil ≥500/µL: Rate ratio (95%CI) = 0.49 (0.37 to 0.65), n=567; Eosinophil ≥700/µL: Rate ratio 
(95%CI) = 0.41 (0.28 to 0.60), n=344. Exacerbation rates were not specified for the subgroups ≥500 and 
≥700 eosinophils/µL 
 
⨁⨁◯◯ 
LOW a,b 
There are significant reductions in exacerbation rates 
with reslizumab compared to placebo in those patients 
with baseline blood eosinophil counts ≥400/µL, 
≥500/µL and ≥700//µL. However there is appreciable 
overlap of the 95% CIs. 
Adverse events 
follow up: range 16 weeks to 52 weeks 
№ of participants: 1652 
(4 RCTs) 1,2,3 
Importance: IMPORTANT  
 
The proportion of patients treated with reslizumab who had any adverse event compared to placebo were: 
Eosinophil ≥ 400/µL: 75% versus 81.6%, RR (95%CI) = 0.92 (0.87 to 0.97), Absolute effect = 65 fewer 
per 1,000 (from 106 fewer to 24 fewer), n=1160. Unspecified baseline blood eosinophil counts: 54.9% 
versus 74.2%, RR (95%CI) = 0.74 (0.64 to 0.86), Absolute effect = 193 fewer per 1,000 (from 267 fewer to 
104 fewer), n=492. Test for subgroup differences, p=0.008. e,f 
 
⨁⨁◯◯ 
LOW a,g 
There are significant decreases in the incidence of 
adverse events with reslizumab compared to placebo 
in patients with baseline blood eosinophil counts  
≥400/µL and with unspecified baseline blood 
eosinophil counts. There are statistically significant 
differences between subgroups. 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Serious adverse events 
follow up: range 16 weeks to 52 weeks 
№ of participants: 1652 
(4 RCTs) 1,2,3 
Importance: IMPORTANT  
 
The proportion of patients treated with reslizumab who had any serious adverse event compared to 
placebo were: Eosinophil ≥ 400/µL: 7.9% versus 10.0%, RR (95%CI) = 0.79 (0.51 to 1.22), Absolute 
effect = 21 fewer per 1,000 (from 49 fewer to 22 more), n=1160. Unspecified baseline blood eosinophil 
counts: 4.1% versus 4.1%, RR (95%CI) = 0.98 (0.34 to 2.87), Absolute effect = 1 fewer per 1,000 (from 27 
fewer to 77 more), n=492. Test for subgroup differences, p=0.71. e 
 
 
 
⨁⨁⨁◯ 
MODERATE 
a,h 
There are no significant increases in the incidence of 
serious adverse events with reslizumab compared to 
placebo in patients with baseline blood eosinophil 
counts  ≥400/µL and with unspecified baseline blood 
eosinophil counts. There are no statistically significant 
differences between subgroups. 
 
CI: Confidence interval; MD: Mean difference; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. All studies included a mixed population of patients with moderate and severe asthma.  
b. Potential risk of bias associated with selective outcome reporting bias (post hoc subgroup analysis).  
c. For both subgroups the ends of the 95% confidence interval include appreciable clinical benefit (MCID 0.5) and no benefit and could lead to opposite clinical decisions. Results from single study with only 106 patients.  
d. For both subgroups the ends of the 95% confidence interval include appreciable clinical benefit (MCID 0.23 L) and no benef it and could lead to opposite clinical decisions. Results from single study with only 104 
patients.  
e. The trial by Corren 2016, which provided results for the subgroup "Unspecified baseline blood eosinophil counts" reported that eosinophils ≥ 400 cells/µL were observed in 20% of patients at baseline , distributed 
similarly between treatment groups.  
f. There was a high incidence of adverse events in both reslizumab and placebo groups. The apparent benefit from reslizumab might be explained by a reduction of asthma-related adverse events with the active drug.   
g.This judgement was based on a arbitrary clinical decision threshold of 15% increase or decrease in absolute effect in the subgroup with unspecified baseline blood eosinophil counts.  
h. This judgement was based on a arbitrary clinical decision threshold of 10% increase or decrease in absolute effect.  
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GRADE Evidence Profile: RESLIZUMAB (according to baseline sputum eosinophils - %) 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
Asthma control (change from baseline)  
assessed with: Asthma Control 
Questionnaire (ACQ-7);                     
Scale from: 0 to 6; lower values indicate 
better asthma control; MCID 0.5 
follow up: 15 weeks 
№ of participants: 105 
(1 RCT) 1                                                       
Study participants meet criteria for the 
diagnosis of severe asthma defined by 
the ERS/ATS Guidelines on Severe 
Asthma3 
Importance: CRITICAL  
Mean change from baseline in ACQ-7 score in patients treated with reslizumab compared to placebo 
were: sputum eosinophils <10%: Mean difference (95% CI) = -0.28 (-0.90 to 0.34), n=52; sputum 
eosinophils ≥10%: Mean difference (95% CI) = -0.42 (-0.91 to 0.07), n=53. Test for subgroup differences, 
p=0.73. 
  
⨁◯◯◯ 
VERY 
LOW a,b 
There are no significant improvements in asthma 
control assessed by the ACQ-7 with reslizumab 
compared to placebo in patients with baseline sputum 
eosinophils <10% or ≥10%. There are no statistically 
significant differences between subgroups. 
Lung function (Pre-bronchodilator 
FEV1 litres) 
follow up: 15 weeks                            
MCID 0.23 litre2 
№ of participants: 103 
(1 RCT) 1                                                                          
Study participants meet criteria for the 
diagnosis of severe asthma defined by 
the ERS/ATS Guidelines on Severe 
Asthma3 
Importance: IMPORTANT 
Mean change from baseline in pre-bronchodilator FEV1 (litres) in patients treated with reslizumab 
compared to placebo were: sputum eosinophils <10%: Mean difference (95% CI) = 0.25 L (0.04 to 0.46 
L), n=50; sputum eosinophils ≥10%: Mean difference (95% CI) = 0.22 L (0 to 0.44 L), n=53. Test for 
subgroup differences, p=0.85.  
 
⨁◯◯◯ 
VERY 
LOW a,c 
There is a significant increase in pre-BD FEV1 (litres) 
with reslizumab compared to placebo in the subgroup 
of patients with sputum eosinophils <10% but not in 
pacient with ≥10% sputum eosinophils. There are no 
statistically significant differences between subgroups. 
BD: bronchodilator; CI: Confidence interval; FEV1: forced expiratory volume in 1 second; MCID: minimal clinically important difference;  MD: Mean difference; RCT: randomised controlled trial 
Outcome 
№ of participants 
(studies)  
Relative effect 
(95% CI)  
Anticipated absolute effects (95% CI)  Certainty  What happens  
  Difference 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Potential risk of bias associated with selective outcome reporting bias (post hoc subgroup analysis).  
b. For both subgroups the ends of the 95% confidence interval include appreciable clinical benefit (MCID 0.5) and no benefit and could lead to opposite clinical decisions. Results from single study with only 105 patients.  
c. For both subgroups the ends of the 95% confidence interval include appreciable clinical benefit (MCID 0.23 L) and no benefit and could lead to opposite clinical decisions. Results from single study with only 103 
patients.  
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Evidence to Decision Framework 
Should the level of eosinophils (in blood or sputum) be used to guide the initiation of a monoclonal antil-IL5 strategy in adults and children with severe asthma? 
POPULATION:  Adults and children with severe asthma BACKGROUND: Patients with severe asthma are characterized by uncontrolled symptoms and signs 
despite treatment with high dose steroids and bronchodilators, or require these 
therapies to maintain control.  IL-5 is the main cytokine involved in the activation of 
eosinophils which are a classic feature of atopic severe asthma.  Monoclonal antibodies 
have been developed that bind the IL-5 cytokine or receptor.   The three drugs in this 
category: mepolizumab, reslizumab and benralizumab have been shown to be efficacious 
in randomized controlled trials at improving outcomes.    However, patients exposed to 
this therapy have variable therapeutic response to this class of drugs which may reflect 
differences in their underlying biology.  This systematic review and meta-analysis 
investigates whether specific levels of eosinophilia in blood or sputum can be used as a 
biomarker to predict therapeutic response to monoclonal anti-IL5 therapies. 
INTERVENTION:  Use of Eosinophil level in blood or sputum identify patients for therapy with 
an anti-interleukin 5 strategy (monoclonal antibodies directed against 
the interleukin 5 or its receptor) 
COMPARISON:  Treatment of all with anti-interleukin 5 strategy (monoclonal antibodies 
directed against the interleukin 5 or its receptor) 
MAIN OUTCOMES: Respiratory symptoms 
Lung function  
Exacerbation rate 
Adverse events 
Serious adverse events  
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the desirable anticipated effects?  
○ Trivial 
○ Small 
● Moderate 
○ Large 
○ Varies 
○Don't know 
 
Results from research evidence (studies) 
There were 13 RCT studies (PMID: 27056586; 27609408; 25306557; 25736990; 28395936; 
27018175; 27609406; 28530840; 27177493; 27097165; 21852542) that performed either 
pre-specified or post hoc subgroup analyses evaluating different treatment responses 
based on baseline sputum or blood eosinophil levels.  The results across anti-IL 5 
medications and well as biomarker level and type varies substantially for outcomes.   
An important outcome for patients includes rate of exacerbation.  Blood eosinophils were 
the most typically measured biomarker and was available for all the medications.   
In one study (PMID: 27177493), baseline serum eosinophils of ≥500/uL were associated 
with a significantly greater response to therapy for mepolizumab only.  For this outcome, 
there was a 73% reduction in exacerbations amongst those with a blood eosinophil level of 
≥500/uL compared to 36-39% non-statistically significant reduction in subgroups with 
eosinophil levels of 150 to <300 cells/ cells/µL and 300 to <500 cells/µL, respectively.  
Notably mepolizumab reduced exacerbation rates in all the subgroups defined by different 
baseline eosinophil thresholds (≥150, ≥300, ≥400 and ≥500 cells/µL) .  
Blood eosinophil levels of greater than 300/µL were associated with  improvement in 
quality of life after treatment with  benralizumab but there was no significant difference 
between subgroups (PMID: 27609408; 25306557; 27609406). 
Sputum eosinophil level was only considered in one study of reslizumab.  Sputum levels 
were categorized as > or ≥ 10%.  There were no differences found between groups. 
Higher blood sputum levels were associated with a greater improvement in asthma control; 
however the differences between levels were not significant. 
As per PICO1, all subjects at eosinophil levels ≥150/uL experienced a significant reduction in 
exacerbations. 
Notably, studies of iv mepolizumab were excluded since only subcutaneous mepolizumab 
have been approved by the FDA/EMA. 
 
Panel considerations 
 
 
One single-blind, placebo controlled 
sequential trial (PMID: 28915080) assessed  
treatment response of weight-adjusted IV 
reslizumab in patients previously treated 
with 100-mg SC mepolizumab. 
  They reported that persistently high 
levels of eosinophils (blood eos >300/uL 
and sputum eos >3%) after treatment with 
mepolizumab characterized non-
responders.  Treatment of this group with 
reslizumab lead to improvements in their 
symptoms and eosinophil levels.  
 
 
 
U
N
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the undesirable anticipated effects?  
○ Large 
○ Moderate 
○ Small 
○ Trivial 
○ Varies 
○ Don't know 
 
There were 5 papers reporting results of six RCTs (PMID: 27609406, 27609408, 27056586, 
25736990, 27018175) that assessed adverse events.  There was no data in mepolizumab.  
The data suggested that overall there was no difference in adverse events amongst those 
with higher vs lower eosinophil counts for benralizumab.  For Reslizumab, the fewest adverse 
events occurred in the group who had no data on eosinophil count.  There was a slight 
reduction in the number of adverse events amongst those with an eosinophil count of 
≥400/uL but it was  8% lower (95% CI: 3, 13%).  
  
There was a high incidence of adverse 
events in both the active-drug 
(benralizumab and reslizumab) and 
placebo groups. The apparent benefit from 
the active-drugs might be explained by a 
reduction of asthma-related adverse 
events with the active drugs. 
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
What is the overall certainty of the evidence of effects?  
● Very low 
○ Low 
○ Moderate 
○ High 
○ No included studies 
 
The level of evidence is very low. 
The evidence is based on pre-specified or post-hoc subgroup analyses of RCTs that tested 
whether baseline eosinophil levels were predictive of the therapeutic response to an anti-
IL5 strategy.  Therefore, there is a potential bias of selective outcome reporting bias.  For 
studies of benralizumab, moderate and severe asthmatics were selected. 
 
V
A
LU
ES
 
Is there important uncertainty about or variability in how much 
people value the main outcomes? 
○ Important uncertainty or variability 
● Possibly important uncertainty or variability 
○ Probably no important uncertainty or variability 
○ No important uncertainty or variability 
○ No known undesirable outcomes 
 
  There is no uncertainty in how patients 
and clinicians value asthma exacerbations.  
However, there is some uncertainty the 
impact of measurement of eosinophil level 
at baseline in predicting outcomes.  The 
data suggests that patients with severe 
asthma benefit from an anti-IL5 strategy 
and those with higher levels >300-500/uL 
derive greater benefit than those with a 
level of <150/uL. 
Different patients may value the benefits / 
harms of the intervention differently (for 
instance more value to avoid harms 
compared to anticipated benefits).  
B
A
LA
N
C
E 
O
F 
EF
FE
C
TS
 
Does the balance between desirable and undesirable effects favor 
the intervention or the comparison?  
○ Favors the comparison 
○ Probably favors the comparison 
● Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
● Varies 
○ Don't know 
 
Most of the data presented suggests that patients with severe asthma benefit from an anti-
IL5 strategy.  Furthermore, there is some evidence that further benefit may be  derived in 
patients with higher levels of baseline blood eosinophilia > 300 – 500/uL compared to 
those with an eosinophil level <150/uL.  
Only mepolizumab showed  a significant reduction in asthma exacerbation amongst 
patients with an eosinophil level of ≥500/uL compared to other levels > 150/uL.  However, 
even subjects with a eosinophil levels between 150 and 300/uL benefited from therapy 
compared to placebo. 
   
 
  
C
O
ST
 E
FF
EC
TI
V
EN
ES
S 
Does the cost-effectiveness of the intervention favor the 
intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
● No included studies 
 
No research evidence available.  
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
O
F 
R
EQ
U
IR
E
D
 
R
E
SO
U
R
C
ES
 
What is the certainty of the evidence of resource requirements 
(costs)? 
○ Very low 
○ Low 
○ Moderate 
○ High 
● No included studies 
No research evidence available on the cost of the intervention (studying eosinophil level). Cost and  feasibility differ based on the 
biomarker.  Blood eosinophil levels are 
easily ascertained in most blood 
laboratories; sputum eosinophils are 
primarily available only in specialized 
centers. 
 
EQ
U
IT
Y 
What would be the impact on health equity?  
○ Reduced 
○ Probably reduced 
○ Probably no impact 
○ Probably increased 
○ Increased 
No research evidence available. Consider: 
Blood eosinophils are very variable and can 
fluctuate dramatically with oral steroid 
treatment.  In areas, where oral steroid 
therapy is more common than the use of 
combination inhalers, blood eosinophils 
○ Varies 
● Don't know 
may be lower. 
Are there groups or settings that might be 
disadvantaged in relation to the problem 
or options that are considered? 
Are there plausible reasons for anticipating 
differences in the relative effectiveness of 
the option for disadvantaged groups or 
settings? 
Are there different baseline conditions 
across groups or settings that affect the 
absolute effectiveness of the option or the 
importance of the problem for 
disadvantaged groups or settings? 
Are there important considerations that 
should be made when implementing the 
intervention (option) in order to ensure 
that inequities are reduced, if possible, and 
that they are not increased? 
A
C
C
EP
TA
B
IL
IT
Y 
Is the intervention acceptable to key stakeholders?  
○ No 
○ Probably no 
○ Probably yes 
○ Yes 
○ Varies 
●  Don't know 
 No research evidence available.   There are no data on the acceptability of 
baseline eosinophil measurement.  More 
data is required to determine whether the 
use of biomarkers such as eosinophil level 
to determine therapeutic response would 
be useful and acceptable. 
However, as noted above, blood 
measurement of eosinophils is more easily 
accessible in standard clinical laboratories 
than sputum eosinophil measurement. 
FE
A
SI
B
IL
IT
Y 
Is the intervention feasible to implement? 
○ No 
○ Probably no 
○ Probably yes 
○ Yes 
● Varies 
○ Don't know 
 
No research evidence available. 
 Patients may find that some practicalities 
limit the use / make less feasible the use of 
the recommended intervention for 
example the use of sputum eosinophils as 
it requires a specialized center. 
 It is feasible to implement baseline blood 
measurement in most settings. 
  
Should a measurement of a specific biomarker be used, in addition to total IgE level, to guide initiation of treatment with a monoclonal anti-IgE antibody in 
adults and children with severe asthma? (biomarkers being exhaled NO, peripheral or sputum eosinophils, and serum periostin) 
 
GRADE Evidence Profile: OMALIZUMAB - PERIOSTIN 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Reduction in exacerbation rates per patient 
Follow up: 48 weeks 
(higher percentage, better reduction)  
1 (534 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Relative reduction in exacerbation rate of omalizumab compared to placebo were: Periostin (≥50 ng/ml): 30% (95% CI: -2 to 51); p-value= 
0.07 Periostin (<50 ng/ml): 3% (95% CI: -43 to 32); p-value= 0.94 Number of patients: 534; test for subgroup differences: no available  
⨁⨁◯◯ 
LOW  
 
Change from baseline at week 48 in AQLQ 
Follow up: 48 weeks 
7-point scale (7 = not impaired at all - 1 = severely impaired; higher values, better QoL) 
1 (534 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Mean change from baseline to week 48 of omalizumab compared to placebo were: Periostin (≥50 ng/ml): Least square mean difference= 
0.10 (95% CI: -0.19 to 0.40); p-value= 0.51 Periostin(<50 ng/ml): Least square mean difference= 0.50 (95% CI: 0.22 to 0.77); p-value= 
0.0005 Number of patients: 534; test for subgroup differences: P=0.05 c  
 
⨁⨁◯◯ 
LOW  
 
Change from baseline in % predicted FEV1 
Follow up: 48 weeks 
(higher change, better outcome) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 (534 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Mean change from baseline to week 48 of omalizumab compared to placebo were: Periostin (≥50 ng/ml): Least square mean difference= 
0.42 (95% CI: -3.22 to 4.06); p-value= 0.82 Periostin (<50 ng/ml): Least square mean difference= 1.79 (95% CI: -1.15 to 4.73); p-value= 
0.23 Number of patients: 534; test for subgroup differences: P=0.57 c 
 
⨁⨁◯◯ 
LOW  
 
Adverse events 
Follow up: 48 weeks 
(higher values, worst outcome) 
1 (534 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Percentage of patients with treatment-related adverse events of omalizumab compared to placebo were: Periostin (≥50 ng/ml): 82% versus 
81%; RR= 1.01 (95% CI= 0.90 to 1.14) Periostin (<50 ng/ml): 84% versus 82%; RR= 1.03 (95% CI= 0.92 to 1.14) Number of pat ients: 534; 
test for subgroup differences: P=0.87  
 
⨁⨁◯◯ 
LOW  
 
Time to first protocol asthma exacerbation 
Follow up: 48 weeks 
(lower values, better outcome) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 (534 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Time to first asthma exacerbation of omalizumab compared to placebo were: Periostin (≥50 ng/ml): HR= 0.72 (95% CI= 0.49 to 1.1) 
Periostin(<50 ng/ml): HR= 1.1 (95% CI= 0.77 to 1.6) Number of patients: 534; test for subgroup differences: P=0.11 
 
⨁⨁◯◯ 
LOW  
 
CI: Confidence interval 
 
Explanations 
a. Risk of bias due to a considerable number of patients was not evaluated at baseline for biomarker levels  
b. Optimal information size not reached for the main objective (and then for the subgroup analysis), reported by authors  
c. P values about Test for subgroup differences were estimated in RevMan and assuming that LSM is similar to Mean differences (just for descriptive purposes)  
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GRADE Evidence Profile: OMALIZUMAB - EOSINOPHIL 
Certainty assessment № of patients Effect 
Certainty 
Importanc
e 
№ of 
studies 
Study 
design 
Risk 
of 
bias 
Inconsistenc
y 
Indirectnes
s 
Imprecisio
n 
Other 
consideration
s 
Omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Exacerbation rates per patient 
Follow up: 24 weeks 
(lower rates, better reduction) 
1 (217 
participants)
1 
randomise
d trials  
seriou
s a 
not serious  not serious  serious b none  Exacerbation rate of omalizumab compared to placebo were: Eosinophil (≥300/uL): 0.25 vs 0.59, Rate ratio 0.41 (95%CI 0.20 to 0.82) Eosinophil 
(<300/uL): 0.17 vs 0.16, Rate ratio 1.07 (95%CI 0.45 to 2.53) Number of patients: 217; test for subgroup differences, p=0.09
 
⨁⨁◯◯ 
LOW  
 
Reduction in exacerbation rates per patient 
Follow up: 48 weeks 
(higher percentage, better reduction) 
1 (797 
participants)
2 
randomise
d trials  
seriou
s a,c 
not serious  not serious  serious b none  Relative reduction in exacerbation rate of omalizumab compared to placebo were: Eosinophil (≥260/uL): 32% (95% CI: 11 to 48); p-value= 0.005 
Eosinophil (<260/uL): 9% (95% CI: -24 to 34); p-value= 0.54 Number of patients: 797; test for subgroup differences: no available  
⨁⨁◯◯ 
LOW  
 
At least one exacerbation 
Follow up: 24 weeks 
(lower rates, better outcome) 
Certainty assessment № of patients Effect 
Certainty 
Importanc
e 
№ of 
studies 
Study 
design 
Risk 
of 
bias 
Inconsistenc
y 
Indirectnes
s 
Imprecisio
n 
Other 
consideration
s 
Omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 (217 
participants) 
1 
randomise
d trials  
seriou
s a 
not serious  not serious  serious b none  Exacerbation rate of omalizumab compared to placebo were: Eosinophil (≥300/uL): Risk ratio 0.52 (95%CI 0.26 to 1.04) Eosinoph il (<300/uL): Risk ratio 
1.00 (95%CI 0.42 to 2.36) Number of patients: 217; test for subgroup differences, p=0.25  
 
⨁⨁◯◯ 
LOW  
 
Relative change from baseline to week 24 in % predicted FEV1 
(higher change, better outcome)  
Follow up: 24 weeks 
1 (217 
participants) 
1 
randomise
d trials  
seriou
s a 
not serious  not serious  serious b none  Relative change in % predicted FEV1 when omalizumab is compared to placebo were: Eosinophil (≥300/uL): Least squares mean treatment (ANOVA): 
7.35% (95% CI: 1.38 to 13.31) Eosinophil (<300/uL): Least squares mean treatment (ANOVA): 3.67% (95% CI: -0.46 to 7.81) Number of patients: 217; 
test for subgroup differences: P= 0.32 d 
 
⨁⨁◯◯ 
LOW  
 
Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) 
Follow up: 48 weeks 
7-point scale (7 = not impaired at all - 1 = severely impaired; higher values, better QoL) 
Certainty assessment № of patients Effect 
Certainty 
Importanc
e 
№ of 
studies 
Study 
design 
Risk 
of 
bias 
Inconsistenc
y 
Indirectnes
s 
Imprecisio
n 
Other 
consideration
s 
Omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 (797 
participants)
2 
randomise
d trials  
seriou
s a,c 
not serious  not serious  serious b none  Mean change from baseline to week 48 of omalizumab compared to placebo were: Eosinophil (≥260/uL): Least square mean difference= 0.14 (95% CI: -
0.11 to 0.36); p-value= 0.29 Eosinophil (<260/uL): Least square mean difference= 0.26 (95% CI: 0.06 to 0.51); p-value= 0.01 Number of patients: 797; 
test for subgroup differences: P= 0.46 d 
 
 
 
 
⨁⨁◯◯ 
LOW  
 
Change from baseline in % predicted FEV1  
Follow up: 48 weeks 
(higher change, better outcome) 
1 (797 
participants) 
2 
randomise
d trials  
seriou
s a,c 
not serious  not serious  serious  none  Mean change from baseline to week 48 of omalizumab compared to placebo were: Eosinophil (≥260/uL): Least square mean difference= 1.3 (95% CI: -
1.23 to 3.84); p-value= 0.31 Eosinophil (<260/uL): Least square mean difference= 1.72 (95% CI: -1.06 to 4.51); p-value= 0.02 Number of patients: 797; 
test for subgroup differences: P=0.83 d 
 
 
⨁⨁◯◯ 
LOW  
 
Certainty assessment № of patients Effect 
Certainty 
Importanc
e 
№ of 
studies 
Study 
design 
Risk 
of 
bias 
Inconsistenc
y 
Indirectnes
s 
Imprecisio
n 
Other 
consideration
s 
Omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Adverse events 
follow up: 48 weeks 
(higher values, worst outcome) 
1 (797 
participants) 
2,e 
randomise
d trials  
seriou
s a,c 
not serious  not serious  serious b none  Percentage of patients with treatment-related adverse events of omalizumab compared to placebo were: Eosinophil (≥260/uL): 80% versus 79.4%; RR= 
1.01 (95% CI= 0.91 to 1.11) Eosinophil (<260/uL): 80.6% versus 81.7%; RR= 0.99 (95% CI= 0.90 to 1.09) Number of patients: 797 ; test for subgroup 
differences: P =0.77  
 
 
 
⨁⨁◯◯ 
LOW  
 
Time to first asthma exacerbation 
Follow up: 48 weeks 
(lower values, better outcome) 
1 (797 
participants) 
2 
randomise
d trials  
seriou
s a,c 
not serious  not serious  serious b none  Time to first asthma exacerbation of omalizumab compared to placebo were: Eosinophil (≥260/uL): HR= 0.64 (95% CI= 0.48 to 0.86) Eosinophil 
(<260/uL): HR= 0.95 (95% CI= 0.68 to 1.3) Number of patients: 797; test for subgroup differences: P=0.08  
 
⨁⨁◯◯ 
LOW  
 
CI: Confidence interval 
Explanations 
a. Risk of bias related to incomplete outcome data: eosinophil counts were not necessarily collected for all patients at base line and may therefore have been missing at random depending on their availability in the original laboratory test records  
b. Optimal information size not reached for the main objective (and then for the subgroup analysis), reported by authors  
c. Potential risk of bias associated with selective reporting bias (subgroups analyses no stated in the protocol)  
d. P values about Test for subgroup differences were estimated in RevMan and assuming that LSM is similar to Mean differences (just for descriptive purposes)  
e. Only Hanania 2013 provided subgroup information for this outcome  
References 
1. Busse W, Spector S,Rosén K,Wang Y,Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol; 2013.  
2. Hanania NA1, Wenzel S,Rosén K,Hsieh HJ,Mosesova S,Choy DF,Lal P,Arron JR,Harris JM,Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med; 2013.  
  
GRADE Evidence Profile: OMALIZUMAB – FeNO 
 Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Reduction in exacerbation rates per patient 
Follow up: 48 weeks 
(higher percentage, better reduction) 
1 (394 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Relative reduction in exacerbation rate of omalizumab compared to placebo were: FENO(≥19.5 ppb): 53% (95% CI: 37 
to 70); p-value= 0.001 FENO(<19.5 ppb): 16% (95% CI: -32 to 46); p-value= 0.45 Number of patients: 394; test for 
subgroup differences: no available  
⨁⨁◯◯ 
LOW  
 
Change from baseline to 48 week in AQLQ 
Follow up: 48 weeks 
7-point scale (7 = not impaired at all - 1 = severely impaired; Higher values, better QoL) 
 
1 (394 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Mean change from baseline to week 48 of omalizumab compared to placebo were: FENO (≥19.5 ppb): Least square 
mean difference= 0.39 (95% CI: 0.06 to 0.73); p-value= 0.02 FENO (<19.5 ppb): Least square mean difference= 0.24 
(95% CI: -0.09 to 0.57); p-value= 0.16 Number of patients: 394; test for subgroup differences: P= 0.53 c  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
⨁⨁◯◯ 
LOW  
 
 Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Change from baseline in % predicted FEV1  
Follow up: 48 weeks 
(higher change, better outcome) 
1 (394 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Mean change from baseline to week 48 of omalizumab compared to placebo were: FENO (≥19.5 ppb): Least square 
mean difference= 3.26 (95% CI: -0.33 to 6.84); p-value= 0.08 FENO (<19.5 ppb): Least square mean difference= 1.97 
(95% CI: -1.83 to 5.77); p-value= 0.31 Number of patients: 394; test for subgroup differences: P = 0.63 c  
 
⨁⨁◯◯ 
LOW  
 
Adverse events 
Follow up: 48 weeks 
(higher values, worst outcome) 
1 (394 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Percentage of patients with treatment-related adverse events of omalizumab compared to placebo were: FENO (≥19.5 
ppb): 80.2% versus 73%; RR= 1.10 (95% CI= 0.94 to 1.28) FENO(<19.5 ppb): 83.5% versus 80%; RR= 1.04 (95% CI= 
0.91 to 1.19) Number of patients: 394; test for subgroup differences: P=0.62  
 
 
 
 
 
⨁⨁◯◯ 
LOW  
 
 Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations omalizumab placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Time to first asthma exacerbation 
Follow up: 48 weeks 
(lower values, better outcome) 
1 (394 
participants)1 
randomised 
trials  
serious a not serious  not serious  serious b none  Time to first asthma exacerbation of omalizumab compared to placebo were: FENO(≥19.5 ppb): HR= 0.38 (95% CI= 
0.24 to 0.61) FENO(<19.5 ppb): HR= 1.0 (95% CI= 0.62 to 1.6) Number of patients: 394; test for subgroup differences: 
P=0.004  
 
⨁⨁◯◯ 
LOW  
 
CI: Confidence interval 
Explanations 
a. Risk of bias due to a considerable number of patients was not evaluated at baseline for biomarker levels  
b. Optimal information size not reached for the main objective (and then for the subgroup analysis), reported by authors  
c. P values about Test for subgroup differences were estimated in RevMan and assuming that LSM is similar to Mean differences (just for descriptive purposes)  
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Evidence to Decision Framework: OMALIZUMAB – PERIOSTIN 
Should measurement of Periostin be used to select patients for initiation of a monoclonal anti-IgE strategy in adults and children with severe asthma? 
POPULATION:  Adults and children (≥12 years) with severe asthma BACKGROUND: Until relatively recently treatment options for patients with severe asthma who 
were refractory to standard treatments have been limited.  Over the last two 
decades there have been major advances in treatment options for patients with 
severe disease.  In the early 2000s omalizumab, a monoclonal antibody therapy 
that targets and neutralises IgE entered the market.  Since that time a number of 
other monoclonal antibody therapies targeting the T2 pathway have emerged. The 
treatments have proven efficacy in reducing exacerbations and oral corticosteroid 
requirements, and improving patient reported outcomes.  With multiple 
treatment options now available it has become increasingly important to ensure 
that the right targeted treatment is delivered to the right patient with severe 
asthma.  This approach allows for the delivery of personalised or precision 
medicine.  It is now critical to understand the population in which targeted 
therapies are likely to have the greatest effect.  Serum periostin does not appear 
useful in predicting reponse to anti-IgE treatment. 
 
 
INTERVENTION: Omalizumab compared to placebo in patients with severe asthma who 
have serum periostin levels  ≥50 ng/ml 
COMPARISON: Omalizumab in patients with severe asthma who have serum periostin 
levels  <50 ng/ml 
MAIN OUTCOMES: Exacerbation rates, time to first exacerbations, asthma related quality 
of life, FEV1, adverse effects 
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the desirable anticipated effects?  
● Trivial 
○ Small 
○ Moderate 
○ Large  
○ Varies 
○Don't know 
 
Results from research evidence (studies) 
 
No differences were detected in terms of relative reduction of exacerbation rates at 48 
weeks or FEV1 when omalizumab was compared to placebo in periostin high (50 ng/ml or 
more) or low (less than 50 ng/ml) patients. There were however improvements in baseline 
AQLQ scores with omalizumab compared to placebo in patients with low (less than 50 
mg/ml) periostin levels at 48 weeks follow-up (MD 0.50 [0.22,0.78]), whereas there are no 
differences patients with high (50 ng/ml and more) periostin levels (MD 0.10 [-0.19,0.39]). 
 
 
 
There are no differences in terms adverse events at 48 weeks of follow-up, when 
omalizumab is compared to placebo in high or low periostin levels at baseline.  
Panel considerations 
 
 
 
U
N
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the undesirable anticipated effects?  
○ Large 
○ Moderate 
● Small 
○ Trivial 
○ Varies 
○ Don't know 
 
  
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
What is the overall certainty of the evidence of effects?  
○ Very low 
● Low 
○ Moderate 
○ High 
○ No included studies 
 
The risk of bias was high for completeness of data, due to a considerable number of 
patients that were not evaluated at baseline for biomarker levels. 
 
V
A
LU
ES
 
Is there important uncertainty about or variability in how much 
people value the main outcomes? 
● Important uncertainty or variability 
○ Possibly important uncertainty or variability 
The test -Serum Periostin: In a study which aimed to evaluate the patient perception of 
tests used for the assessment of asthma and COPD venipuncture had a reseasonabile 
assessment profile, it was rated as more painful that comparator tests eg. Questionaires 
but was acceptable in terms of comfort, difficulty and time taken to do the test1. 
 
 
○ Probably no important uncertainty or variability 
○ No important uncertainty or variability 
○ No known undesirable outcomes 
 
The intervention did not lead to improvements in some outcomes that are valued by 
consumers in the biomarker high group, although there were larger quality of life 
improvements in the biomarker low group. 
B
A
LA
N
C
E 
O
F 
EF
FE
C
TS
 
Does the balance between desirable and undesirable effects favor 
the intervention or the comparison?  
○ Favors the comparison 
○ Probably favors the comparison 
● Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
○ Don't know 
 
There were no differences in terms of % predicted FEV1 mean change at 48 weeks of 
follow-up, when omalizumab is compared to placebo in high (50 ng/ml or more) or low 
(less than 50 ng/ml) periostin levels at baseline.   
There were no differenence in time to first asthma exacerbation with omalizumab 
compared to placebo in those patients with high (50 ng/ml or more) or low (less than 50 
ng/ml) periostin levels at the same follow-up. In addition, there are no statistically 
significant differences between these subgroups 
 
Their were no differences in the adverse effects in patients treated with omalizumab versus 
placebo irrespective of high or low perisotin. 
 
There was a significant mean change of baselines AQLQ scores with omalizumab compared 
to placebo in those patients with low (less than 50 mg/ml) periostin levels at 48 weeks 
follow-up, whereas there were no differences in the same outcome for those patients with 
high (50 ng/ml and more) periostin levels at the same follow-up 
  
C
O
ST
 E
FF
EC
TI
V
EN
ES
S 
Does the cost-effectiveness of the intervention favor the 
intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
● No included studies 
 
No research evidence identified.  
There would be an additional cost of using 
Periostin.   
 
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
O
F 
R
EQ
U
IR
E
D
 
R
E
SO
U
R
C
ES
 
What is the certainty of the evidence of resource requirements 
(costs)? 
○ Very low 
○ Low 
○ Moderate 
○ High 
● No included studies  
No research evidence identified.  
There would be an additional cost of using 
Periostin.   
EQ
U
IT
Y 
What would be the impact on health equity?  
○ Reduced 
○ Probably reduced 
○ Probably no impact 
○ Probably increased 
●Increased 
○ Varies 
○ Don't know 
No research evidence identified. 
 
Perisotin is currently not available and is 
not applicable in children 
A
C
C
EP
TA
B
IL
IT
Y 
Is the intervention acceptable to key stakeholders?  
● No 
○ Probably no 
○ Probably yes 
○ Yes 
○ Varies 
○ Don't know 
No research evidence identified. 
 
Periostin is currently only available 
for research and is not applicable 
to children.  
There is no evidence that periostin 
levels are useful in predicting 
exacerbation and lung function 
response to treatment.  
FE
A
SI
B
IL
IT
Y 
Is the intervention feasible to implement?  
● No 
○ Probably no 
○ Probably yes 
○ Yes 
○ Varies 
○ Don't know 
No research evidence identified. 
 
  
At present periostin is only 
available in research setting and is 
not applicable to children.  
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Evidence to Decision Framework: OMALIZUMAB – EOSINOPHILS 
Should measurement of blood eosinophils be used to select patients for initiation of a monoclonal anti-IgE strategy in adults and children with severe asthma? 
POPULATION:  Adults and children (≥12 years) with severe asthma BACKGROUND:  
 
 
Until relatively recently treatment options for patients with severe asthma 
who were refractory to standard treatments have been limited.  Over the 
last two decades there have been major advances in treatment options for 
patients with severe disease.  In the early 2000s omalizumab, a monoclonal 
antibody therapy that targets and neutralises IgE entered the market.  Since 
that time a number of other monoclonal antibody therapies targeting the 
T2 pathway have emerged. The treatments have proven efficacy in reducing 
exacerbations and oral corticosteroid requirements, and improving patient 
reported outcomes.  With multiple treatment options now available it has 
become increasingly important to ensure that the right targeted treatment 
is delivered to the right patient with severe asthma.  This approach allows 
for the delivery of personalised or precision medicine.  It is now critical to 
understand the population in which targeted therapies are likely to have 
the greatest effect.  An elevation of peripheral blood eosinophils can be 
used as a biomarker to  predict reponse to anti-IgE treatment and enable 
this personalised approach. 
 
  
INTERVENTION: Measurement of blood eosinophil counts and treatment with 
Omalizumab in patients with severe asthma who have 
≥260/μl 
COMPARISON: Measurement of blood eosinophil counts and treatment with 
Omalizumab in patients with severe asthma who have 
<260/μl 
MAIN OUTCOMES: Exacerbation rates, time to first exacerbations, asthma 
related quality of life, FEV1, adverse effects 
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the desirable anticipated effects? 
○ Trivial 
○ Small 
○ Moderate 
● Large  
○ Varies 
○Don't know 
 
Results from research evidence (studies)  
Included in the evidence synthesis were two randomised contolled trials. Pooling of the 
studies was not possible.  In one study1 using there were improvements in exacerbations 
rates (HR 0.41 [0.20, 0.84]) and a small but significantly greater change in FEV1 predicted at 
24 weeks (MD 7.35 [1.38, 13.32]) with omalizumab compared to placebo in patients with a 
high eosinophil count (≥300/μl), whereas there were no differences in patients with low 
eosinophils (< 300/uL).   
In another RCT2 there was a significantly longer time to first asthma exacerbation with 
omalizumab compared to placebo in patients with high (260/uL or more) eosinophil count 
at 48 weeks follow-up (HR 0.64 [0.48. 0.85]), whereas there were no differences in patients 
with low (less than 260/uL) eosinophil count (HR 0.95 [0.68, 1.33]). However, there were no 
statistically significant differences between these subgroups. 
There were no differences in terms of percentage of treatment-related adverse events at 
48 weeks of follow-up, when omalizumab is compared to placebo in patients with high or 
low blood eosinophils.  
Undergoing a test for peripheral blood eosinophils involves venepuncture which may be 
more painful than not having a blood test, as such there may be small undesirable effects 
of the test. 
Panel considerations 
 
 
 
U
N
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the undesirable anticipated effects? 
○ Large 
○ Moderate 
● Small 
○ Trivial 
○ Varies 
○ Don't know 
 
  
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
What is the overall certainty of the evidence of effects?  
○ Very low 
● Low 
○ Moderate 
○ High 
○ No included studies 
 
The risk of bias was high for completeness of data, due to a considerable number of 
patients that were not evaluated at baseline for blood eosinophils. 
 
 
 
V
A
LU
ES
 
Is there important uncertainty about or variability in how much 
people value the main outcomes? 
○ Important uncertainty or variability 
● Possibly important uncertainty or variability 
The test - peripheral blood eosinophils: In a study which aimed to evaluate the patient 
perception of tests used for the assessment of asthma and COPD, venipuncture had a 
reseasonable assessment profile, it was rated as more painful than the comparator tests 
eg. Questionaires, but was acceptable in terms of comfort, difficulty and time taken to do 
the test3. 
 
○ Probably no important uncertainty or variability  
○ No important uncertainty or variability 
○ No known undesirable outcomes 
 
 
The intervention led to improvements in outcomes that are highly valued by the consumer, 
as rated by the representatives on the Taskforce.  In a study in severe asthma evaluating 
which outcomes matter to patients, reduced exacerbations and improved quality of life 
were viewed amongst their highest priorities (Clark V et. al, TSANZ 2019).  
B
A
LA
N
C
E 
O
F 
EF
FE
C
TS
 
Does the balance between desirable and undesirable effects favor 
the intervention or the comparison?  
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
● Favors the intervention  
○ Varies 
○ Don't know 
 
People in the high and low eosinophil groups both experienced adverse effects, with no 
differences according to their subgroups.  People in the eosinophil high group received the 
clinical benefit without any in increase side effects, whereas the low eosinophil group 
experienced the same side effects without the clinical benefit. 
  
C
O
ST
 E
FF
EC
TI
V
EN
ES
S 
Does the cost-effectiveness of the intervention favor the 
intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
● Favors the intervention  
○ Varies 
○ No included studies 
 
 
No research evidence identified. 
The intervention (measurement of 
eosinophils in the blood) is a low cost 
intervention that is already routinely used 
in practice in this population. 
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
O
F 
R
EQ
U
IR
E
D
 
R
E
SO
U
R
C
ES
 
What is the certainty of the evidence of resource requirements 
(costs)? 
○ Very low 
○ Low 
● Moderate 
○ High 
○No included studies 
 
No research evidence identified. 
While no studies evaluated the evidence of 
resource requirements the certainty is high 
as blood eosinophil counts are a low cost 
test already used in most areas of 
medicine, as the biomarker is included in 
the full blood count. 
 
EQ
U
IT
Y 
What would be the impact on health equity?  No research evidence identified. The measurement of peripherial blood 
eosinophil counts is low cost and readily 
○ Reduced 
○ Probably reduced 
● Probably no impact 
○ Probably increased 
○ Increased 
○ Varies 
○ Don't know 
accessible, so all patients are likely to have 
the biomarker measured. 
A
C
C
EP
TA
B
IL
IT
Y 
Is the intervention acceptable to key stakeholders?  
○ No 
○ Probably no 
○ Probably yes 
● Yes 
○ Varies 
○ Don't know 
 
No research evidence identified. 
 The test is already available as a standard 
medical assessment at a low cost, so the 
use of this biomarker should not 
disadvantage any minority groups. 
 
FE
A
SI
B
IL
IT
Y 
Is the intervention feasible to implement? 
○ No 
○ Probably no 
○ Probably yes 
● Yes 
○ Varies 
○ Don't know 
 
No research evidence identified. 
  There are likely to be few limitations since 
this test is already freely available, low 
cost, already used in practice and generally 
acceptable to patients
3
. 
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Evidence to Decision Framework: OMALIZUMAB – FeNO 
Should measurement of exhaled NO be used to select patients for initiation of a monoclonal anti-IgE strategy in adults and children with severe asthma? 
POPULATION:  Adults and children (≥12 years) with severe asthma BACKGROUND: 
 
Until relatively recently treatment options for patients with severe asthma who 
were refractory to standard treatments have been limited.  Over the last two 
decades there have been major advances in treatment options for patients with 
severe disease.  In the early 2000s omalizumab, a monoclonal antibody therapy that 
targets and neutralises IgE entered the market.  Since that time a number of other 
monoclonal antibody therapies targeting the T2 pathway have emerged. The 
treatments have proven efficacy in reducing exacerbations and oral corticosteroid 
requirements, and improving patient reported outcomes.  With multiple treatment 
options now available it has become increasingly important to ensure that the right 
targeted treatment is delivered to the right patient with severe asthma.  This 
approach allows for the delivery of personalised or precision medicine.  It is now 
critical to understand the population in which targeted therapies are likely to have 
the greatest effect.  An elevation of FeNO ≥19.5 ppb can be used as a biomarker to  
predict reponse to anti-IgE treatment and enable this personalised approach. 
 
 
INTERVENTION: Omalizumab compared to placebo in FeNO high (≥19.5 ppb) 
patients with severe asthma 
COMPARISON: Omalizumab compared to placebo in FeNO high (<19.5 ppb) 
patients with severe asthma 
MAIN OUTCOMES: Exacerbation rates, time to first exacerbations, asthma related 
quality of life, FEV1, adverse effects 
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the desirable anticipated effects?  
○ Trivial 
○ Small 
○ Moderate 
● Large  
○ Varies 
○Don't know 
 
Results from research evidence (studies) 
Only one RCT was included in this evidence systhesis 
 
There was a significant relative reduction of exacerbation rates with omalizumab 
compared to placebo in patients with high (19.5 ppb or more) FENO level at 48 weeks 
follow-up (53% [95% Cl 37-70]); p=0.001, whereas there were no differences for those 
patients with low (less than 19.5 ppb) FENO levels (16% [95% CI: -32 to 46]); p= 0.45.  The 
time to first asthma exacerbation with omalizumab compared to placebo was significantly 
longer in patients with high (19.5 ppb or more) FENO level at 48 weeks follow-up (HR 0.38 
[0.24, 0.60]), whereas there were no differences in patients with low (less than 19.5 ppb) 
FENO (HR 1.00 [0.62, 1.61]). There were also larger changes of mean AQLQ with 
omalizumab compared to placebo in FeNO high patients (19.5 ppb or more) at 48 weeks of 
follow-up (MD 0.39 [0.06, 0.72]), whereas there were no differences in FeNO low patients 
(less than 19.5 ppb) (MD 0.24 [-0.09, 0.57]). 
 
 
 
 
Only one RCT was included in this evidence systhesis 
 
U
N
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the undesirable anticipated effects?  
○ Large 
○ Moderate 
● Small 
○ Trivial 
○ Varies 
○ Don't know 
 
  There are no differences in terms of 
percentage of treatment-related adverse 
events at 48 weeks of follow-up, when 
omalizumab is compared to placebo in high 
or low FENO levels at baseline.   
 
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
What is the overall certainty of the evidence of effects?  
○ Very low 
● Low 
○ Moderate 
○ High 
○ No included studies 
 
The risk of bias was high for completeness of data, due to a considerable number of 
patients that were not evaluated at baseline for their FeNO level. 
Each analysis only included single RCTs of 
patients with severe asthma eligible for 
anti-IgE treatment.   
V
A
LU
ES
 
Is there important uncertainty about or variability in how much 
people value the main outcomes? 
○ Important uncertainty or variability 
● Possibly important uncertainty or variability 
○ Probably no important uncertainty or variability 
○ No important uncertainty or variability 
○ No known undesirable outcomes 
 
The test - FeNO: In a study which aimed to evaluate the patient perception of tests used 
for the assessment of asthma and COPD, FeNO had a good assessment profile, with a 
favourable assessment overall compared to completing questionnaires and only being 
associated with some difficulty in test performance1. 
 
The intervention lead to improvements in outcomes that are highly valued by the 
consumer, as rated by the representatives on this Taskforce.  In a study in severe asthma 
evaluating which outcomes matter to patients, reduced exacerbations and improved 
quality of life were viewed amongst their highest priorities (Clark V etal, TSANZ 2019). 
 
B
A
LA
N
C
E 
O
F 
EF
FE
C
TS
 
Does the balance between desirable and undesirable effects favor 
the intervention or the comparison?  
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
● Favors the intervention  
○ Varies 
○ Don't know 
 
  Their were no differences in the adverse 
effects in patients treated with 
omalizumab versus placebo irrespective of 
high or low FeNO.  People in the FeNO high 
group received the clinical benenfit 
without any increase in side effects, 
whereas the low FeNO group experienced 
the same side effects without the clinical 
benefit. 
C
O
ST
 E
FF
EC
TI
V
EN
ES
S 
Does the cost-effectiveness of the intervention favor the 
intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
● No included studies  
 
 
No research evidence identified. 
There would be an additional cost of using 
FeNO to select patients for the treatment 
in non specialist centres.  However, in 
specialist centres FeNO is commonly 
assessed. If the test is used to select 
patients most likely to respond, cost 
benefits are likely. 
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
O
F 
R
EQ
U
IR
E
D
 
R
E
SO
U
R
C
ES
 
What is the certainty of the evidence of resource requirements 
(costs)? 
○ Very low 
○ Low 
○ Moderate 
○ High 
● No included studies  
No research evidence identified.  
Cost of the test may limit widescale 
implementation. 
EQ
U
IT
Y 
What would be the impact on health equity?  
○ Reduced 
● Probably reduced  
○ Probably no impact 
○ Probably increased 
○ Increased 
○ Varies 
○ Don't know 
 
No research evidence identified. 
 There is no evidence of an impact on 
health equity, however given the lack of 
widespread FeNO use, some groups may 
not have access to the test. 
A
C
C
EP
TA
B
IL
IT
Y 
Is the intervention acceptable to key stakeholders? 
○ No 
○ Probably no 
● Probably yes 
○ Yes 
○ Varies 
○ Don't know 
Previous ERS/ATS Taskforce recommends against the use of FeNO to guide therapy of 
adults and children with severe asthma.  This may impact acceptability2. 
 
In terms of patient acceptability, a study which aimed to evaluate the patient perception of 
tests used for the assessment of asthma and COPD, found that FENO had a good 
assessment profile, with a favourable assessment overall compared to completing 
questionnaires, and only being associated with some difficulty in test performance
1
. 
 
 As treatment of omalizumab is initiated in 
specialist severe asthma clinics and FeNO is 
a common measure used in these clinics, it 
is likely that this is acceptable to severe 
asthma clinicians.   
 
FE
A
SI
B
IL
IT
Y 
Is the intervention feasible to implement? 
○ No 
○ Probably no 
● Probably yes 
○ Yes 
○ Varies 
○ Don't know 
 
No research evidence identified. 
 Cost of the test may limit widescale 
implementation.  
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Should a long-acting inhaled muscarinic antagonist (LAMA) be used in adults and children with severe asthma? 
GRADE Evidence Profile: LAMA (tiotropium)  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMA 
(tiotropium) 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Peak FEV1 response - Children 2.5 ug 
1 1 randomised 
trials  
serious a not serious  not serious  not serious  none  135  130  MD 35 higher 
(27.99 lower to 97.99 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Peak FEV1 response - Adolescents 2.5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  serious b none  127  135  MD 111 higher 
(2.01 higher to 219.99 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Peak FEV1 response - Children 5 ug 
1 1 randomised 
trials  
not serious  not serious  not serious  serious b none  128  130  MD 139 higher 
(74.32 higher to 203.68 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Peak FEV1 response - Adolescents 5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  serious b none  130  135   MD 90 higher 
(18.99 lower to 198.99 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Peak FEV1 response - Adults 5 ug 
2 3,4 randomised 
trials  
not serious  not serious  not serious  serious b none  456  456  MD 120.74 higher 
(54.12 higher to 187.36 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMA 
(tiotropium) 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Change in ACQ-7 scores - Children 2.5 ug 
11  randomised 
trials  
not serious  not serious  not serious  not serious  none  136  130   MD 0.02 higher 
(0.14 lower to 0.18 higher)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Change in ACQ-7 scores - Adolescents 2.5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  not serious  none  127  135  MD 0.06 higher 
(0.1 lower to 0.22 higher)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Change in ACQ-7 scores - Children 5 ug 
1 1 randomised 
trials  
not serious  not serious  not serious  not serious  none  126  130  MD 0.08 lower 
(0.24 lower to 0.08 higher)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Change in ACQ-7 scores - Adolescents 5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  not serious  none  130  135   MD 0.04 higher 
(0.12 lower to 0.19 higher)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Change in ACQ-7 scores - Adults 5 ug 
2 3,4 randomised 
trials  
not serious  not serious  not serious  not serious  none  456  456  MD 0.17 lower 
(0.25 lower to 0.09 lower)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Asthma worsening (at least 1) - Children 2.5 ug 
1 1 randomised 
trials  
not serious  not serious  not serious  serious c none  29/135 
(21.5%)  
23/65 (35.4%)  RR 0.61 
(0.38 to 0.96)  
138 fewer 
per 1.000 
(from 219 
fewer to 
14 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMA 
(tiotropium) 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Asthma worsening (at least 1) - Adolescents 2.5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  serious c none  18/127 
(14.2%)  
12/67 (17.9%)  RR 0.79 
(0.41 to 1.54)  
38 fewer 
per 1.000 
(from 106 
fewer to 
97 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Asthma worsening (at least 1) - Children 5 ug 
1 1 randomised 
trials  
not serious  not serious  not serious  serious c none  35/128 
(27.3%)  
23/65 (35.4%)  RR 0.77 
(0.50 to 1.19)  
81 fewer 
per 1.000 
(from 177 
fewer to 
67 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Asthma worsening (at least 1) - Adolescents 5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  serious c none  15/130 
(11.5%)  
12/67 (17.9%)  RR 0.64 
(0.32 to 1.30)  
64 fewer 
per 1.000 
(from 122 
fewer to 
54 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Asthma worsening (at least 1) - Adults 5 ug 
1 4 randomised 
trials  
not serious  not serious  not serious  not serious  none  226/453 
(49.9%)  
287/454 
(63.2%)  
RR 0.79 
(0.70 to 0.89)  
133 fewer 
per 1.000 
(from 190 
fewer to 
70 fewer)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Peak FEV1 % predicted - Children 2.5 ug 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMA 
(tiotropium) 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 1 randomised 
trials  
serious a not serious  not serious  not serious  none  135  130  MD 3.6 higher 
(0.5 higher to 6.7 higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Peak FEV1 % predicted - Children 5 ug 
1 1 randomised 
trials  
serious a not serious  not serious  not serious  none  128  130   MD 6.3 higher 
(3.3 higher to 9.3 higher)  
 
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Peak FEV1 % predicted - Children 5 ug 
1 1 randomised 
trials  
serious a not serious  not serious  very seriousc  none  Narrative report + figure: " Post hoc analyses of adjusted mean 
trough FEV1/FVC responses demonstrated statistically 
significant improvements at all-time points versus placebo with 
both tiotropium doses, with the exception of tiotropium 2.5 mg 
at week 8" 
⨁⨁◯◯ 
LOW  
IMPORTANT  
Peak FEV1 % predicted - Children 5 ug 
1 1 randomised 
trials  
serious a not serious  not serious  very seriousc  none  Narrative report + figure: " Post hoc analyses of adjusted mean 
trough FEV1/FVC responses demonstrated statistically 
significant improvements at all-time points versus placebo with 
both tiotropium doses, with the exception of tiotropium 2.5 mg 
at week 8" 
⨁⨁◯◯ 
LOW  
IMPORTANT  
AQLQ scores - Adults 5 ug 
2 3,4 randomised 
trials  
not serious  not serious  not serious  not serious  none  456  456   MD 0.1 higher 
(0.04 lower to 0.23 higher)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Time to first exacerbation - Adults 5 ug 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMA 
(tiotropium) 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 4 randomised 
trials  
not serious  not serious  not serious  serious d none  -/456  -/456  HR 0.79 
(0.62 to 1.01)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Hospitalizations for asthma - Adults 5 ug 
1 4 randomised 
trials  
not serious  not serious  not serious  serious c none  16/453 (3.5%)  20/454 (4.4%)  RR 0.80 
(0.42 to 1.53)  
9 fewer 
per 1.000 
(from 26 
fewer to 
23 more)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Any adverse event - Children 2.5 ug 
1 1 randomised 
trials  
not serious  not serious  not serious  serious c none  59/136 
(43.4%)  
33/67 (49.3%)  RR 0.88 
(0.65 to 1.20)  
59 fewer 
per 1.000 
(from 172 
fewer to 
99 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Any adverse event - Adolescents 2.5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  serious c none  42/127 
(33.1%)  
24/68 (35.3%)  RR 0.94 
(0.62 to 1.41)  
21 fewer 
per 1.000 
(from 134 
fewer to 
145 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Any adverse event - Children 5 ug 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMA 
(tiotropium) 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 1 randomised 
trials  
not serious  not serious  not serious  serious c none  56/130 
(43.1%)  
33/67 (49.3%)  RR 0.87 
(0.64 to 1.20)  
64 fewer 
per 1.000 
(from 177 
fewer to 
99 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Any adverse event - Adolescents 5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  serious c none  43/130 
(33.1%)  
24/68 (35.3%)  RR 0.94 
(0.63 to 1.40)  
21 fewer 
per 1.000 
(from 131 
fewer to 
141 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Any adverse event - Adults 5 ug 
2 3,4 randomised 
trials  
not serious  not serious  not serious  not serious  none  335/456 
(73.5%)  
366/456 
(80.3%)  
RR 0.92 
(0.86 to 0.98)  
64 fewer 
per 1.000 
(from 112 
fewer to 
16 fewer)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Serious adverse events - Children 2.5 ug 
1 1 randomised 
trials  
not serious  not serious  not serious  very serious 
c 
none  2/136 (1.5%)  1/67 (1.5%)  RR 0.99 
(0.09 to 10.67)  
0 fewer 
per 1.000 
(from 14 
fewer to 
144 more)  
 
⨁⨁◯◯ 
LOW  
IMPORTANT  
Serious adverse events - Adolescents 2.5 ug 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMA 
(tiotropium) 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 2 randomised 
trials  
not serious  not serious  not serious  very serious 
c 
none  0/127 (0.0%)  0/68 (0.0%)  not estimable   ⨁⨁◯◯ 
LOW  
IMPORTANT  
Serious adverse events - Children 5 ug 
1 1 randomised 
trials  
not serious  not serious  not serious  very serious 
c 
none  4/130 (3.1%)  1/67 (1.5%)  RR 2.06 
(0.24 to 18.08)  
16 more 
per 1.000 
(from 11 
fewer to 
255 more)  
⨁⨁◯◯ 
LOW  
IMPORTANT  
Serious adverse events - Adolescents 5 ug 
1 2 randomised 
trials  
not serious  not serious  not serious  very serious 
c 
none  3/130 (2.3%)  0/68 (0.0%)  RR 3.69 
(0.19 to 70.36)  
0 fewer 
per 1.000 
(from 0 
fewer to 0 
fewer)  
⨁⨁◯◯ 
LOW  
IMPORTANT  
Serious adverse events - Adults 5 ug 
2 3,4 randomised 
trials  
not serious  not serious  not serious  serious c none  37/456 (8.1%)  40/456 (8.8%)  RR 0.93 
(0.61 to 1.43)  
6 fewer 
per 1.000 
(from 34 
fewer to 
38 more)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
CI: Confidence interval; MD: Mean difference; SMD: Standardised mean difference; RR: Risk ratio; HR: Hazard Ratio 
Explanations 
a. Selective reporting bias: Some outcomes were assessed post-hoc including peak FEV1 (0-3h)  
b. Although we cannot exclude futility because all estimates do not reach MID, upper 95%CI boundary is next to clinically important effect. Minimal important differences for FEV1 change= 230 
millilitres  
c. Small number of events, large 95%CI  
d. Large 95CI% which includes no effect or a relevant benefit  
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Evidence to Decision Framework: LAMA (tiotropium) 
Should tiotropium vs. no tiotropium be used for children, adolescents, and adults with severe asthma uncontrolled despite GINA step 4-5 or NAEPP step 5 therapies? 
POPULATION: Patients with severe asthma not controlled or experiencing exacerbations 
despite treatment with high-dose inhaled glucocorticoids in combination with 
a long-acting beta2-adrenergic receptor agonist and a third controller such as 
a leukotriene modifier if the patient is treated with medium-dose inhaled 
glucocorticoids. 
BACKGROUND:  
. Several randomized clinical trials have demonstrated that the addition of a long-acting 
muscarinic antagonist as a second long-acting bronchodilator, initially in COPD, but more 
recently in mild to severe asthma cohorts, results in improvement in lung function and 
the prevention of exacerbations. Long-acting muscarinic antagonists such as tiotropium 
are the most frequently used long-acting bronchodilator for COPD and are a cost-
effective and safe adjunct therapy for the management of asthma refractory to a 
combination of therapies which accounts for a substantial proportion of the burden 
related to asthma morbidity. 
  
INTERVENTION: Muscarinic antagonist therapy with tiotropium via soft-mist inhaler (5ug or 
10ug) once daily. Tiotropium 2.5ug or 5ug once daily was also evaluated in 
children and adolescents. 
COMPARISON: Placebo 
MAIN OUTCOMES:  FEV1, PEFR, severe exacerbations, asthma symptoms, ACQ-7, ACQ-6, AQLQ 
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
D
ES
IR
A
B
LE
 E
FF
EC
TS
 
How substantial are the desirable anticipated effects?  
○ Trivial 
○ Small 
○ Moderate 
○ Large 
○ Varies 
○Don't know 
 
Results from research evidence (studies) 
 
There were three randomised placebo-controlled trials in adults greater than 18 years of 
age, one crossover and two parallel design,  and two in either children or adolescents 
which impacted the dose of tiotropium (adults were randomized to 5 to 10ug while 
children and adolescents were randomized to 2.5-5ug once daily). All of these trials 
included individuals with severe asthma uncontrolled on GINA step 4-5 or NAEPP step 5 
therapies. Each trial consistently demonstrated substantial and significant improvements in 
lung function measures and symptom control with the addition of tiotropium and a 
subgroup of sufficient duration demonstrated beneficial effects on time to exacerbation.  
Adverse events were less frequent in the tiotropium arm compared to placebo in these 
four trials, while severe adverse events were equally infrequent across treatment arms. 
 
 
 
U
N
D
ES
IR
A
B
LE
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FF
EC
TS
 
How substantial are the undesirable anticipated effects?  
○ Large 
○ Moderate 
○ Small 
○ Trivial 
○ Varies 
○ Don't know 
 
  
C
ER
T
A
IN
TY
 O
F 
EV
ID
EN
C
E 
What is the overall certainty of the evidence of effects?  
○ Very low 
○ Low 
○ Moderate 
○ High 
○ No included studies 
 
The five included studies were randomised, double-blind, placebo-controlled studies. All of 
the important primary and secondary outcomes were assessed as hiqh quality according to 
GRADE Overall risk of bias was low and methodological procedures for random sequence 
generation, allocation concealment, and blinding were robust. However, one 12-week 
study of children (Szefler 2017 [PMID:28189771]) may be subject to selective reporting bias 
as outcomes related to FEF-25-75%, peak and trough FEV1 responses at week 12, and time 
to exacerbation were assessed post-hoc but presented as main findings. Industry bias is 
also unclear in four of the five included.  
 
V
A
LU
ES
 
Is there important uncertainty about or variability in how much 
people value the main outcomes? 
○ Important uncertainty or variability 
○ Possibly important uncertainty or variability 
There is value placed on the measurement of lung function and the management and 
prevention of asthma exacerbations. Lung function measures derived from spirometry are 
a fundamental measure of lung health, are highly correlated with asthma severity and 
exacerbation risk, and one of the central components determining asthma severity and 
NAEPP guideline-based maintenance treatment (Denlinger Am J Respir Crit Care Med. 
 
○ Probably no important uncertainty or variability 
○ No important uncertainty or variability 
○ No known undesirable outcomes 
 
2017;195(3):302-13. PMID:27556234). Asthma exacerbations account for much of the cost 
related to asthma (Weiss J Allergy Clin Immunol 2001 PMID:11149982). Exacerbations 
defined by the need for an intervention such as treatment with systemic glucocorticoids, an 
emergency room visit, or hospitalization is validated as one the central components for 
determining asthma severity and GINA/NAEPP guideline-based maintenance therapy 
(Fuhlbrigge J Allergy Clin Immunol 2012 PMID: 22386508). 
B
A
LA
N
C
E 
O
F 
EF
FE
C
TS
 
Does the balance between desirable and undesirable effects favor 
the intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
○ Don't know 
 
 
Long-acting muscarinic antagonist treatment was associated with substantial and 
significant improvements in peak lung function, symptom control, and a lower frequency of 
asthma worsening. There was a lower frequency of adverse events associated with 
tiotropium treatment while the frequency of severe adverse events was also low and 
nearly equal to placebo. 
  
C
O
ST
 E
FF
EC
TI
V
EN
ES
S 
Does the cost-effectiveness of the intervention favor the 
intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
X No included studies 
 
No cost-effectiveness analyses were identified. Long-acting muscarinic antagonist therapy 
was associated with beneficial effects on 
asthma control, severe exacerbations, and 
lung function in those severe asthma 
treated with GINA step 4-5 or NAEPP step 
5 therapies. Whether these costs savings 
outweigh the cost of medication is unclear, 
but the addition of this inhaled therapy 
can be done at a lower cost compared to 
biologic therapies.  
C
ER
T
A
IN
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F 
EV
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E 
O
F 
R
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U
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E
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R
E
SO
U
R
C
ES
 
What is the certainty of the evidence of resource requirements 
(costs)? 
○ Very low 
○ Low 
○ Moderate 
○ High 
● No included studies 
No included studies.  
 
EQ
U
IT
Y 
What would be the impact on health equity?  
○ Reduced 
○ Probably reduced 
○ Probably no impact 
○ Probably increased 
○ Increased 
○ Varies 
X Don't know 
Kerstjens and colleagues evaluated subgroups based on age, sex, ethnic and racial groups, 
and BMI/obesity and found equally beneficial effects on peak FEV1 improvement across 
sexes and individuals ages 18 or higher and less than 18 years (Kerjstens Respir Med 2016 
[PMID:27492532]). This analysis was unable to determine whether there were equally 
beneficial effects racial groups such as African Americans (N=41), or Asians (N=93) who 
were the minority of subjects compared to Whites (N=714). In addition, effects were 
unable to be determined for Hispanic ethnicity (N=25) compared to non-Hispanics (N=826). 
An anticipated impact could relate to the access and lower cost of tiotropium when 
compared to biologic drugs which could impact health equity as it relates to socioeconomic 
status and the treatment of severe asthma. 
 
A
C
C
EP
TA
B
IL
IT
Y 
Is the intervention acceptable to key stakeholders?  
○ No 
○ Probably no 
X Probably yes 
○ Yes 
○ Varies 
○ Don't know 
Long-acting muscarinic antagonist therapy improves FEV1 and prevents asthma worsening 
and exacerbations which may be important in this important subgroup of asthma who 
experience a substantial proportion of the burden related to asthma morbidity. An 
introduction of this feasible and cost-effective add-on therapy which effectively impacts 
these important outcomes is assumed to be highly acceptable to patients and healthcare 
providers. 
  
FE
A
SI
B
IL
IT
Y 
Is the intervention feasible to implement?  
○ No 
○ Probably no 
X Probably yes 
○ Yes 
○ Varies 
○ Don't know 
An inhaled therapy delivered once daily is a feasible intervention to implement in terms of 
convenience and ease of use. Feasibility could be limited by cost in individuals who are 
already treated with multiple inhaled therapies. Access to providers with sufficient 
expertise to add-on therapy above GINA step 4-5 or NAEPP step 5 therapies in these 
subgroups. In these settings, implementation of a once-daily inhaled device which could be 
used at home is substantially more feasible compared to more costly biologic therapies 
which are regularly administered in a clinic setting. 
  
  
 
  
Should a macrolide (i.e., azithromycin, clarithromycin) be used in adults and children with severe asthma?   
Evidene Profile: MACROLIDES 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations Macrolide Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Number of exacerbations requiring hospitalisation (follow up: mean 26 weeks) 
1 1 randomised 
trials  
not serious  not serious  not serious  very serious 
a,b 
none  2/55 (3.6% )  2/54 (3.7% )  RR 0.98 
(0.14 to 6.72)  
1 fewer per 1,000 
(from 32 fewer to 
212 more)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Number of 'severe' exacerbations - requiring at least oral corticosteroids (follow up: range 24 weeks to 48 weeks) 
3 1-3 randomised 
trials  
not serious  serious c not serious  serious a none  72/285 (25.3% )  97/280 (34.6% )  RR 0.77 
(0.44 to 1.34)  
80 fewer per 1,000 
(from 118 more to 
194 fewer)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Incidence rate (moderate and severe combined) asthma exacerbations (follow up: mean 48 weeks) 
1 2 randomised 
trials  
not serious  not serious  not serious   none  213  207  Rate ratio 0.59 
(0.47 to 0.74)  
Incidence rate 
(events/patient/year): 
macrolides 1.07; 
placebo 1.86 
-  CRITICAL  
 
Number of patients with at least one moderate or severe asthma exacerbation (follow up: mean 48 weeks) 
1 2 randomised 
trials  
not serious  not serious  not serious  not serious  none  94/213 (44.1% )  127/207 
(61.4% )  
RR 0.72 
(0.60 to 0.87)  
172 fewer per 1,000 
(from 80 fewer to 
245 fewer)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Time to asthma exacerbation (moderate or severe) (follow up: mean 48 weeks) 
1 2 randomised 
trials  
not serious  not serious  not serious  not serious  none  94  127  HR 0.65 
(0.50 to 0.85)  
- ⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations Macrolide Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Note: HR is 0.65 (95% CI up to 0.85) and the median difference (point estimate) almost 200 days which suggests that the HR reduction is substantial. 
Number of lower respiratory tract infections requiring antibiotics (follow up: range 26 weeks to 48 weeks) 
2 1,2 randomised 
trials  
not serious  not serious  not serious  not serious none  56/268 (20.9% )  93/261 (35.6% )  RR 0.60 
(0.45 to 0.79)  
143 fewer per 1,000 
(from 75 fewer to 
196 fewer)  
⨁⨁⨁⨁ 
HIGH  
 
Note: Although exacerbations were designated to be of critical importance by the panel, it is not known how lower respiratory tract infections were considered therefore importance is left blank awaiting outcome of further discussion with the panel.  
Change in Asthma Control Questionnaire (ACQ) score from baseline (follow up: range 16 weeks to 48 weeks; Scale from: 0 to 7; MID 0.5) 
3 1,4,5 randomised 
trials  
not serious  not serious  not serious  not serious  none  140  136  -  MD 0.11 lower 
(0.34 lower to 0.12 
higher)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Post treatment ACQ score (follow up: range 8 weeks to 48 weeks; Scale from: 0 to 7; MID 0.5) 
2 2,6 randomised 
trials  
not serious  not serious  not serious  not serious  none  236  229  -  MD 0.07 lower 
(0.24 lower to 0.11 
higher)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Change in symptom score from baseline (follow up: mean 48 weeks; Scale from: 0 to 4) 
1 4 randomised 
trials  
not serious  not serious  not serious  very serious 
a,b 
none  38  37  -  MD 0.17 higher 
(0.28 lower to 0.63 
higher)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Post treatment total symptom score (follow up: mean 8 weeks; Scale from: 0 to 14) 
1 6 randomised 
trials  
not serious  not serious  not serious  very serious 
a,b 
none  23  22  -  MD 0.3 lower 
(2.08 lower to 1.48 
higher)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Mean end of treatment breathlessness score (Visual Analogue Score) (follow up: mean 48 weeks; Scale from: 0 to 10 cm; MID 1.9 cm) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations Macrolide Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 2 randomised 
trials  
not serious  not serious  not serious  serious a none  212  207  -  MD 0.49 lower 
(1.18 lower to 0.2 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Mean end of treatment wheeze score (Visual Analogue Score) (follow up: mean 48 weeks; Scale from: 0 to 10 cm) 
1 2 randomised 
trials  
not serious  not serious  not serious  serious a none  212  207  -  MD 0.11 lower 
(1.15 lower to 0.94 
higher)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Mean end of treatment sputum production score (Visual Analogue Score) (follow up: mean 48 weeks; Scale from: 0 to 10 cm) 
1 2 randomised 
trials  
not serious  not serious  not serious  serious f none  212  207  -  MD 0.62 lower 
(1.23 lower to 0.002 
lower)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Mean end of treatment cough score (Visual Analogue Score) (follow up: mean 48 weeks; Scale from: 0 to 10 cm, MID 1.7 cm) 
1 2 randomised 
trials  
not serious  not serious  not serious  serious e none  212  207  -  MD 0.73 lower 
(1.42 lower to 0.04 
lower)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Number of patients with at least 1 adverse effect (follow up: mean 26 weeks) 
1 1 randomised 
trials  
not serious  not serious  not serious  very serious 
a,b 
none  37/55 (67.3% )  39/54 (72.2% )  RR 0.93 
(0.73 to 1.19)  
51 fewer per 1,000 
(from 137 more to 
195 fewer)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Number of serious adverse events (including mortality) (follow up: range 16 weeks to 48 weeks) 
4 1,2,4,5 randomised 
trials  
not serious  not serious  not serious  very serious 
a,b 
none  32/353 (9.1% )  39/343 (11.4% )  RR 0.81 
(0.52 to 1.24)  
22 fewer per 1,000 
(from 27 more to 55 
fewer)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations Macrolide Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Number of withdrawals due to adverse events (follow up: range 16 weeks to 48 weeks) 
4 1-4 randomised 
trials  
not serious  not serious  not serious  very serious 
a,b 
none  17/323 (5.3% )  13/317 (4.1% )  RR 1.28 
(0.64 to 2.59)  
11 more per 1,000 
(from 15 fewer to 65 
more)  
⨁⨁◯◯ 
LOW  
CRITICAL  
Note: Note that although serious adverse events were lower in the treatment group, there were more withdrawals due to adverse events, suggesting these results should be considered with low confidence.  
Change in Asthma Quality of Life Questionnaire (AQLQ) from baseline (follow up: range 16 weeks to 48 weeks; Scale from: 1 to 7, MID 0.5) 
3 1,4,5 randomised 
trials  
not serious  not serious  not serious  not serious  none  140  136  -  MD 0.16 higher 
(0.06 lower to 0.37 
higher)  
⨁⨁⨁⨁ 
HIGH 
IMPORTANT  
Mean end of treatment AQLQ score (follow up: mean 48 weeks; Scale from: 1 to 7, MID 0.5) 
1 2 randomised 
trials  
not serious  not serious  not serious  serious e none  209  204  -  MD 0.36 higher 
(0.21 higher to 0.52 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Mean end of treatment nasal symptom score (Visual Analogue Score) (follow up: mean 48 weeks; Scale from: 0 to 10 cm; MID 2.3 cm) 
1 2 randomised 
trials  
not serious  not serious  not serious  serious e none  212  207  -  MD 0.51 lower 
(1.04 lower to 0.02 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Change in post-bronchodilator FEV1 (%  predicted) from baseline (follow up: mean 26 weeks; MID 10.38 % ) 
1 1 randomised 
trials  
not serious  not serious  not serious  serious b none  55  54  -  MD 1.95 higher 
(2.42 lower to 6.32 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Change in pre-bronchodilator FEV1 (%  predicted) from baseline (follow up: range 16 weeks to 26 weeks; MID 10.38 % ) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations Macrolide Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
2 1,5 randomised 
trials  
not serious  not serious  not serious  serious b none  102  99  -  MD 0.37 higher 
(2.17 lower to 2.91 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Change in pre-bronchodilator FEV1 (L) (follow up: mean 16 weeks; MID 0.23 L) 
1 5 randomised 
trials  
not serious  not serious  not serious  serious b none  47  45  -  MD 0  
(0.2 lower to 0.2 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
Mean end of treatment pre-bronchodilator FEV1 (% predicted) (follow up: mean 8 weeks; MID 10.38 % ) 
1 6 randomised 
trials  
not serious  not serious  not serious  very serious 
a,b 
none  23  22  -  MD 5.6 higher 
(5.62 lower to 16.82 
higher)  
⨁⨁◯◯ 
LOW  
IMPORTANT  
Mean end of treatment pre-bronchodilator FEV1 (L) (follow up: mean 48 weeks; MID 0.23 L) 
1 2 randomised 
trials  
not serious  not serious  not serious  serious e none  210  205  -  MD 0.12 lower 
(0.27 lower to 0.03 
higher)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
CI: Confidence interval; RR: Risk ratio; HR: Hazard Ratio; MD: Mean difference 
Explanations 
a. The ends of the 95% CI include both appreciable benefit and appreciable harm and would lead to opposite clinical decisions.  
b. Limited number of patients or events, does not meet OIS  
c. There is variation in point estimates for included studies with an I2 of 70% which may indicate moderate inconsistency  
d. One study reports 'number of patients with at least one primary endpoint' which is a composite of severe asthma exacerbations and lower respiratory tract infections requiring antibiotics. This study 
contributes 42% of events. Inclusion of lower respiratory tract infections means this data cannot be considered completely representative of exacerbations alone.  
e. The lower end of the 95% CI crosses the minimally important difference (MID) for this outcome.  
f. MID not established for this measure however lower end of confidence interval (score 0.002 lower) unlikely to be clinically meaningful.  
Bibliography:  
1. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. 
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2008; 122(6): 1138-44 e4. 
4. Hahn DL, Grasmick M, Hetzel S, Yale S. Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med 2012; 25(4): 442-59. 
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Evidence to Decision Framework: MACROLIDES 
Should a macrolide (i.e., azithromycin, clarithromycin) be used in adults and children with severe asthma?   
 
POPULATION: Adults and children with severe asthma BACKGROUND:  
By definition, patients with severe asthma have disease that is either 
unresponsive to traditional therapies with inhaled corticosteroids and 
bronchodilators or require these therapies to maintain adequate control. To 
address this unmet need for improved therapies, in particular in patients not 
responding to step 5 biologicals or having no access to those treatments, and in 
view of the possible immunomodulatory effect of macrolides,  these 
medications are being used long-term for the management of the disease. This 
systematic review and meta-analysis synthetizes the data from randomized 
controlled trials and meta-analyses investigating the use of macrolides and 
provides treatment recommendations based on the results. 
 
INTERVENTION: Macrolide 
COMPARISON: No macrolide 
MAIN OUTCOMES: Rate of exacerbations 
Time to first asthma exacerbation 
Asthma exacerbations requiring ER visits or hospitalization  
Lung function  
Asthma control  
Maintenance corticosteroid dose reduction  
Adverse events 
Serious adverse events  
Quality of life  
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
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How substantial are the desirable 
anticipated effects? 
○ Trivial 
● Small 
○ Moderate 
○Large 
○ Varies 
○Don't know 
 
We identified a total of 6 clinical trials assessing the effectiveness of macrolide treatment to 
placebo. Four assessed azithromycin (Bruselle 2013, Gibson 2017, Strunk 2008, Hahn 2012) 
and two assessed clarithromycin (Sutherland 2010, Simpson 2008).  
In the largest study to date (Gibson), azithromycin 500mg (three times/week during 48 weeks) 
reduced asthma moderate to severe exacerbations (1·07 per patient-year [95% CI 0·85-1·29]) 
compared with placebo (1·86 per patient-year [1·54-2·18]; incidence rate ratio [IRR] 0·59 
[95% CI 0·47-0·74]) and time to moderate to severe exacerbation; hazard ratio [HR] 0·65 
[95% CI 0·50-0·85]. The proportion of patients experiencing at least one asthma exacerbation 
was reduced by azithromycin treatment (127 [61%] patients in the placebo group vs 94 [44%] 
patients in the azithromycin group; rate ratio [RR] 0·72 [95% CI 0·60-0·87]). Azithromycin 
significantly improved asthma-related quality of life questionnaire (AQLQ) at the end of 
treatment (adjusted mean difference, 0·36 [95% CI 0·21-0·52]). 
Macrolides were not associated to a reduction of severe exacerbations (Bruselle 2013, Gibson 
2017, Strunk 2008), improvements in asthma control questionnaire (ACQ) (Bruselle 2013, 
Gibson 2017, Strunk 2008, Hahn 2012, Sutherland 2010, Simpson 2008) or lung function 
(FEV1) (Bruselle 2013, Gibson 2017, Sutherland 2010, Simpson 2008). 
 In the AZISAST trial, in a predefined subgroup with non-eosinophilic severe asthma (blood 
eosinophilia ≤200/µl), azithromycin was associated with a significantly lower combined primary 
endpoint rate (PEP) than placebo in subjects: 0.44 PEPs (95% CI 0.25 to 0.78) versus 1.03 
PEPs (95% CI 0.72 to 1.48) (p=0.013). Azithromycin significantly improved the AQLQ score 
but there were no significant between-group differences in the ACQ score or lung function 
In the small study by Sutherland et al. clarithromycin improved airway hyperresponsiveness, 
increasing the methacholine PC(20) by 1.2 ± 0.5 doubling doses (P = .02) in the study 
population but had no effect on other outcomes..  
 PEP is a rate of “primary endpoints” which is a combined measure of effect of severe asthma 
exacerbations and LRTI requiring antibiotics 
 
 Rate ratios are difficult to judge (as any relative 
measure of effect). However, the absolute difference 
in this study is -0.46 (-0.79 to -0.14) exacerbations 
per patient-year (Table 2 - primary outcomes). The 
panel can better consider if less 0.14 exacerbations 
per patient-year is something meaningful 
 One approach would be also the NNT (at one year) 
as 1/absolute difference which seems to be 2 (1 to 7). 
The absolute difference estimate is adjusted in the 
trial so this NNT seems reliable. The panel can also 
judge whether treating 7 patients with azithromycin to 
avoid one (moderate or severe) exacerbation a year 
is acceptable.  
 The panel have to consider that patients with 
exacerbations (as defined) will need increased doses 
of steroids, B-agonists, ED visits or hospitalisations  
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How substantial are the 
undesirable anticipated effects? 
○ Large 
○ Moderate 
● Small 
○ Trivial 
○ Varies 
○ Don't know 
 
There were no differences between macrolides and placebo in the number of patients with 
serious adverse events or treatment withdrawal due to toxicity (Bruselle 2013, Gibson 2017, 
Strunk 2008, Hahn 2012, Sutherland 2010). 
The main concern is resistance which has been shown to develop in long-term use of 
macrolides. In the Azistast study azithromycin was associated with increased oropharyngeal 
carriage of macrolide-resistant streptococci (87% of the subjects in the azithromycin group and 
35% of the subjects in the placebo group were colonised with erythromycin-resistant 
oropharyngeal streptococci p<0.001).  
There are more data in the literature about macrolide resistance from studies in other diseases 
where the medication is used long-term, such as non-CF bronchiectasis, where Valery et al. 
showed increased resistance to streptococcus pneumoniae and staph aureus rising from 12% 
to 27% after long term use compared to placebo (p=0.015 and 0.046 respectively). Similar data 
were found in other studies.(Wong LANCET 2012, Altenburg JAMA 2013).  
Diarrhoea is the most common adverse event. In the AZISAST study 72 [34%] azithromycin-
treated patients experienced diarrhea vs 39 [19%] of those on placebo p=0·001). 
 This is the most important consideration. However 
studies in non CF bronchiectasis showed that these 
bacteria were susceptible to other antibiotics.  
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What is the overall certainty of the 
evidence of effects? 
● Very low 
● Low 
○ Moderate 
○ High 
○ No included studies 
 
As shown in the table by Sarah Diver, the certainty of the evidence is low.  Our certainty assessment relies on study design 
(randomized controlled trials), risk of bias, 
inconsistency, indirectness , and imprecision .  
Further the certainty is based on the quality of 
evidence that is lowest among critical outcomes. 
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Is there important uncertainty 
about or variability in how much 
people value the main outcomes? 
○ Important uncertainty or variability 
○ Possibly important uncertainty or 
variability 
○ Probably no important uncertainty 
or variability 
● No important uncertainty or 
variability 
○ No known undesirable outcomes 
 
 
No evidence identified. 
There is no important uncertainty about how patients 
and clinicians assess asthma exacerbations. There is 
more variability concerning QoL which however is a 
patient related outcome. Regarding the interpretation of 
lung function which is more objective there doesn‟t 
seem to be any effect of macrolide treatment on lung 
function. 
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Does the balance between 
desirable and undesirable effects 
favor the intervention or the 
comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the 
intervention or the comparison 
● Probably favors the intervention 
○ Favors the intervention 
○ Varies 
○ Don't know 
 
Diarrhea does not seem to be a major concern, however the problem of resistance needs to 
be evaluated long-term  in actual clinical studies (not only laboratory testing).  
The group placed a higher value on the potential 
benefit of reduction in exacerbations which can be life-
threating and the potential positive impact in quality of 
life. Potential adverse events were considered to have 
a lower value.  
Regarding resistance in particular, which is a concern, 
the studies show that the bacteria are susceptible to 
other commonly used antibiotics 
 
.   
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Does the cost-effectiveness of the 
intervention favor the intervention 
or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the 
intervention or the comparison 
○ Probably favors the intervention 
●  Favors the intervention 
○ Varies 
○ No included studies 
 
If, as the statistician points out, 7 patients need to be treated to avoid 1 exacerbation then 
probably the cost-effectiveness favors the intervention as the cost of the intervention is low 
while direct/indirect costs of exacerbations are high 
 
No cost-effectiveness studies have been identified 
however the impact of asthma exacerbations on health 
care costs among patients with moderate and severe 
persistent asthma are estimated to be 9,223 USD 
compared to 5,011 USD in those asthmatic patients 
without exacerbations (Ivanova 2012).  
The estimated total healthcare cost of patients with 
exacerbations is 4,212 USD per year.  
Considering that macrolides are low-cost interventions, 
the panel considers that the intervention will be cost-
saving.   
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What is the certainty of the 
evidence of resource requirements 
(costs)? 
○ Very low 
○ Low 
○ Moderate 
○ High 
● No included studies 
No specific studies were identified, however due to the relatively low cost of macrolides 
resource requirements are expected to be low.  
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What would be the impact on 
health equity? 
○ Reduced 
○ Probably reduced 
○ Probably no impact 
 
No evidence identified. 
In the US, racial and ethnic minorities, and individuals 
of lower socioeconomic status have been documented 
to have less access to specialty clinics and are less 
likely to use expensive controller therapy for asthma. 
Macrolides might be an easy and feasible strategy. 
● Probably increased 
○ Increased 
○ Varies 
○ Don't know 
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Is the intervention acceptable to 
key stakeholders? 
○ No 
○ Probably no 
○ Probably yes 
○ Yes 
● Varies 
○ Don't know 
No evidence identified.  Most patients with severe asthma welcome any  
possibility of improvement through treatment although 
they are concerned about medication use 
Health insurance companies and clinic administrations 
should find  macrolides acceptable due to their 
relatively  low cost however there is concern about the 
resistance. 
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Is the intervention feasible to 
implement? 
○ No 
○ Probably no 
● Probably yes 
○ Yes 
○ Varies 
○ Don't know 
Probably yes. Macrolides are relatively cheap and are available 
world-wide. .  
 
  
Should an anti-interleukin 4/13 strategy be used for adults and children with severe asthma? 
Evidence Profile:300 mg of dupilumab every 2 weeks compared to placebo for patients with severe asthma according to blood eosinophils  
Bibliography: Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y,  Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, 
Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-2496. 
doi: 10.1056/NEJMoa1804092. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. 
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal 
phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5.  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
EXACERBATION - annualised severe exacerbation event rate at week 24 (according to blood eosinophil 300 cells/mm3 or more) 
2 1,2 randomised 
trials  
serious a not serious  not serious  not serious  none  -/109  -/112  Rate ratio 0.25 
(0.14 to 0.46)  
Low ⨁⨁⨁◯ 
MODERATE  
 
84 less severe exacerbations 
per 100 patients per year  
(from 49 to 139)  
High 
124 less severe exacerbations 
per 100 patients per year  
(from 94 to 155)  
EXACERBATION - annualised severe exacerbation event rate at week 24 (according to blood eosinophil <300 cells/mm3) 
2 1,2 randomised 
trials  
serious a not serious  not serious  not serious  none  0/156  0/148  Rate ratio 0.49 
(0.31 to 0.76)  
Low ⨁⨁⨁◯ 
MODERATE  
 
47 less severe exacerbations 
per 100 patients per year  
(from 32 to 65)  
High 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
66 less severe exacerbations 
per 100 patients per year  
(from 54 to 76)  
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil 300 cells/mm3 or more) (assessed with: Liters) 
2 1,2 randomised 
trials  
serious a not serious  not serious  serious b none  103  91  -  least square MD 0.21 Liters 
more 
(0.06 more to 0.35 more)  
⨁⨁◯◯ 
LOW  
 
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil <300 cells/mm3) (assessed with: Liters) 
2 1,2 randomised 
trials  
serious a not serious  not serious  not serious  none  137  138  -  least square MD 0.14 Liters 
more 
(0.05 more to 0.22 more)  
⨁⨁⨁◯ 
MODERATE  
 
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil 300 cells/mm3 or more) (assessed with: % of change; Scale from: 0 to 100) 
1 1 randomised 
trials  
serious c not serious  not serious  serious d none  58  52  -  least square MD 12.09 
percentage points more 
(3.2 more to 20.97 more)  
⨁⨁◯◯ 
LOW  
 
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil <300 cells/mm3) (assessed with: % of change; Scale from: 0 to 100) 
1 1 randomised 
trials  
serious c not serious  not serious  serious d none  85  73  -  least square MD 7.9 percentage 
points more 
(1.98 more to 13.81 more)  
⨁⨁◯◯ 
LOW  
 
ASTHMA CONTROL - at week 24 according to blood eosinophil 300 cells/mm3 or more (assessed with: ACQ-5; Scale from: 0 to 6)e 
1 1 randomised 
trials  
serious c not serious f not serious  serious b none  58  52  -  least square MD 0.55 ACQ-5 
units lower 
(0.9 lower to 0.2 lower)  
⨁⨁◯◯ 
LOW  
 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
ASTHMA CONTROL - at week 24 according to blood eosinophil <300 cells/mm3 (assessed with: ACQ-5; Scale from: 0 to 6)e 
1 1 randomised 
trials  
serious c not serious f not serious  not serious  none  87  75  -  least square MD 0.17 ACQ-5 
units lower 
(0.44 lower to 0.1 higher)  
⨁⨁⨁◯ 
MODERATE  
 
QUALITY OF LIFE - at week 24 according to blood eosinophil 300 cells/mm3 or more (assessed with: AQLQ ; Scale from: 0 to 7)g 
1 1 randomised 
trials  
serious c not serious f not serious  serious b none  56  53  -  least square MD 0.78 AQLQ 
units higher 
(0.42 higher to 1.15 higher)  
⨁⨁◯◯ 
LOW  
 
QUALITY OF LIFE - at week 24 according to blood eosinophil <300 cells/mm3 (assessed with: AQLQ; Scale from: 0 to 7)g 
1 1 randomised 
trials  
serious c not serious f not serious  not serious  none  85  74  -  least square MD 0.06 AQLQ 
units higher 
(0.24 lower to 0.36 higher)  
⨁⨁⨁◯ 
MODERATE  
 
Reduction in the glucocorticoid dose at week 24 ( according to blood eosinophil 300 cells/mm3 or more) (assessed with: % reduction; Scale from: 0 to 100) 
1 2 randomised 
trials  
serious h not serious f not serious  serious i none  48  41  -  least square MD 36.38 
percentage points lower 
(54.7 lower to 18.9 lower)  
⨁⨁◯◯ 
LOW  
 
Reduction in the glucocorticoid dose at week 24 ( according to blood eosinophil <300 cells/mm3) (Scale from: 0 to 100) 
1 2 randomised 
trials  
serious h not serious f not serious  serious i none  55  66  -  least square MD 21.3 
percentage points lower 
(38.8 lower to 3.9 lower)  
⨁⨁◯◯ 
LOW  
 
CI: Confidence interval 
Explanations 
a. Relevant and differential attrition bias in NCT01854047 (Wenzel 2016) for placebo and dupilumab groups (more than 20% and around 10% respectively); Randomization was not stratified by blood 
eosinophil count and current 300 cells/mm3 was not included as a co-variate in the analysis (Rabe 2018)  
b. the lower CI boundary crosses the threshold for minimal important difference  
c. Relevant and differential attrition bias in NCT01854047 (Wenzel 2016) for placebo and dupilumab groups (more than 20% and around 10% respectively)  
d. Minimal important differences not known for % reduction in the FEV1, however the 95CI is wide and does not exclude important benefit or no effect.  
e. minimal important difference for ACQ-5 is 0.5; lower values indicate better asthma control.  
f. not applicable (findings from 1 trial)  
g. minimal important difference for AQLQ is 0.5; higher scores indicates better QoL.  
h. Subgroup analysis, randomization was not stratified by blood eosinophil count and current 300 cells/mm3 was not included as a co-variate in the analysis.  
i. Minimal important differences not known for % reduction in the glucocorticoid doses, however the 95CI is wide and does not exclude important benefit or no effect.  
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Evidence Profile: 300 mg of dupilumab every 2 weeks compared to placebo for patients with uncontrolled asthma  
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Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
EXACERBATION - annualised severe exacerbation event rate (dupilumab during 24 weeks) 
1  randomise
d trials  
serious a not serious b not serious  not serious  none  NCT01854047 (Wenzel 2016) reported a risk reduction in event rates of 70·5%  
(45·4 to 84·1) in favour of 24 weeks of treatment (exacerbation rate for dupilumab 
0·265 (0·157 to 0·445) versus exacerbation rate for placebo 0·897 (0·619 to 
1·300)).  
⨁⨁⨁◯ 
MODERATE  
 
EXACERBATION - annualised severe exacerbation event rate (dupilumab during 52 weeks) 
1  randomise
d trials  
serious c not serious b not serious  not serious  none  NCT02414854 (Castro 2018) reported a risk reduction in event rates of 46%  (32 to 
57) in favour of 52 weeks of treatment (exacerbation rate for dupilumab 0.456 
(0.389 to 0.534) versus exacerbation rate for placebo 0.970 (0.810 to 1.160))  
⨁⨁⨁◯ 
MODERATE  
 
ASTHMA CONTROL (assessed with: ACQ-5 (dupilumab during 24 weeks); Scale from: 0 to 6)d 
2  randomise
d trials  
serious a,c not serious  not serious  not serious  none  790  479  -  least square MD 0.22 ACQ-
5 units lower 
(0.34 lower to 0.11 lower)  
⨁⨁⨁◯ 
MODERATE  
 
ASTHMA CONTROL (assessed with: ACQ-5 (dupilumab during 52 weeks); Scale from: 0 to 6)d 
1  randomise
d trials  
serious c not serious b not serious  not serious  none  633  321  -  least square MD 0.22 ACQ-
5 units lower 
(0.36 lower to 0.08 lower) e 
⨁⨁⨁◯ 
MODERATE  
 
QUALITY OF LIFE (assessed with: AQLQ (dupilumab during 24 weeks); Scale from: 0 to 7)f 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
2  randomise
d trials  
serious a,c not serious  not serious  not serious  none  790  479  -  least square MD 0.23 AQLQ 
units higher 
(0.03 higher to 0.43 higher)  
⨁⨁⨁◯ 
MODERATE  
 
QUALITY OF LIFE (assessed with: AQLQ (dupilumab during 52 weeks); Scale from: 0 to 7)f 
1  randomise
d trials  
serious c not serious b not serious  not serious  none  633  321  -  least square MD 0.26 AQLQ 
units higher 
(0.12 higher to 0.4 higher) e 
⨁⨁⨁◯ 
MODERATE  
 
SIDE EFFECTS (assessed with: any side effect (dupilumab during 24 weeks)) 
1  randomise
d trials  
serious a not serious b not serious  not serious  none  121/156 
(77.6% )  
118/158 
(74.7% )  
RR 1.04 
(0.92 to 
1.18)  
3 more per 100 
(from 6 fewer to 13 more)  
⨁⨁⨁◯ 
MODERATE  
 
SIDE EFFECTS (assessed with: any side effect (dupilumab during 52 weeks)) 
1  randomise
d trials  
serious c not serious b not serious  not serious  none  515/632 
(81.5% )  
270/321 
(84.1% )  
RR 0.97 
(0.91 to 
1.03)  
3 fewer per 100 
(from 8 fewer to 3 more)  
⨁⨁⨁◯ 
MODERATE  
 
SIDE EFFECTS (assessed with: any serious side effect (dupilumab during 24 weeks)) 
1  randomise
d trials  
serious a not serious b not serious  serious g none  13/156 (8.3% )  9/158 (5.7% )  RR 1.46 
(0.64 to 
3.32)  
3 more per 100 
(from 2 fewer to 13 more)  
⨁⨁◯◯ 
LOW  
 
SIDE EFFECTS (assessed with: any serious side effect (dupilumab during 52 weeks)) 
1  randomise
d trials  
serious c not serious b not serious  serious h none  55/632 (8.7% )  27/321 (8.4% )  RR 1.03 
(0.67 to 
1.61)  
0 fewer per 100 
(from 3 fewer to 5 more)  
⨁⨁◯◯ 
LOW  
 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
SIDE EFFECTS (assessed with: injection site reactions (dupilumab during 24 weeks)) 
1  randomise
d trials  
serious a not serious b not serious  serious g none  41/156 (26.3% )  21/158 (13.3% )  RR 1.98 
(1.23 to 
3.19)  
13 more per 100 
(from 3 more to 29 more)  
⨁⨁◯◯ 
LOW  
 
SIDE EFFECTS (assessed with: injection site reactions (dupilumab during 52 weeks)) 
1  randomise
d trials  
serious c not serious b not serious  serious h none  116/632 
(18.4% )  
33/321 (10.3% )  RR 1.79 
(1.24 to 
2.57)  
8 more per 100 
(from 2 more to 16 more)  
⨁⨁◯◯ 
LOW  
 
CI: Confidence interval; RR: Risk ratio 
Explanations 
a. potential attrition bias in NCT01854047 (Wenzel 2016): trial report described an intention to treat analysis but results reported in tables does not fit with the intention to treat population  
b. not applicable (findings from 1 trial)  
c. potential attrition bias in NCT02414854 (Castro 2018): 75% participants completed the study. Reasons for discontinuation were not declared for 46% of patients that did not completed the 52 
weeks intervention period.  
d. minimal important difference for ACQ-5 is 0.5; lower values indicate better asthma control.  
e. Castro 2018 reported effect estimates with standard errors. The effect estimated in the SoF table has been recalculated with the RevMan 5.3 statistical package  
f. minimal important difference for AQLQ is 0.5; higher scores indicates better QoL.  
g. low event rate, resulting in imprecise effect estimate  
h. imprecision of results resulting from the results from Castro 2018 (planned treatment duration of 52 weeks)  
  
Evidence Profile: 300 mg of dupilumab every 2 weeks compared to placebo for glucocorticoid dependent severe asthma  
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Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
EXACERBATION - annualised severe exacerbation event rate (dupilumab during 24 weeks) 
1  randomised 
trials  
not serious  not serious a not serious  not serious  none  NCT02528214 (Rabe 2018) reported a risk reduction in event rates of 59·3%  (37 to 
73·7) favouring 24 weeks of treatment (exacerbation rate for dupilumab 0.649 (0.442 
to 0.955) versus exacerbation rate for placebo 1.597 (1.248 to 2.043).  
⨁⨁⨁⨁ 
HIGH  
 
ASTHMA CONTROL (assessed with: ACQ-5 (dupilumab during 24 weeks))b 
1  randomised 
trials  
not serious  not serious a not serious  serious b none  NCT02528214 (Rabe 2018) reported a least square MD of −0.47 (−0.76 to −0.18) 
favouring 24 weeeks of treatment with dupilumab  
⨁⨁⨁◯ 
MODERATE  
 
LUNG FUNCTION (change in FEV1 from baseline to end of treatment) (assessed with: liters) 
1  randomised 
trials  
not serious  not serious a not serious  serious c none  NCT02528214 (Rabe 2018) reported a least square MD of 0.22 (0.09 to 0.34) L 
favouring 24 weeeks of treatment with dupilumab (dupilumab 0.22 (0.05) versus 
placebo 0.01 (0.05)).  
⨁⨁⨁◯ 
MODERATE  
 
SYSTEMIC STEROIDS USE (patients with ≥50% reduction in oral glucocorticoid dose at 24 w) 
1  randomised 
trials  
not serious  not serious a not serious  not serious  none  82/103 (79.6% )  57/107 (53.3% )  RR 1.49 
(1.22 to 1.83)  
26 more per 100 
(from 12 more to 44 more)  
⨁⨁⨁⨁ 
HIGH  
 
SYSTEMIC STEROIDS USE (patients with oral glucocorticoid reduced to <5 mg/day at 24 w) 
1  randomised 
trials  
not serious  not serious a not serious  not serious  none  74/103 (71.8% )  40/107 (37.4% )  RR 1.92 
(1.46 to 2.53)  
344 more per 1.000 
(from 172 more to 572 
more)  
⨁⨁⨁⨁ 
HIGH  
 
SYSTEMIC STEROIDS USE (patients with maximum possible reduction of oral glucocorticoid dose at 24 w) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
300 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1  randomised 
trials  
not serious  not serious a not serious  not serious  none  54/103 (52.4% )  32/107 (29.9% )  RR 1.75 
(1.24 to 2.47)  
224 more per 1.000 
(from 72 more to 440 
more)  
⨁⨁⨁⨁ 
HIGH  
 
SYSTEMIC STEROIDS USE (patients no longer requiring oral glucocorticoid at 24 w) 
1  randomised 
trials  
not serious  not serious a not serious  not serious  none  54/103 (52.4% )  31/107 (29.0% )  RR 1.81 
(1.28 to 2.57)  
235 more per 1.000 
(from 81 more to 455 
more)  
⨁⨁⨁⨁ 
HIGH  
 
SIDE EFFECTS (assessed with: any side effect (dupilumab during 24 weeks)) 
1  randomised 
trials  
not serious  not serious a not serious  serious d none  64/103 (62.1% )  69/107 (64.5% )  RR 0.96 
(0.78 to 1.18)  
3 fewer per 100 
(from 14 fewer to 12 more)  
⨁⨁⨁◯ 
MODERATE  
 
SIDE EFFECTS (assessed with: any serious side effect (dupilumab during 24 weeks)) 
1  randomised 
trials  
not serious  not serious a not serious  serious d none  9/103 (8.7% )  6/107 (5.6% )  RR 1.56 
(0.58 to 4.22)  
3 more per 100 
(from 2 fewer to 18 more)  
⨁⨁⨁◯ 
MODERATE  
 
SIDE EFFECTS (assessed with: injection site reactions (dupilumab during 24 weeks)) 
1  randomised 
trials  
not serious  not serious a not serious  serious d none  9/103 (8.7% )  4/107 (3.7% )  RR 2.34 
(0.74 to 7.35)  
5 more per 100 
(from 1 fewer to 24 more)  
⨁⨁⨁◯ 
MODERATE  
 
CI: Confidence interval; RR: Risk ratio 
Explanations 
a. not applicable (findings from 1 trial)  
b. minimal important difference for ACQ-5 is 0.5; lower values indicate better asthma control.  
c. minimal important difference for FEV1 is 0.23.  
d. low event rate, resulting in imprecise effect estimate  
  
Evidence Profile: 200 mg of dupilumab every 2 weeks compared to placebo for patients with severe asthma according to blood eosinophils  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
200 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
EXACERBATION - annualised severe exacerbation event rate at week 24 (according to blood eosinophil 300 cells/mm3 or more) 
1 1 randomised 
trials  
not serious  not serious a not serious  not serious  none  0/65  0/68  Rate ratio 0.29 
(0.11 to 0.76)  
74 less severe exacerbations 
per 100 patients per year  
(from 44 to 122)  
⨁⨁⨁⨁ 
HIGH  
 
EXACERBATION - annualised severe exacerbation event rate at week 24 (according to blood eosinophil <300 cells/mm3) 
1 1 randomised 
trials  
not serious  not serious a not serious  not serious  none  0/85  0/90  Rate ratio 0.32 
(0.14 to 0.74)  
53 less severe exacerbations 
per 100 patients per year  
(from 37 to 71)  
⨁⨁⨁⨁ 
HIGH  
 
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil 300 cells/mm3 or more) (assessed with: Liters) 
1 1 randomised 
trials  
serious b not serious a not serious  serious c none  59  52  -  least square 0.16 Liters more 
(0.02 more to 0.31 more)  
⨁⨁◯◯ 
LOW  
 
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil <300 cells/mm3) (assessed with: Liters) 
1 1 randomised 
trials  
serious b not serious a not serious  serious c none  76  73  -  least square 0.14 Liters more 
(0.03 more to 0.25 more)  
⨁⨁◯◯ 
LOW  
 
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil 300 cells/mm3 or more) (assessed with: % of change; Scale from: 0 to 100) 
1 1 randomised 
trials  
serious b not serious a not serious  serious d none  59  52  -  least square 10.07 percentage 
points more 
(1.23 more to 18.9 more)  
⨁⨁◯◯ 
LOW  
 
LUNG FUNCTION - change in FEV1 from baseline at week 24 (according to blood eosinophil <300 cells/mm3) (assessed with: % of change; Scale from: 0 to 100) 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
200 mg of 
dupilumab 
every 2 weeks 
placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
1 1 randomised 
trials  
serious b not serious a not serious  serious d none  76  73  -  least square 8.75 percentage 
points more 
(2.7 more to 14.81 more)  
⨁⨁◯◯ 
LOW  
 
ASTHMA CONTROL - at week 24 according to blood eosinophil 300 cells/mm3 or more (assessed with: ACQ-5; Scale from: 0 to 6)e 
1 1 randomised 
trials  
serious b not serious a not serious  serious c none  59  52  -  least square MD 0.42 ACQ-5 
units lower 
(0.76 lower to 0.07 lower)  
⨁⨁◯◯ 
LOW  
 
ASTHMA CONTROL - at week 24 according to blood eosinophil <300 cells/mm3 (assessed with: ACQ-5; Scale from: 0 to 6)e 
1 1 randomised 
trials  
serious b not serious a not serious  serious c none  75  75  -  least square MD 0.33 ACQ-5 
units lower 
(0.61 lower to 0.05 lower)  
⨁⨁◯◯ 
LOW  
 
QUALITY OF LIFE - at week 24 according to blood eosinophil 300 cells/mm3 or more (assessed with: AQLQ ; Scale from: 0 to 7)f 
1 1 randomised 
trials  
serious b not serious a not serious  serious c none  58  53  -  least square MD 0.67 AQLQ 
units higher 
(0.31 higher to 1.03 higher)  
⨁⨁◯◯ 
LOW  
 
QUALITY OF LIFE - at week 24 according to blood eosinophil <300 cells/mm3 (assessed with: AQLQ; Scale from: 0 to 7)f 
1 1 randomised 
trials  
serious b not serious a not serious  not serious  none  74  74  -  least square MD 0.05 AQLQ 
units higher 
(0.26 lower to 0.36 higher)  
⨁⨁⨁◯ 
MODERATE  
 
CI: Confidence interval 
Explanations 
a. not applicable (findings from 1 trial)  
b. Relevant and differential attrition bias in NCT01854047 (Wenzel 2016) for placebo and dupilumab groups (more than 20% and around 10% respectively)  
c. the lower CI boundary crosses the threshold for minimal important difference  
d. Minimal important differences not known for FEV1 % of change, however the 95CI is wide and does not exclude important benefit or no effect.  
e. minimal important difference for ACQ-5 is 0.5; lower values indicate better asthma control.  
f. minimal important difference for AQLQ is 0.5; higher scores indicates better QoL.  
References 
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Evidence to Decision Framework:DUPILUMAB 
Should an anti-interleukin 4/13 strategy be used for adults and children with severe asthma? 
POPULATION: Adults and children with severe asthma BACKGROUND:  
Approximately half of patients with asthma exhibit elevated markers of type 2 
inflammation. Two of the cytokines that orchestrate this type of inflammation 
are interleukins (IL) 4 and 13, each of which independently elicits pathobiologic 
changes in airway structural and immune cells characteristic of asthma. IL4 is 
required for the skewing of T helper cells into Th2 cells, and for the switching of 
B cell antibody production into the IgE isotype crucial for allergic inflammation. 
IL13 is a prime inducer of airway hyperresponsiveness and is implicated in 
airway remodeling. Both cytokines engage and signal through the interleukin 4 
receptor subunit alpha.  
A monoclonal antibody that targets the interleukin 4 receptor subunit alpha, 
dupilumab, has been found to be efficacious in randomized controlled trials to 
improve asthma-related outcomes. This systematic review and meta-analysis 
synthesizes the data from three randomized controlled trials that have 
investigated the anti-IL4/13 strategy and provides treatment recommendations 
based on the results. 
 
INTERVENTION: Anti-interleukin 4/13 strategy (dupilumab, a monoclonal antibody 
directed against the interleukin 4 receptor subunit alpha) 
COMPARISON: No anti-interleukin 4/13 
MAIN OUTCOMES: Rate of exacerbations 
Time to first asthma exacerbation 
Asthma exacerbations requiring ER visits or hospitalization  
Lung function  
Asthma control  
Maintenance corticosteroid dose reduction  
Adverse events 
Serious adverse events  
Quality of life  
  
  
 
  
 
Assessment 
 JUDGEMENT RESEARCH EVIDENCE ADDITIONAL CONSIDERATIONS 
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How substantial are the desirable anticipated effects? 
○ Trivial 
○ Small 
○ Moderate 
● Large 
○ Varies 
○Don't know 
 
 
Asthma exacerbations are a critically important outcome for the patients with 
asthma who experience these and the clinicians who care for them.  
Relative to participants assigned to placebo, those assigned to dupilumab 
experienced substantial (46-70.5%) reduction in their rates of asthma exacerbations 
(PMID: 29782224, PMID: 29782217, PMID: 27130691)  (insert evidence tables for 
the two doses and time intervals). 
One RCT evaluated the effects of dupilumab therapy in oral corticosteroid (OCS) 
dependent asthma (Rabe 2018. PMID: 29782224). Dupilumab therapy was 
associated with greater number of participants that experienced > 50% reduction in 
OCS dose (RR 1.49; 95% Ci 1.22-1.83), were able to reduce OCS dose to < 5mg/d 
(RR 1.92; 95% CI 1.46-2.53) and were able to discontinue maintenance OCS (RR 
1.81; 95% CI 1.28-2.57). 
Asthma symptom scores are another critically important outcome in asthma studies. 
Although the evidence favors dupilumab relative to placebo on these outcomes, 
their relative change was not as large compared to the improvement observed with 
asthma exacerbations. Relative to participants assigned to placebo, those assigned 
to dupilumab experienced a 0.22-0.47 point decrease (i.e. improvement) in Asthma 
Control Questionnaire (ACQ) (insert evidence table). Although statistically 
significant, these decreases in ACQ-5 scores did not surpass the 0.5-point MCID for 
the ACQ symptom score for trials in asthma.  
Similarly, although the improvements in lung function (FEV1) were statistically 
significant (see evidence tables), they were small and did not cross the MCID 
threshold of 0.23 L.  
Efficacy is similar between doses. The effect size for all above outcomes was larger 
in subgroup of patients with higher blood eosinophil count. 
Meta-analytical results on other outcomes appear in the online supplement.  
 
Although a defined threshold for 
clinically meaningful reductions in 
asthma exacerbations has not been 
universally agreed upon, the effect 
sizes in reductions in asthma 
exacerbations for this drug would be 
considered clinically substantial by 
most practitioners. 
The decision to consider changes in 
lung function [forced expiratory volume 
in the first second (FEV1)] as 
„important‟ outcomes as opposed to 
„critical‟ outcomes is due to their place 
relative to other critical outcomes. We 
understand that most clinicians would 
prescribe dupilumab due to its efficacy 
in reducing asthma exacerbations 
despite only modest improvements in 
lung function. Results from our meta-
analysis on the modest effect on lung 
function relative to the effect on asthma 
exacerbations led us to downgrade the 
importance of lung function to an 
important outcome, as suggested by 
the methodological approach endorsed 
by Guyatt et al (PMID: 21194891) 
Taken together, the reduction in 
asthma exacerbations is substantial 
enough for this committee to judge the 
desirable effects of an anti-IL4/13 
strategy as large, regardless of 
relatively smaller effects on symptom 
scores and lung function. 
Dupilumab is currently FDA approved 
in patients > 12 years of age with 
moderate to severe eosinophilic 
asthma or those with systemic 
corticosteroid dependent asthma.   
Dupilumab is available in two doses for 
indication of asthma: 200 mg every 2 
weeks after a loading dose of 400 mg; 
300 mg every 2 weeks after a loading 
dose of 600 mg. This panel agrees with 
FDA recommendation to consider the 
higher dose for patients with OCS 
dependent asthma or comorbid atopic 
dermatitis. 
FDA notes that “the adolescent 
subgroup demonstrated a statistically 
significant improvement in lung function 
for both dose groups; however, the 
exacerbation benefit was not clearly 
demonstrated for either dose group. 
This review recommends approval in 
this age group, as there are no age-
related differences in the 
pharmacokinetic and 
pharmacodynamic parameters, and no 
safety concerns for dupilumab in 
adolescent patients.” 
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How substantial are the undesirable anticipated effects? 
○ Large 
○ Moderate 
● Small 
○ Trivial 
○ Varies 
○ Don't know 
 
In the RCTs analysed, the relative risk of a study participant developing an adverse 
event was 0.96-1.08 for those participants assigned to dupilumab compared to 
placebo. Similarly, the relative risk of participant developing a serious adverse event 
when assigned to dupilumab vs. placebo was 0.93-1.56. (insert evidence tables). 
 
Relative risk for injection site reactions varied from 1.47 (95% CI 0.88-2.47; 200 mg 
dose at 24 weeks) to 2.34 (95% CI 0.74-7.35; 300 mg dose at 24 weeks) 
 
Dupilumab has been well tolerated, 
receiving its first FDA approval for 
atopic dermatitis in 2017 followed by its 
approval for asthma in 2018.  
Treatment related eosinophilia that met 
criteria for adverse event was observed 
in 4.1% of participants assigned to 
dupilumab vs. 0.6% in those assigned 
to placebo (PMID: 29782217).  
Associated symptoms of eosinophilia 
were noted in 0.2% of the total trial 
population in this study. Similarly, in 
another study of patients with 
corticosteroid-dependent asthma 
(PMID: 29782224), treatment related 
eosinophilia AE was observed in 13% 
of participants as compared to 1% of 
participants assigned to placebo. Long 
term follow-up for this and other side 
effects is unavailable. Monitoring for 
eosinophilia is not mandated in the 
package insert.  
Injection site reactions were the most 
common side effects and were dose-
related.  
The ocular side effects seen in studies 
of dupilumab in atopic dermatitis were 
not observed in asthma trials. 
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What is the overall certainty of the evidence of effects? 
○ Very low 
○ Low 
● Moderate 
○ High 
○ No included studies 
 
 Overall population (patients with moderate and severe persistent asthma): low 
quality of evidence;  
 Population that meets criteria for the diagnosis of severe asthma defined by the 
ERS/ATS Guidelines: low quality of evidence 
 
Our certainty assessment relies on 
study design (randomized controlled 
trials), risk of bias (not serious), 
inconsistency (not serious), 
indirectness (not serious), and 
imprecision (not serious).  
Further the certainty is based on the 
quality of evidence that is lowest 
among critical outcomes. 
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Is there important uncertainty about or variability in how 
much people value the main outcomes? 
○ Important uncertainty or variability 
○ Possibly important uncertainty or variability 
○ Probably no important uncertainty or variability 
● No important uncertainty or variability 
○ No known undesirable outcomes 
 
No evidence identified There is no important uncertainty about 
how patients and the clinicians who 
care for them assess asthma 
exacerbations. On the other hand, 
asthma exacerbations are not the only 
critical outcome for patients and 
clinicians, who also consider the effect 
of interventions on other outcomes, 
such as changes in lung function, 
change in maintenance dose of 
systemic corticosteroids, asthma 
symptoms, and quality of life. Although 
the effect size of anti-IL4/13 strategy 
drug is not uniform across these other 
outcomes, these drugs tended to 
improve to varying degrees all asthma 
related outcomes.  Further, patients 
and clinicians rarely decide to prescribe 
these drugs based on only one of these 
outcomes in isolation.  
Further, many pharmacy formularies for 
physician groups and hospitals restrict 
these drugs to patients with severe 
asthma and a recent history of asthma 
exacerbations. The decision whether or 
not to prescribe these drugs is likely to 
be  important in this population.    
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Does the balance between desirable and undesirable effects 
favor the intervention or the comparison? 
○ Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
● Favors the intervention 
○ Varies 
○ Don't know 
 
 
Dupilumab therapy was associated with large desirable and small undesirable 
effects. 
 Dupilumab was well tolerated in the 
clinical trials. Frequency of both serious 
and non-serious side effects were 
similar in placebo and intervention 
groups.  Thus, considering the 
substantial benefit in terms of reducing 
asthma exacerbations, the balance 
favors using an anti-IL4/13 strategy.   
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 Does the cost-effectiveness of the intervention favor the 
intervention or the comparison? 
● Favors the comparison 
○ Probably favors the comparison 
○ Does not favor either the intervention or the comparison 
○ Probably favors the intervention 
○ Favors the intervention 
○ Varies 
○ No included studies 
 
The December 2018 report by the Institute for Clinical and Economic Review (ICER) 
states that dupilumab costs >$400,000 per quality-adjusted life years (QALY) 
gained when compared to standard of care (ICER 2018). These figures far exceed 
the accepted threshold for a cost-effective intervention of $150,000 per QALY 
gained.  
Therefore, the alternative is favored 
over an anti-IL4/13 strategy from a 
cost-effectiveness standpoint. 
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What is the certainty of the evidence of resource 
requirements (costs)? 
○ Very low 
○ Low 
○ Moderate 
● High 
○ No included studies 
The manufacturers‟ listed annual net price for dupilumab is $36,000 (ICER 2018). 
The certainty of these costs is therefore high.   
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 What would be the impact on health equity? No evidence identified. In the US, racial and ethnic minorities, 
and individuals of lower socioeconomic 
○ Reduced 
● Probably reduced 
○ Probably no impact 
○ Probably increased 
○ Increased 
○ Varies 
○ Don't know 
status have been documented to have 
less access to specialty clinics and are 
less likely to use controller therapy for 
asthma. Since dupilumab is mainly 
prescribed by specialists it is likely that 
racial and ethnic minorities will be less 
likely to be prescribed one of these 
drugs. Other groups may thus 
experience greater reductions in 
asthma exacerbations due to access to 
these drugs, which will thus reduce 
health equity. Similarly, patients with 
severe asthma who live in regions with 
fewer specialists will be less likely to 
receive these drugs, thus reducing 
equity between areas with high and low 
access to specialty care.  
On the other hand, the manufacturers 
of these drugs have programs in place 
to reduce patients‟ out of pocket costs 
for these drugs, which may partly 
mitigate the decrease in equity posed 
by differences in access by 
socioeconomic status and 
race/ethnicity. 
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Is the intervention acceptable to key stakeholders? 
○ No 
○ Probably no 
○ Probably yes 
○ Yes 
● Varies 
○ Don't know 
No evidence identified.  Most patients with severe asthma 
welcome the possibility of relief from 
asthma through dupilumab, as long as 
the potential benefit is not offset by 
adverse effects, costs or other 
inconveniences (travel or prolonged 
waiting times in clinic, etc.).  
Health insurance companies and clinic 
administrations find anti-IL4/13 strategy 
drugs less acceptable due to their high 
cost. 
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 Is the intervention feasible to implement? 
○ No 
○ Probably no 
○ Probably yes 
○ Yes 
No evidence identified.  The feasibility to implement is 
dependent on many variables including 
access to asthma specialists,  clinical 
resources to train patients to self-
administer this drug, clinical set up that 
allows close follow-up of patients on 
● Varies 
○ Don't know 
therapy, as well as a laboratory that 
can measure blood eosinophils in these 
patients. Patients without access to 
these resources are unlikely to receive 
this therapy.  
 
 
  
PRISMA FLOW CHARTS 
Should a monoclonal anti-IL5 antibody be used in adults and children with severe asthma? 
 
  
 
Records identified through 
database searching 
(n = 1194) 
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Additional records identified 
through other sources 
(n = 1) 
Records after duplicates removed 
(n = 1143) 
Records screened 
(n = 1143 ) 
Records excluded 
(n = 1114 ) 
Full-text articles assessed 
for eligibility 
(n = 29) 
Full-text articles excluded, 
with reasons 
(n =8) 
 
Studies included non-severe asthma:  
N=4 
 
Not RCT or meta-analysis: N=3 
 
Single dose only: N=1 
 
 
 
 
 
Studies included in 
qualitative synthesis 
(n = 21) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 12 publications 
reporting on 13 RCTs) 
Full-text articles excluded, 
with reasons 
(n =9) 
 
RCTs with non-FDA/EMA approved 
drug administration route. N=3 
 
Meta-analysis reviewed to confirm 
all relevant RCTs already included in 
analysis: N=6 
 
 
 
 
 
Should a measurement of a specific biomarker be used to guide initiation of treatment with a monoclonal anti-IL5 or IL5Rα antibody in adults and children 
with severe asthma? (biomarkers being exhaled NO, peripheral or sputum eosinophils, and serum periostin) 
 
  
 
Records identified through 
database searching 
(n = 1193) 
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Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 1157) 
Records screened 
(n = 1157) 
Records excluded 
(n = 1124) 
Full-text articles assessed 
for eligibility 
(n = 34) 
Full-text articles excluded, 
with reasons 
(n = 23) 
 
Studies included patients with non-
severe asthma:  n = 3 
 
Narrative review, systematic review 
or meta-analysis: n = 5 
 
No analysis by eos level: n = 10 
 
RCTs with non-FDA/EMA approved  
dose: n = 3 
 
Acute asthma: n = 1 
 
Incomplete outcome data: n = 1 
 
 
 
 
 
Studies included in 
qualitative and 
quantitative synthesis 
(meta-analysis) 
(n = 11 publications 
reporting on 13 RCTs) 
Should a measurement of a specific biomarker be used, in addition to total IgE level, to guide initiation of treatment with a monoclonal anti-IgE antibody in 
adults and children with severe asthma? (biomarkers being exhaled NO, peripheral or sputum eosinophils, and serum periostin) 
 
  
 
Records identified through 
database searching 
(n = 2313) 
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Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 2242) 
Records screened 
(n = 2242) 
Records excluded 
(n = 2174) 
Full-text articles assessed 
for eligibility 
(n = 68) 
Full-text articles excluded, 
with reasons 
(n = 63) 
 
RCT only included patients with non-
severe asthma:  N=8 
 
Did not meet PICO eligibility: N=55 
 
 
 
 
 
 
 
 
Studies included in 
qualitative synthesis 
(n = 5) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =2) 
Should a long-acting inhaled muscarinic antagonist (LAMA) be used in adults and children with severe asthma? 
 
 
 
  
Should a macrolide (i.e., azithromycin, clarithromycin) be used in adults and children with severe asthma?  
 
 
  
 
 
Total records identified through 
database searching ( Feb 2018 and 
again November 2018)  
(n = 1142) 
 
 
 
(n = 1142) 
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Records after removing: 
-          Non English 
-          Double references 
-          Case reports, letters, editorials 
-          References with no abstracts 
-          References with irrelevant titles 
(n = 149) 
Records excluded  
(n = 993) 
Records after removing: 
- Abstract not containing the terms 
severe asthma, macrolides or 
azithromycin or clarithromycin 
(n = 96) 
Records after reading full articles:  
- Clinical trials (n=19) 
- Basic or translational (n=14) 
- Relevant reviews and/or meta-
analysis (n=10) 
Total = 43 
Records excluded  
(n = 53) 
Records excluded  
(n = 53) 
Records excluded after TF and 
methodologist review:  
 
Total Studies included (n = 6) 
 
- Records excluded  
(n = 37)  
- Not relevant, small 
numbers, not 
focused in SA  (n=29) 
- Pediatric studies not 
meeting SA criteria) 
(n=8) 
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Should an anti-interleukin 4/13 strategy be used for adults and children with severe asthma? 
 
 
 
 
Records identified through 
database searching  
(n = 258) 
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Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed  
(n = 249) 
Records screened  
(n = 249) 
Records excluded  
(n = 243) 
Studies unrelated to dupilumab: N=42 
Studies unrelated to asthma: N=44 
Not RCT or meta-analysis: N=146 
Conference abstracts: N=10 
Citation inaccurate, Study not found (N=1) 
 
 
 
Full-text articles assessed 
for eligibility  
(n = 6) 
Full-text articles excluded, 
with reasons  
(n =1) 
 
RCT methods but no results (1) 
 
 
 
 
 
 
 
 
Studies included in 
qualitative synthesis  
(n = 5) 
Studies included in 
quantitative synthesis 
(meta-analysis)  
(n = 3) 
Full-text articles excluded, 
with reasons  
(n =2) 
RCT using non-FDA approved dose (1) 
Meta-analysis of two studies; only one 
met criteria for inclusion. (1) 
 
 
 
 
